Cancer Research and Treatment

Volume 51(3); July 2019

Review Article

Autoimmune Diseases and Gastric Cancer Risk: A Systematic Review and Meta-Analysis: Minkyo Song, Gonzalo Latorre, Danisa Ivanovic-Zuvic, M. Constanza Camargo, Charles S. Rabkin; Cancer Res Treat. 2019;51(3):841-850. Published online May 3, 2019; DOI: https://doi.org/10.4143/crt.2019.151

Abstract PDF Supplementary Material PubReader ePub

Purpose
Autoimmunity is an alternative etiology of gastric inflammation, the initiating event in the gastric carcinogenic cascade. This mechanism may be an increasingly important cause of gastric cancer with the waning prevalence of its primary etiologic factor, chronic Helicobacter pylori infection.
Materials and Methods
PubMed and EMBASE were searched up to September 2018. Autoimmunity and 96 specific manifestations were considered for associations with gastric cancer risk. Random effects analysis was used to calculate pooled relative risk estimates (RR) and 95% confidence intervals (CI).
Results
We found a total of 52 observational studies representing 30 different autoimmune diseases. Overall, the presence of an autoimmune condition was associated with a gastric cancer pooled RR of 1.37 (95% CI, 1.24 to 1.52). Among the 24 autoimmune conditions with two or more independent reports, nine were significantly associated with increased gastric cancer risk: dermatomyositis (RR, 3.69; 95% CI, 1.74 to 7.79), pernicious anemia (RR, 2.84; 95% CI, 2.30 to 3.50), Addison disease (RR, 2.11; 95% CI, 1.26 to 3.53), dermatitis herpetiformis (RR, 1.74; 95% CI, 1.02 to 2.97; n=3), IgG4-related disease (RR, 1.69; 95% CI, 1.00 to 2.87), primary biliary cirrhosis (RR, 1.64; 95% CI, 1.13 to 2.37), diabetes mellitus type 1 (RR, 1.41; 95% CI, 1.20 to 1.67), systemic lupus erythematosus (RR, 1.37; 95% CI, 1.01 to 1.84), and Graves disease (RR, 1.27; 95% CI, 1.06 to 1.52).
Conclusion
Our analysis documents the wide range of autoimmune diseases associated with gastric cancer. These associations may reflect unreported links between these conditions and autoimmune gastritis. Further studies are warranted to investigate potential causal mechanisms.

Citations

Citations to this article as recorded by

Implementation of the updated Sydney system biopsy protocol improves the diagnostic yield of gastric preneoplastic conditions: Results from a real-world study
Gonzalo Latorre, José Ignacio Vargas, Shailja C. Shah, Danisa Ivanovic-Zuvic, Pablo Achurra, Martín Fritzsche, Jai-Sen Leung, Bernardita Ramos, Elisa Jensen, Javier Uribe, Isabella Montero, Vicente Gandara, Camila Robles, Miguel Bustamante, Felipe Silva,
Gastroenterología y Hepatología.2024; 47(8): 793. CrossRef
Pathology and Clinical Relevance of Gastric Epithelial Dysplasia
Tetsuo Ushiku, Gregory Y. Lauwers
Gastroenterology Clinics of North America.2024; 53(1): 39. CrossRef
RE.GA.IN.: the Real-world Gastritis Initiative–updating the updates
Massimo Rugge, Robert M Genta, Peter Malfertheiner, Mario Dinis-Ribeiro, Hashem El-Serag, David Y Graham, Ernst J Kuipers, Wai Keung Leung, Jin Young Park, Theodore Rokkas, Christian Schulz, Emad M El-Omar
Gut.2024; : gutjnl-2023-331164. CrossRef
Autoimmunity and epithelial dysplasia in patients with oral lichenoid diseases
Jeong‐Hyun Kang, Ji Eun Kwon
Oral Diseases.2024;[Epub] CrossRef
Ex Vivo-Generated Tolerogenic Dendritic Cells: Hope for a Definitive Therapy of Autoimmune Diseases
Jonny, Enda Cindylosa Sitepu, Chairul A. Nidom, Soetojo Wirjopranoto, I. Ketut Sudiana, Arif N. M. Ansori, Terawan Agus Putranto
Current Issues in Molecular Biology.2024; 46(5): 4035. CrossRef
Autoimmune conditions and gastric cancer risk in a population-based study in the United Kingdom
John D. Murphy, Shahinaz M. Gadalla, Lesley A. Anderson, Charles S. Rabkin, Chris R. Cardwell, Minkyo Song, M. Constanza Camargo
British Journal of Cancer.2024; 131(1): 138. CrossRef
Non-Invasive Markers for the Detection of Gastric Precancerous Conditions
Marcin Romańczyk, Malgorzata Osmola, Alexander Link, Amaury Druet, Caroline Hémont, Jerome Martin, Nicolas Chapelle, Tamara Matysiak-Budnik
Cancers.2024; 16(12): 2254. CrossRef
Implementation of the updated Sydney system biopsy protocol improves the diagnostic yield of gastric preneoplastic conditions: Results from a real-world study
Gonzalo Latorre, José Ignacio Vargas, Shailja C. Shah, Danisa Ivanovic-Zuvic, Pablo Achurra, Martín Fritzsche, Jai-Sen Leung, Bernardita Ramos, Elisa Jensen, Javier Uribe, Isabella Montero, Vicente Gandara, Camila Robles, Miguel Bustamante, Felipe Silva,
Gastroenterología y Hepatología (English Edition).2024; 47(8): 793. CrossRef
Is autoimmunity associated with the development of premalignant oral conditions and the progression to oral squamous cell carcinoma?: A literature review
Jeong-Hyun Kang, Seok Woo Hong
Journal of Stomatology, Oral and Maxillofacial Surgery.2024; : 102139. CrossRef
Antinuclear Positivity and Malignant Transformation Potential of Oral Potentially Malignant Disorder
Seok Woo Hong, Jeong‐Hyun Kang
Oral Diseases.2024;[Epub] CrossRef
Autoimmune gastritis: long-term natural history in naïveHelicobacter pylori-negative patients
Massimo Rugge, Ludovica Bricca, Stefano Guzzinati, Diana Sacchi, Marco Pizzi, Edoardo Savarino, Fabio Farinati, Manuel Zorzi, Matteo Fassan, Angelo Paolo Dei Tos, Peter Malfertheiner, Robert M Genta, David Y Graham
Gut.2023; 72(1): 30. CrossRef
Risk factors for gastric cancer: A comprehensive analysis of observational studies
Yuqing Hui, Chunyi Tu, Danlei Liu, Huijie Zhang, Xiaobing Gong
Frontiers in Public Health.2023;[Epub] CrossRef
Incidence of Gastric Neoplasms Arising from Autoimmune Metaplastic Atrophic Gastritis: A Systematic Review and Case Reports
Chuyan Chen, Yi Yang, Peng Li, Haiyi Hu
Journal of Clinical Medicine.2023; 12(3): 1062. CrossRef
Metachronous tumors of the stomach in a patient with autoimmune gastritis
N.V. Pachuashvili, D.P. Nagornaya, A.S. Tertychnyi
Arkhiv patologii.2023; 85(1): 57. CrossRef
Global burden of gastric cancer: epidemiological trends, risk factors, screening and prevention
Aaron P. Thrift, Theresa Nguyen Wenker, Hashem B. El-Serag
Nature Reviews Clinical Oncology.2023; 20(5): 338. CrossRef
Atrophic Gastritis and Autoimmunity: Results from a Prospective, Multicenter Study
Malgorzata Osmola, Caroline Hemont, Nicolas Chapelle, Marie-Anne Vibet, David Tougeron, Driffa Moussata, Dominique Lamarque, Edith Bigot-Corbel, Damien Masson, Justine Blin, Maxime Leroy, Regis Josien, Jean-François Mosnier, Jérôme Martin, Tamara Matysiak
Diagnostics.2023; 13(9): 1599. CrossRef
Epstein–Barr virus positive gastric adenocarcinoma with systemic EBV reactivation in a patient with persistently active systemic lupus erythematosus
Rada Miskovic, Danijela Miljanovic, Maja Dimic Cumic, Ivana Lazarevic, Ana Banko
Oncologie.2023; 25(1): 93. CrossRef
Dual direction associations between common autoimmune diseases and leukemia among children and young adults: A systematic review
Julia Ventelä, Anni Alanko, Anssi Auvinen, Olli Lohi, Atte Nikkilä
Cancer Epidemiology.2023; 86: 102411. CrossRef
Latin American and the Caribbean Code Against Cancer 1st edition: Infections and cancer
Rolando Herrero, Loretto J. Carvajal, M. Constanza Camargo, Arnoldo Riquelme, Carolina Porras, Ana Patricia Ortiz, Luis Aranha Camargo, Valeria Fink, Vanessa van De Wyngard, Eduardo Lazcano-Ponce, Carlos Canelo-Aybar, Graciela Balbin-Ramon, Ariadna Feliu,
Cancer Epidemiology.2023; 86: 102435. CrossRef
Association between Gastric Cancer and 12 Autoimmune Diseases: A Mendelian Randomization Study
Qi Wei, Ziyu Wang, Xuanyu Liu, Haibin Liang, Lei Chen
Genes.2023; 14(10): 1844. CrossRef
The risk of malignancy in patients with IgG4-related disease: a systematic review and meta-analysis
Tingfeng Yu, Yaxian Wu, Jia Liu, Yanyan Zhuang, Xiaoyan Jin, Lingyun Wang
Arthritis Research & Therapy.2022;[Epub] CrossRef
Associations Between Autoimmune Conditions and Gastric Cancer Risk Among Elderly Adults in the United States
Minkyo Song, M. Constanza Camargo, Andriy Derkach, Charles S. Rabkin, Eric A. Engels
American Journal of Gastroenterology.2022; 117(3): 486. CrossRef
IgG4-Related Disease With Gastrointestinal Involvement: Case Reports and Literature Review
Xinhe Zhang, Xing Jin, Lin Guan, Xuyong Lin, Xuedan Li, Yiling Li
Frontiers in Immunology.2022;[Epub] CrossRef
Autoimmungastritis
Marino Venerito, Sabrina Sulzer, Dörthe Jechorek
DMW - Deutsche Medizinische Wochenschrift.2022; 147(08): 451. CrossRef
Rare case of pernicious anaemia from a university hospital of Nepal: A case report
Suyesh Raj Shrestha, Pramit Ram Shrestha, Abhyuday Kumar Yadav, Sneha Shrestha, Ashish Shrestha, Pawan Katwal
Annals of Medicine and Surgery.2022; 80: 104151. CrossRef
Academy of Medicine, Singapore clinical guideline on endoscopic surveillance and management of gastric premalignant lesions
Vikneswaran Namasivayam, Calvin J Koh, Stephen Tsao, Jonathan Lee, Khoon Lin Ling, Christopher Khor, Tony Lim, James Weiquan Li, Aung Myint Oo, Benjamin CH Yip, Ikram Hussain, Tju Siang Chua, Bin Chet Toh, Hock Soo Ong, Lai Mun Wang, Jimmy BY So, Ming Teh
Annals of the Academy of Medicine, Singapore.2022; 51(7): 417. CrossRef
Sex differences in cancer incidence and mortality among patients managed at King Hussein Cancer Center
Abdallah Al‐Ani, Justin Z. Amarin, Leen Al‐Huneidy, Maysa Al‐Hussaini
International Journal of Cancer.2022; 151(11): 1960. CrossRef
Feasibility of ERAS in Patients With Gastric Cancer Complicated by Diabetes Mellitus
Ying Wang, He Han, Said Abdulrahman Salim Mzee, Deqian Wang, Jixiang Chen, Xin Fan
Technology in Cancer Research & Treatment.2022;[Epub] CrossRef
Research priorities in pernicious anaemia: James Lind Alliance Priority Setting Partnership
Kristina Staley, Kourosh R Ahmadi, Karyl Carter, Katherine Cowan, Heidi Seage, Petra Visser, Nicola Ward, Martyn Hooper
BMJ Open.2022; 12(8): e065166. CrossRef
Treatment of gastric cancer with dermatomyositis as the initial symptom: Two case reports and review of literature
Xiang-Fei Sun, Xiao-Dong Gao, Kun-Tang Shen
World Journal of Clinical Cases.2022; 10(27): 9727. CrossRef
The Diagnostic Value of Anti-Parietal Cell and Intrinsic Factor Antibodies, Pepsinogens, and Gastrin-17 in Corpus-Restricted Atrophic Gastritis
Petra Kriķe, Zakera Shums, Inese Poļaka, Ilze Kikuste, Aigars Vanags, Ivars Tolmanis, Sergejs Isajevs, Inta Liepniece-Karele, Daiga Santare, Lilian Tzivian, Dace Rudzīte, Minkyo Song, M. Constanza Camargo, Gary L. Norman, Mārcis Leja
Diagnostics.2022; 12(11): 2784. CrossRef
Cancer incidence and factors associated with malignancies in coeliac disease during long‐term follow‐up
Inka Koskinen, Kaisa Hervonen, Eero Pukkala, Timo Reunala, Katri Kaukinen, Pekka Collin
GastroHep.2021; 3(2): 107. CrossRef
Acute myelomonocytic leukaemia and pernicious anaemia in a patient with systemic lupus erythematosus: a rare coexistence of three immunological disorders
Francisco Espinoza-Gomez, Hector Carranza-Garcia, Estefania Velasco-Ibarra
British Journal of Hospital Medicine.2021; 82(5): 1. CrossRef
Autoimmunity as an Etiological Factor of Cancer: The Transformative Potential of Chronic Type 2 Inflammation
Chris M. Li, Zhibin Chen
Frontiers in Cell and Developmental Biology.2021;[Epub] CrossRef
The Relationship between Diabetes Mellitus and Gastric Cancer and the Potential Benefits of Metformin: An Extensive Review of the Literature
Chin-Hsiao Tseng
Biomolecules.2021; 11(7): 1022. CrossRef
Autoimmune disease and oral squamous cell carcinoma: A systematic review
Anjali Pillai, Dauren Adilbay, Konstantina Matsoukas, Ian Ganly, Snehal G. Patel
Journal of Oral Pathology & Medicine.2021; 50(9): 855. CrossRef
Can Cancer Patients With Autoimmune Diseases Use Immunotherapy?
Yefei Shu
American Journal of Clinical Oncology.2021; 44(8): 442. CrossRef
Autoimmune gastritis, with or without pernicious anemia: epidemiology, risk factors, and clinical management
Sheila D. Rustgi, Priyesha Bijlani, Shailja C. Shah
Therapeutic Advances in Gastroenterology.2021;[Epub] CrossRef
Clinicopathological characteristics of early gastric cancer associated with autoimmune gastritis
Shinji Kitamura, Naoki Muguruma, Koichi Okamoto, Kaizo Kagemoto, Yoshifumi Kida, Yasuhiro Mitsui, Hiroyuki Ueda, Tomoyuki Kawaguchi, Hiroshi Miyamoto, Yasushi Sato, Rika Aoki, Joji Shunto, Yoshimi Bando, Tetsuji Takayama
JGH Open.2021; 5(10): 1210. CrossRef
Six Autoimmune Disorders Are Associated With Increased Incidence of Gastric Cancer: A Systematic Review and Meta-Analysis of Half a Million Patients
Noémi Zádori, Lajos Szakó, Szilárd Váncsa, Nóra Vörhendi, Eduard Oštarijaš, Szabolcs Kiss, Levente Frim, Péter Hegyi, József Czimmer
Frontiers in Immunology.2021;[Epub] CrossRef
Autoimmune Gastritis in Pediatrics
Tania Mitsinikos, Nick Shillingford, Harry Cynamon, Vrinda Bhardwaj
Journal of Pediatric Gastroenterology and Nutrition.2020; 70(2): 252. CrossRef
AGA Technical Review on Gastrointestinal Evaluation of Iron Deficiency Anemia
Don C. Rockey, Osama Altayar, Yngve Falck-Ytter, Denise Kalmaz
Gastroenterology.2020; 159(3): 1097. CrossRef
Cancer risk in systemic sclerosis: identifying risk and managing high-risk patients
George E. Fragoulis, Dimitris Daoussis, Eleni Pagkopoulou, Alexandros Garyfallos, George D. Kitas, Theodoros Dimitroulas
Expert Review of Clinical Immunology.2020; 16(12): 1105. CrossRef
///
ii ivanov
Medicine of Extreme Situations.2020;[Epub] CrossRef
Role of heredity, endogenous and exogenous factors in gastric cancer
PV Ershov
Medicine of Extreme Situations.2020;[Epub] CrossRef
Editorial: determinants of diagnostic delay in autoimmune atrophic gastritis—a salutary lesson
Marjorie M. Walker
Alimentary Pharmacology & Therapeutics.2019; 50(4): 458. CrossRef
Functional Dyspepsia in the Elderly
Marjorie M. Walker, Nicholas J. Talley
Current Gastroenterology Reports.2019;[Epub] CrossRef

12,642 View
527 Download
45 Web of Science
47 Crossref

Special Article

Behaviors and Attitudes toward the Use of Complementary and Alternative Medicine among Korean Cancer Patients: Jung Hye Kwon, Sang-Cheol Lee, Myung Ah Lee, Yu Jung Kim, Jung Hun Kang, Jin Young Kim, Hyo Jin Lee, Woo Kyun Bae, Mi-Jung Kim, Eui Kyu Chie, Jin Kim, Yeul Hong Kim, Hyun Cheol Chung, Sun Young Rha; Cancer Res Treat. 2019;51(3):851-860. Published online June 7, 2019; DOI: https://doi.org/10.4143/crt.2019.137

Abstract PDF Supplementary Material PubReader ePub

Purpose
A cross-sectional survey was conducted to explore the current awareness and use of complementary and alternative medicine (CAM), as well as attitudes toward CAM, in patients with cancer and their family members in South Korea.
Materials and Methods
Between September 21 and October 31, 2017, a 25-item questionnaire regarding CAM experiences among cancer patients and their family members was conducted in 10 oncology clinics in South Korea after institutional review board approval at each institution.
Results
In total, 283/310 patients were analyzed. The median age was 60 years, and 60% were male. Most of the patients were actively receiving anticancer treatment at the time of the survey. A total of 106 patients (37%) had experienced a median of two types (interquartile range, 1 to 3) of CAM. Belief in CAM (odds ratio [OR], 3.015; 95% confidence interval [CI], 1.611 to 5.640) and duration of disease (OR, 1.012; 95% CI, 1.004 to 1.020) were independent factors for using CAM in multivariable analysis. Belief in CAM was significantly associated with current use of CAM (OR, 3.633; 95% CI, 1.567 to 8.424). Lay referral was the most common reason for deciding to use CAM, and only 25% of patients (72/283) discussed CAM with their physicians.
Conclusion
Patient attitudes toward and confidence in CAM modalities were strongly associated with their CAM experiences, and only a small number of patients had an open discussion about CAM with their physicians. A patient education program for CAM is needed.

Citations

Citations to this article as recorded by

The Relationship Between Cancer Patients’ Supportive Care Needs and Their Attitudes Toward Complementary and Alternative Medicine
H Çelik, H Aslan
Nigerian Journal of Clinical Practice.2024; 27(4): 415. CrossRef
Alternative and complementary medicine in neurological disorders and neurological disability patients: Prevalence, factors, opinions and reasons
Paul Carrillo-Mora, Marlene A. Rodríguez-Barragán, Jimena Quinzaños-Fresnedo, María del Refugio Pacheco-Gallegos, María Soto-Lara, Monserrat Velázquez-Ortega, María Fernanda Villarreal-Azamar, Ilse Jocelyn Aguirre-Medina, Mariana Rubalcava-Gracia-Medrano
Complementary Therapies in Medicine.2023; 72: 102920. CrossRef
Status of Using Complementary and Alternative Medicine among Patients with Cancer in Korea: an Online Survey of Online Cancer Support Groups (KCSG PC21-20)
Jung Sun Kim, Jung Hye Kwon, Sun Young Rha, Sang-Cheol Lee, Yoon Jung Chang, In-Sun Kwon, Kyung Han You, Ho Young Yoon
Cancer Research and Treatment.2023; 55(2): 442. CrossRef
Effects of COVID-19 fear and anxiety on attitudes towards complementary and alternative medicine use in women with gynecological cancer during the COVID-19 pandemic
Fatma Uslu-Sahan, Ilknur Yesilcınar, Gonul Kurt, Elif Hancer, Gulten Guvenc
Journal of Integrative Medicine.2023; 21(4): 377. CrossRef
Use of Complementary and Alternative Medicine for Prostate Cancer among African Americans, African Immigrants and Caribbean Immigrants
Nipher Malika, Lisa Roberts, Carlos Casiano, Susanne Montgomery
Journal of Community Health.2022; 47(2): 284. CrossRef
Traditional and complementary medicine use among cancer patients in Nepal: a cross-sectional survey
Soo Jeung Choi, Sangita Karki Kunwor, Hyea Bin Im, Jung Hye Hwang, Dain Choi, Dongwoon Han
BMC Complementary Medicine and Therapies.2022;[Epub] CrossRef
The effect of cancer on traditional, complementary and alternative medicine utilization in Korea: a fixed effect analysis using Korea Health Panel data
Dongsu Kim, Soo-Hyun Sung, Seungwon Shin, Minjung Park
BMC Complementary Medicine and Therapies.2022;[Epub] CrossRef
Use of Complementary and Alternative Medicine (CAM) in Patients With Colorectal Cancer
Jeongwon Yeom, Jung Mi Lee
Clinical Nutrition Research.2022; 11(4): 255. CrossRef
Cancer Research Trends in Traditional Korean Medical Journals since 2000 - Topic Modeling Using Latent Dirichlet Allocation and Keyword Network Analysis
Kyeore Bae
The Journal of Internal Korean Medicine.2022; 43(6): 1075. CrossRef
Borders between integrative medicine and EBM: significance, potential for use and legal issues in European Union member states. Narrative review
Aneta Brygida Jędrzejewska, Barbara Janina Ślusarska, Grzegorz Józef Nowicki
Pielegniarstwo XXI wieku / Nursing in the 21st Century.2022; 21(2): 122. CrossRef
Evaluation of outpatient cancer patients’ use of nonpharmacological methods in the management of chemotherapy-induced nausea and vomiting
Eda ERGİN, Tülay SAĞKAL MİDİLLİ, Eda AKDAĞ, Ceyda KIRGÖZ
Cukurova Medical Journal.2021; 46(2): 574. CrossRef
The Current Status of Integrative Oncology in Korea
Eun-Bin Kwag, Soo-Dam Kim, Ji Hye Park, So-Jung Park, Mi-Kyung Jeong, Hwa-Seung Yoo
Integrative Cancer Therapies.2021;[Epub] CrossRef
Biologically-Based Complementary and Alternative Medicine (CAM) Use in Cancer Patients: The Good, the Bad, the Misunderstood
Kathryn Knecht, David Kinder, Amy Stockert
Frontiers in Nutrition.2020;[Epub] CrossRef
Efficacy of Chemotherapy Integrated With Traditional Korean Medicine in Patients With Metastatic Pancreatic Cancer: A Single-Center Retrospective Study
Eun Hye Kim, Jee-Hyun Yoon, Sung Soo Yoon, Jee Young Lee, Seong Woo Yoon
Integrative Cancer Therapies.2020;[Epub] CrossRef

9,209 View
225 Download
15 Web of Science
14 Crossref

Original Articles

A Phage Display-Identified Peptide Selectively Binds to Kidney Injury Molecule-1 (KIM-1) and Detects KIM-1-Overexpressing Tumors in vivo: Md. Enamul Haque, Fatima Khan, Lianhua Chi, Smriti Gurung, Sri Murugan Poongkavithai Vadevoo, Rang-Woon Park, Dong-Kyu Kim, Sang Kyoon Kim, Byungheon Lee; Cancer Res Treat. 2019;51(3):861-875. Published online October 1, 2018; DOI: https://doi.org/10.4143/crt.2018.214

Abstract PDF PubReader ePub

Purpose
This study was carried out to identify a peptide that selectively binds to kidney injury molecule-1 (KIM-1) by screening a phage-displayed peptide library and to use the peptide for the detection of KIM-1overexpressing tumors in vivo.
Materials and Methods
Biopanning of a phage-displayed peptide library was performed on KIM-1–coated plates. The binding of phage clones, peptides, and a peptide multimer to the KIM-1 protein and KIM-1–overexpressing and KIM-1–low expressing cells was examined by enzyme-linked immunosorbent assay, fluorometry, and flow cytometry. A biotin-peptide multimer was generated using NeutrAvidin. In vivo homing of the peptide to KIM-1–overexpressing and KIM1–low expressing tumors in mice was examined by whole-body fluorescence imaging.
Results
A phage clone displaying the CNWMINKEC peptide showed higher binding affinity to KIM-1 and KIM-1–overexpressing 769-P renal tumor cells compared to other phage clones selected after biopanning. The CNWMINKEC peptide and a NeutrAvidin/biotin-CNWMINKEC multimer selectively bound to KIM-1 over albumin and to KIM-1–overexpressing 769-P cells and A549 lung tumor cells compared to KIM-1-low expressing HEK293 normal cells. Co-localization and competition assays using an anti–KIM-1 antibody demonstrated that the binding of the CNWMINKEC peptide to 769-P cells was specifically mediated by KIM-1. The CNWMINKEC peptide was not cytotoxic to cells and was stable for up to 24 hours in the presence of serum. Whole-body fluorescence imaging demonstrated selective homing of the CNWM-INKEC peptide to KIM-1–overexpressing A498 renal tumor compared to KIM1–low expressing HepG2 liver tumor in mice.
Conclusion
The CNWMINKEC peptide is a promising probe for in vivo imaging and detection of KIM-1‒overexpressing tumors.

Citations

Citations to this article as recorded by

Bi-functional KIT-PR1P peptides combine with VEGF to protect ischemic kidney in rats by targeting to Kim-1
Runxue Zhou, Hang Liu, Xianglin Hou, Qi Liu, Shuwei Sun, Xiaoge Li, Wenxuan Cao, Weihong Nie, Chunying Shi, Wei Chen
Regenerative Therapy.2024; 25: 162. CrossRef
Improving Pharmacokinetics of Peptides Using Phage Display
Mallika Asar, Jessica Newton-Northup, Mette Soendergaard
Viruses.2024; 16(4): 570. CrossRef
Unveiling Invisible Extracellular Vesicles: Cutting‐Edge Technologies for Their in Vivo Visualization
Prakash Gangadaran, Fatima Khan, Ramya Lakshmi Rajendran, Akanksha Onkar, Anshika Goenka, Byeong‐Cheol Ahn
WIREs Nanomedicine and Nanobiotechnology.2024;[Epub] CrossRef
Modified Bacteriophage for Tumor Detection and Targeted Therapy
Yuanzhao Shen, Jingyu Wang, Yuting Li, Chih-Tsung Yang, Xin Zhou
Nanomaterials.2023; 13(4): 665. CrossRef
Tumor microenvironment signaling and therapeutics in cancer progression
Anshika Goenka, Fatima Khan, Bhupender Verma, Priyanka Sinha, Crismita C. Dmello, Manasi P. Jogalekar, Prakash Gangadaran, Byeong‐Cheol Ahn
Cancer Communications.2023; 43(5): 525. CrossRef
Specific bFGF targeting of KIM-1 in ischemic kidneys protects against renal ischemia-reperfusion injury in rats
Siqi Song, Xianglin Hou, Weiwei Zhang, Xinyu Liu, Wei Wang, Xiaoya Wang, Wenxuan Cao, Yujun Xia, Wei Chen, Chunying Shi
Regenerative Biomaterials.2022;[Epub] CrossRef
Application of Phage-Displayed Peptides in Tumor Imaging Diagnosis and Targeting Therapy
Chunyan Li, Jia Li, Ying Xu, Ying Zhan, Yu Li, Tingting Song, Jiao Zheng, Hong Yang
International Journal of Peptide Research and Therapeutics.2021; 27(1): 587. CrossRef
Detection of kidney disease biomarkers based on fluorescence technology
Bicheng Yao, Marie-Claire Giel, Yuning Hong
Materials Chemistry Frontiers.2021; 5(5): 2124. CrossRef
Screening and Identification of a Specific Binding Peptide to Ovarian Cancer Cells from a Phage-Displayed Peptide Library
Shuhui Zhao, Chunyan Li, Yunge Gao, Luomeng Qian, Jian Dong, Lianghao Zhai, Biliang Chen, Jianfang Zhang
International Journal of Peptide Research and Therapeutics.2021; 27(3): 1741. CrossRef

10,280 View
390 Download
11 Web of Science
9 Crossref

Comparison of the 7th and the 8th AJCC Staging System for Non-metastatic D2-Resected Lymph Node–Positive Gastric Cancer Treated with Different Adjuvant Protocols: Jeong Il Yu, Do Hoon Lim, Jeeyun Lee, Won Ki Kang, Se Hoon Park, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Seung Tae Kim, Su Jin Lee, Sung Kim, Tae Sung Sohn, Jun Ho Lee, Ji Yeong An, Min Gew Choi, Jae Moon Bae, Heejin Yoo, Kyunga Kim; Cancer Res Treat. 2019;51(3):876-885. Published online October 1, 2018; DOI: https://doi.org/10.4143/crt.2018.401

Abstract PDF Supplementary Material PubReader ePub

Purpose
The purpose of this study was to compare prognostic differentiation performances of the 7th and the 8th edition of American Joint Commission on Cancer (AJCC) staging system for gastric cancer (GC) patients.
Materials and Methods
A total of 1,633 GC patients who underwent curative D2 resection followed by adjuvant chemotherapy alone (CA) or concurrent chemo-radiotherapy (CCRT) from 2004 to 2013 were included. Concordance index (c-index) was applied to compare the discriminatory ability.
Results
In the 8th edition, migration of stage was detected in 248 patients (15.2%). Among them, 121 patients were up-staged while 127 patients were down-staged. Overall, there was no statistically significant difference in the discriminatory ability between the 7th and 8th editions. The new edition of staging system, however, showed a trend of better prognostic performance not only in recurrence-free survival (c-index=0.734; 95% confidence interval [CI], 0.706 to 0.762 in the 7th edition vs. c-index=0.740; 95% CI, 0.712 to 0.768 in the 8th edition; p=0.14), but also in overall survival (c-index=0.717; 95% CI, 0.688 to 0.745 in the 7th edition vs. c-index=0.722; 95% CI, 0.694 to 0.751 in the 8th edition; p=0.19), especially in stage III. This finding was repeated in the subgroup analysis regardless of adjuvant CA or CCRT.
Conclusion
Generally, the 8th edition of AJCC staging system had failed to show a superior discriminatory ability for curatively D2 resected GC patients than the 7th edition, although there was a trend of better prognostic performance of the new edition, regardless of adjuvant treatment method.

Citations

Citations to this article as recorded by

An analysis of the relationship of triglyceride glucose index with gastric cancer prognosis: A retrospective study
Chao Cai, Cheng Chen, Xiuli Lin, Huihui Zhang, Mingming Shi, Xiaolei Chen, Weisheng Chen, Didi Chen
Cancer Medicine.2024;[Epub] CrossRef
Revolutionizing T3-4N0-2M0 gastric cancer staging with an innovative pathologic N classification system
Kailai Yin, Xuanhong Jin, Yang Pan, Mengli Zi, Yingsong Zheng, Yubo Ma, Chuhong Pang, Kang liu, Jinxia Chen, Yizhou Wei, Dujiang Liu, Xiangdong Cheng, Li Yuan
Journal of Gastrointestinal Surgery.2024; 28(8): 1283. CrossRef
A Comprehensive Review of Prognostic Factors in Patients with Gastric Adenocarcinoma
Styliani Mantziari, Penelope St Amour, Francesco Abboretti, Hugo Teixeira-Farinha, Sergio Gaspar Figueiredo, Caroline Gronnier, Dimitrios Schizas, Nicolas Demartines, Markus Schäfer
Cancers.2023; 15(5): 1628. CrossRef
Normalization weighted combination scores re-evaluate TNM staging of gastric cancer: a retrospective cohort study based on a multicenter database
Junpeng Wu, Hao Wang, Xin Yin, Yufei Wang, Zhanfei Lu, Jiaqi Zhang, Yao Zhang, Yingwei Xue
International Journal of Surgery.2023;[Epub] CrossRef
A Substage Increase in The AJCC Classification System Improves Prognostic Prediction in Stage III Gastric Cancer With Insufficient Lymph Nodes Removed
Ri-Sheng Zhao, Yi-Nan Liu, Wei-Gang Dai, Si-Le Chen, Jin-Ning Ye, Er-Tao Zhai, Shi-Rong Cai, Jian-Hui Chen
Frontiers in Oncology.2021;[Epub] CrossRef
Current therapeutic options for gastric adenocarcinoma
C.R. Akshatha, Smitha Bhat, R. Sindhu, Dharini Shashank, Sarana Rose Sommano, Wanaporn Tapingkae, Ratchadawan Cheewangkoon, Shashanka K. Prasad
Saudi Journal of Biological Sciences.2021; 28(9): 5371. CrossRef
Outcomes of Radiotherapy for Mesenchymal and Non-Mesenchymal Subtypes of Gastric Cancer
Jeong Il Yu, Hee Chul Park, Jeeyun Lee, Changhoon Choi, Won Ki Kang, Se Hoon Park, Seung Tae Kim, Tae Sung Sohn, Jun Ho Lee, Ji Yeong An, Min Gew Choi, Jae Moon Bae, Kyoung-Mee Kim, Heewon Han, Kyunga Kim, Sung Kim, Do Hoon Lim
Cancers.2020; 12(4): 943. CrossRef

11,207 View
216 Download
8 Web of Science
7 Crossref

Jab1 Silencing Inhibits Proliferation and Sensitizes to Cisplatin in Biliary Tract Cancer: Ah-Rong Nam, Ji-Won Kim, Ji Eun Park, Ju-Hee Bang, Mei Hua Jin, Do-Youn Oh, Yung-Jue Bang; Cancer Res Treat. 2019;51(3):886-900. Published online October 1, 2018; DOI: https://doi.org/10.4143/crt.2018.375

Abstract PDF Supplementary Material PubReader ePub

Purpose
Jab1 is a coactivator of c-Jun that enhances the transcriptional function of c-Jun. Jab1 is frequently overexpressed in various cancers and is associatedwith poor prognosis of cancer patients. Thus, Jab1 could be a potential therapeutic target in cancer. However, the role of Jab1 in biliary tract cancer (BTC) has not been studied.
Materials and Methods
We performed in vitro and in vivo experiments to evaluate the therapeutic potential ofJab1 inhibition in BTC.
Results
Among 8 BTC cell lines, many showed higher Jab1 expression levels. In addition, Jab1 silencing by siRNA increased p27 expression levels. SNU478 and HuCCT-1 cells exhibited profound Jab1 knockdown and increased p27 expression by Jab1-specific siRNA transfection. Jab1 silencing induced anti-proliferative and anti-migratory effects and resulted in G1 cell cycle arrest in SNU478 and HuCCT-1 cells. In addition, Jab1 silencing potentiated the anti-proliferative and anti-migratory effects of cisplatin by increasing DNA damage. Interestingly,Jab1 knockdown increased PTEN protein half-life, resulting in increased PTEN expression. In the HuCCT-1 mouse xenograft model, stable knockdown of Jab1 by shRNA also showed anti-proliferative effects in vivo, with decreased Ki-67 expression and AKT phosphorylation and increased Terminal deoxynucleotidyl transferase–mediated dUTP nick end labeling and p27 expression.
Conclusion
Jab1 knockdown demonstrated anti-proliferative and anti-migratory effects in BTC cells by increasing DNA damage and stabilizing PTEN, resulting in G1 cell cycle arrest. In addition, Jab1 silencing potentiated the anti-proliferative effects of cisplatin. Our data suggest that Jab1 may be a potential therapeutic target in BTC that is worthy of further investigations.

Citations

Citations to this article as recorded by

COP9 signalosome complex is a prognostic biomarker and corresponds with immune infiltration in hepatocellular carcinoma
Jiahui Liu, Dexing Han, Junfeng Xuan, Jinye Xie, Weijia Wang, Quan Zhou, Kang Chen
Aging.2024; 16(6): 5264. CrossRef
Pan-cancer analyses of Jab1/COPS5 reveal oncogenic role and clinical outcome in human cancer
Liping Wang, Xiaojiao Zeng, Gui Yang, Guohong Liu, Yunbao Pan
Heliyon.2022; 8(12): e12553. CrossRef
Jab1/Cops5: a promising target for cancer diagnosis and therapy
Chunjue Yuan, Dong Wang, Guohong Liu, Yunbao Pan
International Journal of Clinical Oncology.2021; 26(7): 1159. CrossRef

8,474 View
225 Download
6 Web of Science
3 Crossref

Clinical Benefit of Maintenance Therapy for Advanced Biliary Tract Cancer Patients Showing No Progression after First-Line Gemcitabine Plus Cisplatin: Jaewon Hyung, Bumjun Kim, Changhoon Yoo, Kyo-pyo Kim, Jae Ho Jeong, Heung-Moon Chang, Baek-Yeol Ryoo; Cancer Res Treat. 2019;51(3):901-909. Published online October 4, 2018; DOI: https://doi.org/10.4143/crt.2018.326

Abstract PDF Supplementary Material PubReader ePub

Purpose
Gemcitabine plus cisplatin (GemCis) is the standard first-line chemotherapy for patients with advanced biliary tract cancer (BTC). In ABC-02 study, the BTC patients received up to 6-8 cycles of 3-weekly GemCis; however, those without progression often receive more than 6-8 cycles. The clinical benefit of maintenance treatment in patients without progression is uncertain.
Materials and Methods
Advanced BTC patients treated with GemCis between April 2010 and February 2015 at Asan Medical Center, Seoul, Korea, were retrospectively analysed. The patients without progression after 6-8 cycles were stratified according to further treatment i.e., with or without further cycles of GemCis (maintenance vs. observation groups). The primary endpoint was overall survival (OS) and progression-free survival (PFS).
Results
Among the 740 BTC patients in the initial screen, 231 cases (31.2%) were eligible for analysis (111 in the observation group, 120 in the maintenance group). The median OS from the GemCis initiation was 20.5 months (95% confidence interval [CI], 15.4 to 25.6) and 22.4 months (95% CI, 17.0 to 27.8) in the observation and maintenance groups, respectively (p=0.162). The median PFS was 10.4 months (95% CI, 7.0 to 13.8) and 13.2 months (95% CI, 11.3 to 15.2), respectively (p=0.320).
Conclusions
GemCis maintenance is not associated with an improved survival outcome.

Citations

Citations to this article as recorded by

Biliary tract cancers: French national clinical practice guidelines for diagnosis, treatments and follow-up (TNCD, SNFGE, FFCD, UNICANCER, GERCOR, SFCD, SFED, AFEF, SFRO, SFP, SFR, ACABi, ACHBPT)
Gael S. Roth, Loic Verlingue, Matthieu Sarabi, Jean-Frédéric Blanc, Emmanuel Boleslawski, Karim Boudjema, Anne-Laure Bretagne-Bignon, Marine Camus-Duboc, Romain Coriat, Gilles Créhange, Thierry De Baere, Christelle de la Fouchardière, Clarisse Dromain, Ju
European Journal of Cancer.2024; 202: 114000. CrossRef
Durvalumab or placebo plus gemcitabine and cisplatin in participants with advanced biliary tract cancer (TOPAZ-1): updated overall survival from a randomised phase 3 study
Do-Youn Oh, Aiwu Ruth He, Mohamed Bouattour, Takuji Okusaka, Shukui Qin, Li-Tzong Chen, Masayuki Kitano, Choong-kun Lee, Jin Won Kim, Ming-Huang Chen, Thatthan Suksombooncharoen, Masafumi Ikeda, Myung Ah Lee, Jen-Shi Chen, Piotr Potemski, Howard A Burris,
The Lancet Gastroenterology & Hepatology.2024; 9(8): 694. CrossRef
Bevacizumab Erlotinib Switch Maintenance in Chemo-Responsive Advanced Gallbladder and Cholangiocarcinoma (BEER BTC): A Multicenter, Open-Label, Randomized, Phase II Trial
Anant Ramaswamy, Prabhat Bhargava, Sujay Srinivas, Akhil Kapoor, Bal Krishna Mishra, Anuj Gupta, Sarika Mandavkar, Sadhana Kannan, Deepali Chaugule, Rajshree Patil, Manali Parulekar, Chaitali Nashikkar, Suman Kumar Ankathi, Rajiv Kumar Kaushal, Deepali Na
Journal of Clinical Oncology.2024; 42(27): 3218. CrossRef
Defining the mode of action of cisplatin combined with NUC-1031, a phosphoramidate modification of gemcitabine
Dillum Patel, Alison L. Dickson, Greice M. Zickuhr, In Hwa Um, Oliver J. Read, Clarissa M. Czekster, Peter Mullen, David J. Harrison, Jennifer Bré
Translational Oncology.2024; 50: 102114. CrossRef
Rational development of combination therapies for biliary tract cancers
James J. Harding, Danny N. Khalil, Luca Fabris, Ghassan K. Abou-Alfa
Journal of Hepatology.2023; 78(1): 217. CrossRef
Optimizing Patient Pathways in Advanced Biliary Tract Cancers: Recent Advances and a French Perspective
Cindy Neuzillet, Pascal Artru, Eric Assenat, Julien Edeline, Xavier Adhoute, Jean-Christophe Sabourin, Anthony Turpin, Romain Coriat, David Malka
Targeted Oncology.2023; 18(1): 51. CrossRef
Prolonged survival with first-line chemotherapy in advanced extrahepatic cholangiocarcinoma
Mascarenhas Chrystle, D'souza Sanyo
BMJ Case Reports.2023; 16(3): e249681. CrossRef
Survival Analysis of 1140 Patients with Biliary Cancer and Benefit from Concurrent Renin-Angiotensin Antagonists, Statins, or Aspirin with Systemic Therapy
Valerie Gunchick, Rachel L McDevitt, Elizabeth Choi, Katherine Winslow, Mark M Zalupski, Vaibhav Sahai
The Oncologist.2023; 28(6): 531. CrossRef
A Practical Guide for the Systemic Treatment of Biliary Tract Cancer in Canada
Ravi Ramjeesingh, Prosanto Chaudhury, Vincent C. Tam, David Roberge, Howard J. Lim, Jennifer J. Knox, Jamil Asselah, Sarah Doucette, Nirlep Chhiber, Rachel Goodwin
Current Oncology.2023; 30(8): 7132. CrossRef
A Systematised Literature Review of Real-World Treatment Patterns and Outcomes in Unresectable Advanced or Metastatic Biliary Tract Cancer
Vivian Peirce, Michael Paskow, Lei Qin, Ruby Dadzie, Maria Rapoport, Samantha Prince, Sukhvinder Johal
Targeted Oncology.2023; 18(6): 837. CrossRef
Diagnosis and treatment of cholangiocarcinoma in Italy: A Delphi consensus statement
Lorenza Rimassa, Giovanni Brandi, Monica Niger, Nicola Normanno, Davide Melisi
Critical Reviews in Oncology/Hematology.2023; 192: 104146. CrossRef
Mutational signatures and processes in hepatobiliary cancers
Ekaterina Zhuravleva, Colm J. O’Rourke, Jesper B. Andersen
Nature Reviews Gastroenterology & Hepatology.2022; 19(6): 367. CrossRef
Prognostic Factors in Patients Treated with Pembrolizumab as a Second-Line Treatment for Advanced Biliary Tract Cancer
Chan Su Park, Min Je Sung, So Jeong Kim, Jung Hyun Jo, Hee Seung Lee, Moon Jae Chung, Seungmin Bang, Seung Woo Park, Si Young Song, Jeong Youp Park
Cancers.2022; 14(17): 4323. CrossRef
Emerging Systemic Therapies in Advanced Unresectable Biliary Tract Cancer: Review and Canadian Perspective
Vincent C. Tam, Ravi Ramjeesingh, Ronald Burkes, Eric M. Yoshida, Sarah Doucette, Howard J. Lim
Current Oncology.2022; 29(10): 7072. CrossRef
Effect of Combining EGFR Tyrosine Kinase Inhibitors and Cytotoxic Agents on Cholangiocarcinoma Cells
Boonyakorn Boonsri, Kiren Yacqub-Usman, Pakpoom Thintharua, Kyaw Zwar Myint, Thannicha Sae-Lao, Pam Collier, Chinnawut Suriyonplengsaeng, Noppadol Larbcharoensub, Brinda Balasubramanian, Simran Venkatraman, Isioma U. Egbuniwe, Dhanwant Gomez, Abhik Mukher
Cancer Research and Treatment.2021; 53(2): 457. CrossRef
PD-1 Inhibitors Plus Capecitabine as Maintenance Therapy for Advanced Intrahepatic Cholangiocarcinoma: A Case Report and Review of Literature
Zhihong Wang, Tianmei Zeng, Yong Li, Ding Zhang, Zhengang Yuan, Mengli Huang, Yuan Yang, Weiping Zhou
Frontiers in Immunology.2021;[Epub] CrossRef
Efficacy and Safety of Pembrolizumab in Patients with Refractory Advanced Biliary Tract Cancer: Tumor Proportion Score as a Potential Biomarker for Response
Junho Kang, Jae Ho Jeong, Hee-Sang Hwang, Sang Soo Lee, Do Hyun Park, Dong Wook Oh, Tae Jun Song, Ki-Hun Kim, Shin Hwang, Dae Wook Hwang, Song Cheol Kim, Jin-hong Park, Seung-Mo Hong, Kyu-pyo Kim, Baek-Yeol Ryoo, Changhoon Yoo
Cancer Research and Treatment.2020; 52(2): 594. CrossRef
Inhibition of ATR Increases the Sensitivity to WEE1 Inhibitor in Biliary Tract Cancer
Ah-Rong Nam, Mei-Hua Jin, Ju-Hee Bang, Kyoung-Seok Oh, Hye-Rim Seo, Do-Youn Oh, Yung-Jue Bang
Cancer Research and Treatment.2020; 52(3): 945. CrossRef
Treatment of Metastatic or High-Risk Solid Cancer Patients by Targeting the Immune System and/or Tumor Burden: Six Cases Reports
Andrea Nicolini, Paola Ferrari, Riccardo Morganti, Angelo Carpi
International Journal of Molecular Sciences.2019; 20(23): 5986. CrossRef

10,245 View
337 Download
19 Web of Science
19 Crossref

Retrospective Study of the Significant Predictive Role of Inflammatory Degree in Initial and Repeat Prostate Biopsy Specimens for Detecting Prostate Cancer: Sung Han Kim, Boram Park, Jae Young Joung, Jinsoo Chung, Ho Kyung Seo, Kang Hyun Lee, Weon Seo Park; Cancer Res Treat. 2019;51(3):910-918. Published online October 2, 2018; DOI: https://doi.org/10.4143/crt.2018.314

Abstract PDF Supplementary Material PubReader ePub

Purpose
The purpose of this study was to determine whether histologic inflammation (HI) in initial and repeat prostate biopsy specimens was significantly associated with the detection of prostate cancer.
Materials and Methods
Between 2005 and 2017, the clinicopathological records of patients with high prostatespecific antigen (PSA) levels who underwent initial and repeat prostate biopsies were retrospectively reviewed. The presence of HI and its degree in each biopsied specimen were interpreted by one uropathologist with 20 years of experience. The association between HI and cancer diagnosis was statistically assessed, with p < 0.05 considered significant, and the cancer and non-cancer groups were compared.
Results
Among the 522 patients with a median PSA levels of 6.5 ng/dL, including 258 (49.4%) whose cancer was diagnosed following repeat biopsy, the median degrees of HI in the initial and repeat biopsies were 25.0% and 41.7%, respectively. Furthermore, 211 (40.4%) and 247 (47.3%) patients had HI (> 0%) on biopsied specimens, respectively. Comparison of the cancer and noncancer groups revealed that a greater rate of HI specimens in the initial biopsy was associated with fewer prostate cancer diagnoses following repeat biopsy (p < 0.001). Other comparisons between the cancer and non-cancer groups showed that the cancer group had a significantly higher rate of hypertension, whereas those non-cancer group had a significantly higher rate of benign prostatic hyperplasia and prostatitis (p < 0.05).
Conclusion
A finding of a lesser degree of HI in the initial and a greater degree of HI in the repeat biopsied specimens was associated with the higher probability of cancer diagnosis in patients with high PSA levels.

Citations

Citations to this article as recorded by

Growth and differentiation factor 15 and NF‐κB expression in benign prostatic biopsies and risk of subsequent prostate cancer detection
Benjamin A. Rybicki, Sudha M. Sadasivan, Yalei Chen, Oleksandr Kravtsov, Watchareepohn Palangmonthip, Kanika Arora, Nilesh S. Gupta, Sean Williamson, Kevin Bobbitt, Dhananjay A. Chitale, Deliang Tang, Andrew G. Rundle, Kenneth A. Iczkowski
Cancer Medicine.2021; 10(9): 3013. CrossRef

6,076 View
144 Download
1 Web of Science
1 Crossref

Dose-Dense Rituximab-CHOP versus Standard Rituximab-CHOP in Newly Diagnosed Chinese Patients with Diffuse Large B-Cell Lymphoma: A Randomized, Multicenter, Open-Label Phase 3 Trial: Xueying Li, He Huang, Bing Xu, Hongqiang Guo, Yingcheng Lin, Sheng Ye, Jiqun Yi, Wenyu Li, Xiangyuan Wu, Wei Wang, Hongyu Zhan, Derong Xie, Jiewen Peng, Yabing Cao, Xingxiang Pu, Chengcheng Guo, Huangming Hong, Zhao Wang, Xiaojie Fang, Yong Zhou, Suxia Lin, Qing Liu, Tongyu Lin; Cancer Res Treat. 2019;51(3):919-932. Published online October 2, 2018; DOI: https://doi.org/10.4143/crt.2018.230

Abstract PDF PubReader ePub

Purpose
Rituximab with cyclophosphamide, doxorubicin, vincristine, and prednisone administered every 3 weeks (R-CHOP-21) is the standard care for diffuse large B-cell lymphoma (DLBCL). It is unknown whether the dose-dense R-CHOP (R-CHOP-14) could improve the outcome of the disease in Asian population.
Materials and Methods
Newly diagnosed DLBCL patients were centrally, randomly assigned (1:1) to receive R-CHOP- 14 or R-CHOP-21. R-CHOP-14 was administered every 2 weeks, and R-CHOP-21 was administered every 3 weeks. Primary end point was disease-free survival (DFS). Secondary end points included overall survival (OS), progression-free survival (PFS), response rate and toxicities.
Results
Seven hundred and two patients were randomly assigned to receive R-CHOP-14 (n=349) or R-CHOP-21 (n=353). With a median follow-up of 45.6 months, the two groups did not differ significantly in 3-year DFS (79.6% for R-CHOP-14 vs. 83.2% for R-CHOP-21, p=0.311), 3-year OS (77.5% for R-CHOP-14 vs. 77.6% for R-CHOP-21, p=0.903), or 3-year PFS (63.2% for R-CHOP-14 vs. 66.1% for R-CHOP-21, p=0.447). Patients with an International Prognostic Index (IPI) score ≥ 2 had a poorer prognosis compared to those with an IPI score < 2. Grade 3/4 hematologic and non-hematologic toxicities were manageable and similar between R-CHOP-14 and R-CHOP-21.
Conclusion
R-CHOP-14 did not improve the outcome of DLBCL compared to R-CHOP-21 in Asian population. With manageable and similar toxicities, both of the two regimens were suitable for Asian DLBCL patients. For high-risk patients with IPI ≥ 2, new combination regimens based on R-CHOP deserve further investigation to improve efficacy.

Citations

Citations to this article as recorded by

Prediction of 5‐year overall survival of diffuse large B‐cell lymphoma on the pola‐R‐CHP regimen based on 2‐year event‐free survival and progression‐free survival
Wan‐Ru Zhang, Xin Liu, Qiu‐Zi Zhong, Tao Wu, Yong Yang, Bo Chen, Hao Jing, Yuan Tang, Jing Jin, Yue‐Ping Liu, Yong‐Wen Song, Hui Fang, Ning‐Ning Lu, Ning Li, Yi‐Rui Zhai, Wen‐Wen Zhang, Shu‐Lian Wang, Fan Chen, Lin Yin, Shu‐Nan Qi, Ye‐Xiong Li
Cancer Medicine.2024;[Epub] CrossRef
Long-term outcomes with HLX01 (HanliKang®), a rituximab biosimilar, in previously untreated patients with diffuse large B-cell lymphoma: 5-year follow-up results of the phase 3 HLX01-NHL03 study
Yan Qin, Yongping Song, Dong Wang, Ou Bai, Jifeng Feng, Xiuhua Sun, Lihua Qiu, Jianmin Yang, Yu Yang, Zhao Wang, Jianda Hu, Huaqing Wang, Hang Su, Zhengming Jin, Wenbin Qian, Chuan Jin, Mingzhi Zhang, Ding Yu, Li Liu, Guoan Chen, Yarong Li, Tao Sun, Jie J
BMC Cancer.2024;[Epub] CrossRef
Palmitic acid reduces the methylation of the FOXO1 promoter to suppress the development of diffuse large B-cell lymphoma via modulating the miR-429/DNMT3A axis
Weiming LI, Ming GAO, Weili XUE, Xiaoli LI, Yu CHANG, Kaixin ZHANG, Chenyu WEN, Mingzhi ZHANG
Chinese Journal of Natural Medicines.2024; 22(6): 554. CrossRef
Prophylaxis forPneumocystis cariniipneumonia in non-Hodgkin’s lymphoma undergoing R-CHOP21 in China: a meta-analysis and cost-effectiveness analysis
Xiaojia Huang, Xiaoting Huang, Shen Lin, Shaohong Luo, Liangliang Dong, Dong Lin, Yaping Huang, Chen Xie, Dongni Nian, Xiongwei Xu, Xiuhua Weng
BMJ Open.2023; 13(3): e068943. CrossRef
Intensified First Cycle of Rituximab Plus Eight Cycles of Cyclophosphamide, Doxorubicin, Vincristine, and Prednisolone with Rituximab Chemotherapy for Advanced-Stage or Bulky Diffuse Large B-Cell Lymphoma: A Multicenter Phase II Consortium for Improving S
Yu Ri Kim, Jin Seok Kim, Won Seog Kim, Hyeon Seok Eom, Deok-Hwan Yang, Sung Hwa Bae, Hyo Jung Kim, Jae Hoon Lee, Suk-Joong Oh, Sung-Soo Yoon, Jae-Yong Kwak, Chul Won Choi, Min Kyoung Kim, Sung Young Oh, Hye Jin Kang, Seung Hyun Nam, Hyeok Shim, Joon Seong
Cancer Research and Treatment.2023; 55(4): 1355. CrossRef
Radiation and Dose-densification of R-CHOP in Aggressive B-cell Lymphoma With Intermediate Prognosis: The UNFOLDER Study
Lorenz Thurner, Marita Ziepert, Christian Berdel, Christian Schmidt, Peter Borchmann, Dominic Kaddu-Mulindwa, Andreas Viardot, Mathias Witzens-Harig, Judith Dierlamm, Mathias Haenel, Bernd Metzner, Gerald Wulf, Eva Lengfelder, Ulrich B. Keller, Norbert Fr
HemaSphere.2023; 7(7): e904. CrossRef
Treatment of Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma: A Literature Review and Meta-Analysis
Aleksander Sergeevich Luchinin
Clinical oncohematology.2022; 15(2): 130. CrossRef
The prognostic roles of hepatitis B virus antibody in diffuse large B-cell lymphoma patients
Shunfeng Hu, Na Chen, Kang Lu, Changqing Zhen, Xiaohui Sui, Xiaosheng Fang, Ying Li, Yingshu Luo, Xiangxiang Zhou, Xin Wang
Leukemia & Lymphoma.2021; 62(6): 1335. CrossRef
Primary diffuse large B-cell lymphoma of the fallopian tube treated with a combination of surgery and chemotherapy
Ye Zhou, Chao Zhang, Yingying Gong, Linqing Yang, Yunfei Wang
Medicine.2021; 100(3): e24049. CrossRef
Impact and Intricacies of Bone Marrow Microenvironment in B-cell Lymphomas: From Biology to Therapy
Anuvrat Sircar, Sayan Chowdhury, Amber Hart, William Bell, Satishkumar Singh, Lalit Sehgal, Narendranath Epperla
International Journal of Molecular Sciences.2020; 21(3): 904. CrossRef
Association of progression-free or event-free survival with overall survival in diffuse large B-cell lymphoma after immunochemotherapy: a systematic review
Jie Zhu, Yong Yang, Jin Tao, Shu-Lian Wang, Bo Chen, Jian-Rong Dai, Chen Hu, Shu-Nan Qi, Ye-Xiong Li
Leukemia.2020; 34(10): 2576. CrossRef
Front-Line Treatment of High Grade B Cell Non-Hodgkin Lymphoma
Murali Kesavan, Toby A. Eyre, Graham P. Collins
Current Hematologic Malignancy Reports.2019; 14(4): 207. CrossRef
Immunohistochemical Subtype and Parameters of International Prognostic Index in the New Prognostic Model of Diffuse Large B-Cell Lymphoma
Svetlana Valer'evna Samarina, A.S. Luchinin, N.V. Minaeva, I.V. Paramonov, D.A. D'yakonov, E.V. Vaneeva, V.A. Rosin, S.V. Gritsaev
Clinical oncohematology.2019; 12(4): 25. CrossRef

10,129 View
285 Download
12 Web of Science
13 Crossref

The Health Burden of Cancer Attributable to Obesity in Korea: A Population-Based Cohort Study: Joo Eun Lee, Chung Mo Nam, Sang Gyu Lee, Sohee Park, Tae Hyun Kim, Eun-Cheol Park; Cancer Res Treat. 2019;51(3):933-940. Published online October 4, 2018; DOI: https://doi.org/10.4143/crt.2018.301

Abstract PDF Supplementary Material PubReader ePub

Purpose
Considering the health impact of obesity and cancer, it is important to estimate the burden of cancer attributable to high body mass index (BMI). Therefore, the present study attempts to measure the health burden of cancer attributable to excess BMI, according to cancer sites.
Materials and Methods
The present study used nationwide medical check-up sample cohort data (2002-2015). The study subjects were 496,390 individuals (268,944 men and 227,446 women). We first calculated hazard ratio (HR) in order to evaluate the effect of excess BMI on cancer incidence and mortality. Then, the adjusted HR values and the prevalence of excess BMI were used to calculate the population attributable risk. This study also used the Global Burden of Disease method, to examine the health burden of obesity-related cancers attributable to obesity.
Results
The highest disability-adjusted life year (DALY) values attributable to overweight and obesity in men were shown in liver cancer, colorectal cancer, and gallbladder cancer. Among women, colorectal, ovarian, and breast (postmenopausal) cancers had the highest DALYs values attributable to overweight and obesity. Approximately 8.0% and 12.5% of cancer health burden (as measured by DALY values) among obesity-related cancers in men and women, respectively, can be prevented.
Conclusions
Obesity has added to the health burden of cancer. By measuring the proportion of cancer burden attributable to excess BMI, the current findings provide support for the importance of properly allocating healthcare resources and for developing cancer prevention strategies to reduce the future burden of cancer.

Citations

Citations to this article as recorded by

Population attributable fractions of modifiable cancer risk factors in Korea: A systematic review
Mi Ah Han, Seo‐Hee Kim, Eu Chang Hwang, Jae Hung Jung, Sun Mi Park
Asia-Pacific Journal of Clinical Oncology.2024; 20(2): 299. CrossRef
Obesity in the Asia-Pacific Region: Current Perspectives
David Tak Wai Lui, Junya Ako, Jamshed Dalal, Alan Fong, Masashi Fujino, Ari Horton, Rungroj Krittayaphong, Wael Almahmeed, Anne Thushara Matthias, Adam J Nelson, Stephen J Nicholls, Richard O’Brien, Kian Keong Poh, Khalida Soomro, Khung Keong Yeo, Kathryn
Journal of Asian Pacific Society of Cardiology.2024;[Epub] CrossRef
Cancers attributable to overweight and obesity in Italy
Matteo Di Maso, Claudio Pelucchi, Giulia Collatuzzo, Gianfranco Alicandro, Matteo Malvezzi, Fabio Parazzini, Eva Negri, Paolo Boffetta, Carlo La Vecchia, Federica Turati
Cancer Epidemiology.2023; 87: 102468. CrossRef
Dietary supplementation with Tolypocladium sinense mycelium prevents dyslipidemia inflammation in high fat diet mice by modulation of gut microbiota in mice
Xiaolong Wang, Lin Li, Mingjian Bai, Jiaxin Zhao, Xiaojie Sun, Yu Gao, Haitao Yu, Xia Chen, Chunjing Zhang
Frontiers in Immunology.2022;[Epub] CrossRef
Disease Burden and Attributable Risk Factors of Ovarian Cancer From 1990 to 2017: Findings From the Global Burden of Disease Study 2017
Zhangjian Zhou, Xuan Wang, Xueting Ren, Linghui Zhou, Nan Wang, Huafeng Kang
Frontiers in Public Health.2021;[Epub] CrossRef
Integrated traditional Chinese and Western medicine in hepatocellular carcinoma treatment
Kai-Feng Wang, Yi-Dan Chen, Li-Qin Mo, Zhen Zhang, Ya-Juan Liu, Jiang-Xiang Chen, Xin-Bing Sui, Tian Xie, Shi-Xiu Wu
World Chinese Journal of Digestology.2019; 27(7): 459. CrossRef
Diagnosis of Obesity and Related Biomarkers
Chang Seok Bang, Jung Hwan Oh
The Korean Journal of Medicine.2019; 94(5): 414. CrossRef

7,091 View
268 Download
4 Web of Science
7 Crossref

Clinical and Genetic Characteristics of BRCA1/2 Mutation in Korean Ovarian Cancer Patients: A Multicenter Study and Literature Review: Byung Su Kwon, Jung Mi Byun, Hyun Joo Lee, Dae Hoon Jeong, Tae Hwa Lee, Kyung-Hwa Shin, Dong Soo Suh, Ki Hyung Kim; Cancer Res Treat. 2019;51(3):941-950. Published online October 8, 2018; DOI: https://doi.org/10.4143/crt.2018.312

Abstract PDF Supplementary Material PubReader ePub

Purpose
We investigated the clinical relevance and spectrum of BRCA1/2 mutations in Korean ovarian cancer (KoOC) patients.
Materials and Methods
Two hundred seventy-nine KoOC patients were enrolled from three university hospitals between 2012 and 2017. Their peripheral blood samples were obtained for BRCA1/2 mutation analysis by direct sequencing. Clinicopathological characteristics were retrospectively reviewed, and spectrum analyses of BRCA1/2 mutation were assessed by systematic literature review.
Results
Frequency of BRCA1/2 mutations was 16.5% in KoOC patients. BRCA1/2 mutations were significantly associated with family history of breast/ovarian cancer (p<0.001), serous histology (p=0.044), and advanced International Federation of Gynecology and Obstetrics (FIGO) stage (III/IV, p=0.018) but not with early age-of-onset (age < 50, p=0.729). Literature review of BRCA1/2 mutations in KoOC patients found 111 (55 distinct) mutations with high proportion of Korean-specific mutations (24/55, 43.6%). Comparing the spectrum of BRCA1/2 mutation between KoOC and Korean breast cancer (KoBC) patients, the ratio of BRCA1-to-BRCA2 mutations was different, with BRCA1 (78.4%) being predominant in KoOC and BRCA2 in KoBC (59.2%). The most common mutation also differed between the two (c.3627insA of BRCA1 in KoOC and c.7480C>T of BRCA2 in KoBC).
Conclusion
The clinical relevance of BRCA1/2 mutations in KoOC patients was confirmed but that of early age-of-onset was not. Possible inconsistency in the ratio of BRCA1-to-BRCA2 mutations and the most common mutation between KoOC and KoBC may probably suggest presence of mutation sequence-associated penetrance tendency in hereditary Korean breast and ovarian cancer. These data may provide insights for optimal genetic counseling and prophylactic treatment for at-risk relatives of KoOC patients.

Citations

Citations to this article as recorded by

Exploring the effect of BRCA1/2 status on chemotherapy-induced hematologic toxicity in patients with ovarian cancer
In Hee Lee, Soo Jung Lee, Juhyung Kim, Yoon Hee Lee, Gun Oh Chong, Jong Mi Kim, Juhun Lee, Nan Young Lee, Seo Young Park, Dea Gy Hong, Yee Soo Chae
Cancer Chemotherapy and Pharmacology.2024; 94(1): 103. CrossRef
Utility of Next-Generation Sequencing Panel Including Hereditary Breast and Ovarian Cancer-Related Genes for Pathogenic Variant Detection
Jae Hee Lee, Do-Hoon Kim
Keimyung Medical Journal.2024; 43(1): 44. CrossRef
Basic knowledge for counseling patients undergoing risk-reducing salpingo-oophorectomy
Jihye Kim, Chel Hun Choi
Obstetrics & Gynecology Science.2024; 67(4): 343. CrossRef
Prevalence of BRCA1 and BRCA2 mutations in ovarian cancer patients from Yunnan Province in southwest China
Yongmei Peng, Jiaqian Liao, Xian He, Yongchun Zhou, Lei Zhang, Yue Jia, Hongying Yang
European Journal of Cancer Prevention.2024;[Epub] CrossRef
Validation of multi-gene panel next-generation sequencing for the detection of BRCA mutation in formalin-fixed, paraffin-embedded epithelial ovarian cancer tissues
Eun Taeg Kim, Ha Eun Jeong, Hyung Joon Yoon, Ki Hyung Kim, Dong Soo Suh
Taiwanese Journal of Obstetrics and Gynecology.2023; 62(1): 66. CrossRef
Using species richness calculations to model the global profile of unsampled pathogenic variants: Examples from BRCA1 and BRCA2
Nandana D. Rao, Brian H. Shirts, Alvaro Galli
PLOS ONE.2023; 18(2): e0278010. CrossRef
Mutational Analysis of BRCA1 and BRCA2 Genes in Breast Cancer Patients from Eastern Sicily
Stefania Stella, Silvia Rita Vitale, Federica Martorana, Michele Massimino, Giuliana Pavone, Katia Lanzafame, Sebastiano Bianca, Chiara Barone, Cristina Gorgone, Marco Fichera, Livia Manzella
Cancer Management and Research.2022; Volume 14: 1341. CrossRef
How to start niraparib in real-world Asian ovarian cancer patients?
Sook-Hee Hong
Journal of Gynecologic Oncology.2021;[Epub] CrossRef
Identification of BRCA1:c.5470_5477del as a Founder Mutation in Chinese Ovarian Cancer Patients
Jun Li, Sile Han, Cuiyun Zhang, Yanlin Luo, Li Wang, Ping Wang, Yi Wang, Qingxin Xia, Xiaoyan Wang, Bing Wei, Jie Ma, Hongle Li, Yongjun Guo
Frontiers in Oncology.2021;[Epub] CrossRef
Prevalence and clinical characterization of BRCA1 and BRCA2 mutations in Korean patients with epithelial ovarian cancer
E Sun Paik, Eun Jin Heo, Chel Hun Choi, Jae‐Hoon Kim, Jae‐Weon Kim, Yong‐Man Kim, Sang‐Yoon Park, Jeong‐Won Lee, Jong‐Won Kim, Byoung‐Gie Kim
Cancer Science.2021; 112(12): 5055. CrossRef
Impact of proactive high-throughput functional assay data on BRCA1 variant interpretation in 3684 patients with breast or ovarian cancer
Hyun-Ki Kim, Eun Jin Lee, Young-Jae Lee, Jisun Kim, Yongsub Kim, Kyunggon Kim, Shin-Wha Lee, Suhwan Chang, Young Joo Lee, Jong Won Lee, Woochang Lee, Sail Chun, Byung Ho Son, Kyung Hae Jung, Yong-Man Kim, Won-Ki Min, Sei-Hyun Ahn
Journal of Human Genetics.2020; 65(3): 209. CrossRef
Clinical and histopathologic analysis of gynecological cancer: a single institute experience over 7 years
Soo-Young Lee, Eunbyeol Kim, Hyo-Shin Kim, Yu-Jin Koo, Dae-Hyung Lee
Yeungnam University Journal of Medicine.2020; 37(3): 179. CrossRef

10,493 View
349 Download
11 Web of Science
12 Crossref

Acquired Resistance of MET-Amplified Non-small Cell Lung Cancer Cells to the MET Inhibitor Capmatinib: Seulki Kim, Tae Min Kim, Dong-Wan Kim, Soyeon Kim, Miso Kim, Yong-Oon Ahn, Bhumsuk Keam, Dae Seog Heo; Cancer Res Treat. 2019;51(3):951-962. Published online October 10, 2018; DOI: https://doi.org/10.4143/crt.2018.052

Abstract PDF Supplementary Material PubReader ePub

Purpose
Amplified mesenchymal-epithelial transition factor, MET, is a receptor tyrosine kinase (RTK) that has been considered a druggable target in non-small cell lung cancer (NSCLC). Although multiple MET tyrosine kinase inhibitors (TKIs) are being actively developed for MET-driven NSCLC, the mechanisms of acquired resistance to MET-TKIs have not been well elucidated. To understand the mechanisms of resistance and establish therapeutic strategies, we developed an in vitro model using the MET-amplified NSCLC cell line EBC-1.
Materials and Methods
We established capmatinib-resistant NSCLC cell lines and identified alternative signaling pathways using 3′ mRNA sequencing and human phospho-RTK arrays. Copy number alterations were evaluated by quantitative polymerase chain reaction and cell proliferation assay; activation of RTKs and downstream effectors were compared between the parental cell line EBC-1 and the resistant cell lines.
Results
We found that EBC-CR1 showed an epidermal growth factor receptor (EGFR)‒dependent growth and sensitivity to afatinib, an irreversible EGFR TKI. EBC-CR2 cells that had overexpression of EGFR-MET heterodimer dramatically responded to combined capmatinib with afatinib. In addition, EBC-CR3 cells derived from EBC-CR1 cells that activated EGFR with amplified phosphoinositide-3 kinase catalytic subunit α (PIK3CA) were sensitive to combined afatinib with BYL719, a phosphoinositide 3-kinase α (PI3Kα) inhibitor.
Conclusion
Our in vitro studies suggested that activation of EGFR signaling and/or genetic alteration of downstream effectors like PIK3CA were alternative resistance mechanisms used by capmatinib-resistant NSCLC cell lines. In addition, combined treatments with MET, EGFR, and PI3Kα inhibitors may be effective therapeutic strategies in capmatinib-resistant NSCLC patients.

Citations

Citations to this article as recorded by

Immunohistochemical characteristics and potential therapeutic regimens of hepatoid adenocarcinoma of the stomach: a study of 139 cases
Xuesong Yang, Yan Wu, Anqiang Wang, Xiuli Ma, Kai Zhou, Ke Ji, Xin Ji, Ji Zhang, Xiaojiang Wu, ZhongWu Li, Zhaode Bu
The Journal of Pathology: Clinical Research.2024;[Epub] CrossRef
My battle with cancer. Part 1
Mikhail V. Blagosklonny
Oncoscience.2024; 11: 1. CrossRef
SOS2 modulates the threshold of EGFR signaling to regulate osimertinib efficacy and resistance in lung adenocarcinoma
Patricia L. Theard, Amanda J. Linke, Nancy E. Sealover, Brianna R. Daley, Johnny Yang, Katherine Cox, Robert L. Kortum
Molecular Oncology.2024; 18(3): 641. CrossRef
Synthetic approaches and application of representative clinically approved fluorine-enriched anti-cancer medications
He-Nan Liu, Ying Zhu, Yuan Chi, Fei-Fei Sun, Li-Shen Shan, Ya-Tao Wang, Bing Dai
European Journal of Medicinal Chemistry.2024; 276: 116722. CrossRef
Multifunctional dendrimer-peptide conjugates for MET receptor-specific imaging of cancer cells
Jin Woong Lee, Kwangok P. Nickel, Rachel L. Minne, Justin J. Jeffery, Eduardo Aluicio-Sarduy, Carter Kim, DaWon Kim, Piper A. Rawding, Michael J. Poellmann, Narsimha Mamidi, Jonathan W. Engle, Jung Heon Lee, Hansoo Park, Reinier Hernandez, Randall J. Kimp
Nano Today.2024; 59: 102509. CrossRef
Non-small cell lung carcinoma (NSCLC): Implications on molecular pathology and advances in early diagnostics and therapeutics
Hafiza Padinharayil, Jinsu Varghese, Mithun Chacko John, Golgodu Krishnamurthy Rajanikant, Cornelia M. Wilson, Minnatallah Al-Yozbaki, Kaviyarasi Renu, Saikat Dewanjee, Rupa Sanyal, Abhijit Dey, Anirban Goutam Mukherjee, Uddesh Ramesh Wanjari, Abilash Val
Genes & Diseases.2023; 10(3): 960. CrossRef
Synergistic therapeutic potential of alpelisib in cancers (excluding breast cancer): Preclinical and clinical evidences
Yuhao Ye, Zhiyu Huang, Maoqing Zhang, Jiayue Li, Yiqiong Zhang, Chenghua Lou
Biomedicine & Pharmacotherapy.2023; 159: 114183. CrossRef
Quinolines: Privileged Scaffolds for Developing New Anti‐neurodegenerative Agents
M.Sc.Shivani Chauhan, Tarana Umar, Manpreet K. Aulakh
ChemistrySelect.2023;[Epub] CrossRef
A multiparametric fluorescent visualization approach for detecting drug resistance in living cancer cells
Zhilan Zhou, Ya Wang, Zhengtao Shao, Guixi Zhang, Hang Jiang, Yiyuan Tang, Zening Huang, Yingdi Zhu, Juan Li
Talanta.2023; 259: 124564. CrossRef
Targeting MET: Discovery of Small Molecule Inhibitors as Non-Small Cell Lung Cancer Therapy
Chaofan Wang, Xiaoyun Lu
Journal of Medicinal Chemistry.2023; 66(12): 7670. CrossRef
Current Indications and Future Landscape of Bispecific Antibodies for the Treatment of Lung Cancer
Hugo Arasanz, Luisa Chocarro, Leticia Fernández-Rubio, Ester Blanco, Ana Bocanegra, Miriam Echaide, Ibone Labiano, Ana Elsa Huerta, Maria Alsina, Ruth Vera, David Escors, Grazyna Kochan
International Journal of Molecular Sciences.2023; 24(12): 9855. CrossRef
An Observatory for the MET Oncogene: A Guide for Targeted Therapies
Dogus M. Altintas, Paolo M. Comoglio
Cancers.2023; 15(18): 4672. CrossRef
Advances of clinically approved small-molecule drugs for the treatment of non-small cell lung cancer
Zhen-Xi Niu, Ya-Tao Wang, Nan Lu, Jin-Feng Sun, Peng Nie, Piet Herdewijn
European Journal of Medicinal Chemistry.2023; 261: 115868. CrossRef
Epigenetic regulation in lung cancer
Shahin Ramazi, Maedeh Dadzadi, Zahra Sahafnejad, Abdollah Allahverdi
MedComm.2023;[Epub] CrossRef
SOS1 and KSR1 modulate MEK inhibitor responsiveness to target resistant cell populations based on PI3K and KRAS mutation status
Brianna R. Daley, Heidi M. Vieira, Chaitra Rao, Jacob M. Hughes, Zaria M. Beckley, Dianna H. Huisman, Deepan Chatterjee, Nancy E. Sealover, Katherine Cox, James W. Askew, Robert A. Svoboda, Kurt W. Fisher, Robert E. Lewis, Robert L. Kortum
Proceedings of the National Academy of Sciences.2023;[Epub] CrossRef
KRAS and MET in non-small-cell lung cancer: two of the new kids on the ‘drivers’ block
Juan Esteban Garcia-Robledo, Rafael Rosell, Alejandro Ruíz-Patiño, Carolina Sotelo, Oscar Arrieta, Lucia Zatarain-Barrón, Camila Ordoñez, Elvira Jaller, Leonardo Rojas, Alessandro Russo, Diego de Miguel-Pérez, Christian Rolfo, Andrés F. Cardona
Therapeutic Advances in Respiratory Disease.2022;[Epub] CrossRef
MET Exon 14 Splice-Site Mutations Preferentially Activate KRAS Signaling to Drive Tumourigenesis
Daniel Lu, Amy Nagelberg, Justine LM Chow, Yankuan T Chen, Quentin Michalchuk, Romel Somwar, William W. Lockwood
Cancers.2022; 14(6): 1378. CrossRef
hOA-DN30: a highly effective humanized single-arm MET antibody inducing remission of ‘MET-addicted’ cancers
Ilaria Martinelli, Chiara Modica, Cristina Chiriaco, Cristina Basilico, James M. Hughes, Simona Corso, Silvia Giordano, Paolo M. Comoglio, Elisa Vigna
Journal of Experimental & Clinical Cancer Research.2022;[Epub] CrossRef
PIK3CAMutations Drive Therapeutic Resistance in Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer
Aryana R. Rasti, Amy Guimaraes-Young, Farrah Datko, Virginia F. Borges, Dara L. Aisner, Elena Shagisultanova
JCO Precision Oncology.2022;[Epub] CrossRef
Protein tyrosine kinase inhibitor resistance in malignant tumors: molecular mechanisms and future perspective
Yang Yang, Shuo Li, Yujiao Wang, Yi Zhao, Qiu Li
Signal Transduction and Targeted Therapy.2022;[Epub] CrossRef
MET Signaling Pathways, Resistance Mechanisms, and Opportunities for Target Therapies
Solange Rivas, Arnaldo Marín, Suraj Samtani, Evelin González-Feliú, Ricardo Armisén
International Journal of Molecular Sciences.2022; 23(22): 13898. CrossRef
Advances in the Lung Cancer Immunotherapy Approaches
Hafiza Padinharayil, Reema Rose Alappat, Liji Maria Joy, Kavya V. Anilkumar, Cornelia M. Wilson, Alex George, Abilash Valsala Gopalakrishnan, Harishkumar Madhyastha, Thiyagarajan Ramesh, Ezhaveni Sathiyamoorthi, Jintae Lee, Raja Ganesan
Vaccines.2022; 10(11): 1963. CrossRef
A comprehensive review on the biological interest of quinoline and its derivatives
Basavarajaiah Suliphuldevara Matada, Raviraj Pattanashettar, Nagesh Gunavanthrao Yernale
Bioorganic & Medicinal Chemistry.2021; 32: 115973. CrossRef
Combination of HGF/MET-targeting agents and other therapeutic strategies in cancer
Fatemeh Moosavi, Elisa Giovannetti, Godefridus J. Peters, Omidreza Firuzi
Critical Reviews in Oncology/Hematology.2021; 160: 103234. CrossRef
Novel Therapies for Metastatic Non-Small Cell Lung Cancer with MET Exon 14 Alterations: A Spotlight on Capmatinib
Aaron Tan, Tracy J Loh, Xue Lin Kwang, Gek San Tan, Kiat Hon Lim, Daniel SW Tan
Lung Cancer: Targets and Therapy.2021; Volume 12: 11. CrossRef
Discovery of Potent, Selective Triazolothiadiazole-Containing c-Met Inhibitors
Qing Tang, Alex M. Aronov, David D. Deininger, Simon Giroux, David J. Lauffer, Pan Li, Jianglin Liang, Kira McGinty, Steven Ronkin, Rebecca Swett, Nathan Waal, Diane Boucher, Pamella J. Ford, Cameron S. Moody
ACS Medicinal Chemistry Letters.2021; 12(6): 955. CrossRef
Tyrosine Kinase Inhibitors, Antibody-Drug Conjugates, and Proteolysis-Targeting Chimeras: The Pharmacology of Cutting-Edge Lung Cancer Therapies
Jennifer W. Carlisle, R. Donald Harvey
American Society of Clinical Oncology Educational Book.2021; (41): e286. CrossRef
Response to crizotinib in a patient with MET‐amplified hepatocellular carcinoma
Qinglian Chen, Chunfeng Xie, Kunliang Feng, Haijun Huang, Chengming Xiong, Tengjiao Lin, Wenjing Wang, Mian Xu, Xianwei Yang, Chong Zhong
Hepatology Research.2021; 51(11): 1164. CrossRef
New FDA oncology small molecule drugs approvals in 2020: Mechanism of action and clinical applications
Thais Cristina Mendonça Nogueira, Marcus Vinicius Nora de Souza
Bioorganic & Medicinal Chemistry.2021; 46: 116340. CrossRef
Genetic evolution to tyrosine kinase inhibitory therapy in patients with EGFR-mutated non-small-cell lung cancer
Alex Martinez-Marti, Enriqueta Felip, Francesco Mattia Mancuso, Ginevra Caratú, Judit Matito, Paolo Nuciforo, Irene Sansano, Nely Diaz-Mejia, Susana Cedrés, Ana Callejo, Patricia Iranzo, Nuria Pardo, Josep Maria Miquel, Alejandro Navarro, Ana Vivancos, Mi
British Journal of Cancer.2021; 125(11): 1561. CrossRef
A Biparatopic Antibody–Drug Conjugate to Treat MET-Expressing Cancers, Including Those that Are Unresponsive to MET Pathway Blockade
John O. DaSilva, Katie Yang, Oliver Surriga, Thomas Nittoli, Arthur Kunz, Matthew C. Franklin, Frank J. Delfino, Shu Mao, Feng Zhao, Jason T. Giurleo, Marcus P. Kelly, Sosina Makonnen, Carlos Hickey, Pamela Krueger, Randi Foster, Zhaoyuan Chen, Marc W. Re
Molecular Cancer Therapeutics.2021; 20(10): 1966. CrossRef
Development and full validation of an LC–MS/MS methodology to quantify capmatinib (INC280) following intragastric administration to rats
Xiaoguang Fan, Guanghu Yang, Wenjuan Cui, Qin Liu, Zhaolong Zhang, Zhikun Zhang
Biomedical Chromatography.2020;[Epub] CrossRef
A Randomized-Controlled Phase 2 Study of the MET Antibody Emibetuzumab in Combination with Erlotinib as First-Line Treatment for EGFR Mutation–Positive NSCLC Patients
Giorgio Scagliotti, Denis Moro-Sibilot, Jens Kollmeier, Adolfo Favaretto, Eun Kyung Cho, Heidrun Grosch, Martin Kimmich, Nicolas Girard, Chun-Ming Tsai, Te-Chun Hsia, Matteo Brighenti, Christian Schumann, Xuejing Aimee Wang, Sameera R. Wijayawardana, Aaro
Journal of Thoracic Oncology.2020; 15(1): 80. CrossRef
Targeted Therapy and Checkpoint Immunotherapy in Lung Cancer
Roberto Ruiz-Cordero, Walter Patrick Devine
Surgical Pathology Clinics.2020; 13(1): 17. CrossRef
Meta-analysis of functional expression and mutational analysis of c-Met in various cancers
Murugesan Sivakumar, Murugesan Jayakumar, Palaniappan Seedevi, Palaniappan Sivasankar, Muthu Ravikumar, Sundharaiyya Surendar, Tamilselvi Murugan, Shahid S. Siddiqui, Sivakumar Loganathan
Current Problems in Cancer.2020; 44(4): 100515. CrossRef
Targeting the HGF/MET Axis in Cancer Therapy: Challenges in Resistance and Opportunities for Improvement
Xing Huang, Enliang Li, Hang Shen, Xun Wang, Tianyu Tang, Xiaozhen Zhang, Jian Xu, Zengwei Tang, Chengxiang Guo, Xueli Bai, Tingbo Liang
Frontiers in Cell and Developmental Biology.2020;[Epub] CrossRef
Statins use and its impact in EGFR‐TKIs resistance to prolong the survival of lung cancer patients: A Cancer registry cohort study in Taiwan
Phung‐Anh Nguyen, Chih‐Cheng Chang, Cooper J. Galvin, Yao‐Chin Wang, Soo Yeon An, Chih‐Wei Huang, Yu‐Hsiang Wang, Min‐Huei Hsu, Yu‐Chuan (Jack) Li, Hsuan‐Chia Yang
Cancer Science.2020; 111(8): 2965. CrossRef
A Single-Step, High-Dose Selection Scheme Reveals Distinct Mechanisms of Acquired Resistance to Oncogenic Kinase Inhibition in Cancer Cells
Kenneth J. Finn, Scott E. Martin, Jeff Settleman
Cancer Research.2020; 80(1): 79. CrossRef
Emerging therapies for non-small cell lung cancer
Chao Zhang, Natasha B. Leighl, Yi-Long Wu, Wen-Zhao Zhong
Journal of Hematology & Oncology.2019;[Epub] CrossRef
Capmatinib for the treatment of non-small cell lung cancer
Johan Filip Vansteenkiste, Charlotte Van De Kerkhove, Els Wauters, Pierre Van Mol
Expert Review of Anticancer Therapy.2019; 19(8): 659. CrossRef
Afatinib Overcomes Pemetrexed-Acquired Resistance in Non-Small Cell Lung Cancer Cells Harboring an EML4-ALK Rearrangement
Ji-Hyun Kwon, Kui-Jin Kim, Ji Hea Sung, Koung Jin Suh, Ji Yun Lee, Ji-Won Kim, Se Hyun Kim, Jeong-Ok Lee, Jin Won Kim, Yu Jung Kim, Keun-Wook Lee, Jee Hyun Kim, Soo-Mee Bang, Soyeon Kim, Sung-Soo Yoon, Jong Seok Lee
Cells.2019; 8(12): 1538. CrossRef
DYRK1A inhibition suppresses STAT3/EGFR/Met signalling and sensitizes EGFR wild‐type NSCLC cells to AZD9291
Yang‐ling Li, Ke Ding, Xiu Hu, Lin‐wen Wu, Dong‐mei Zhou, Ming‐jun Rao, Neng‐ming Lin, Chong Zhang
Journal of Cellular and Molecular Medicine.2019; 23(11): 7427. CrossRef
MiR-1246 Promotes Metastasis and Invasion of A549 cells by Targeting GSK-3β‒Mediated Wnt/β-Catenin Pathway
Fan Yang, Hairong Xiong, Li Duan, Qian Li, Xin Li, Yongqin Zhou
Cancer Research and Treatment.2019; 51(4): 1420. CrossRef

12,220 View
568 Download
44 Web of Science
43 Crossref

Laparoscopy versus Open Nephroureterectomy in Prognostic Outcome of Patients with Advanced Upper Tract Urothelial Cancer: A Retrospective, Multicenter, Propensity-Score Matching Analysis: Sung Han Kim, Mi Kyung Song, Jung Kwon Kim, Bumsik Hong, Seok Ho Kang, Ja Hyeon Ku, Byong Chang Jeong, Ho Kyung Seo, On behalf of Urothelial Cancer-Advanced Research and Treatment (UCART) Study Group; Cancer Res Treat. 2019;51(3):963-972. Published online October 12, 2018; DOI: https://doi.org/10.4143/crt.2018.465

Abstract PDF Supplementary Material PubReader ePub

Purpose
The purpose of this study was to compare oncologic outcomes between open nephroureterectomy (ONU) and laparoscopic nephroureterectomy (LNU) in patients with upper tract urothelial carcinoma.
Materials and Methods
The medical records of consecutive ONU and LNU cases from five tertiary institutions were retrospectively analyzed between 2000 and 2012. The propensity-score matching methodology was used to compare the two surgical approaches in terms of age, body mass index, American Society of Anesthesiologists score, tumor location, grade, pathologic T and N categories, the presence of lymphovascular invasion, and follow-up duration. The Kaplan-Meier with log-rank tests and clustered Cox regression were used to compare the estimated rates of survival for each surgical approach and to investigate the effect of the surgical approach on each prognostic outcome.
Results
Six hundred thirty-eight propensity-score matching pairs (n=1,276) were compared; LNU was significantly better than ONU in all types of survival, including intravesical recurrencefree survival (IVRFS), disease-free survival, overall survival (OS), and cancer-specific survival (CSS) (p < 0.05). The 3-year OS and CSS rates were significantly higher with LNU than with ONU (p < 0.05). Compared with ONU, LNU had significantly better 3-year OS and CSS rates (82.9% and 86.2% vs. 78.3% and 81.8%); there were no differences at 5 years. In subgroup analysis of the early-staged group, advanced-stage group, lymph node–positive group, and lymph node–negative group, the two approaches did not significantly affect prognostic outcomes, except LNU improved the IVRFS in the lymph node–negative or no history of previous bladder cancer group.
Conclusion
LNU had a significantly better prognostic outcome than ONU after propensity-score matching.

Citations

Citations to this article as recorded by

Laparoscopic Versus Open Nephroureterectomy for Upper Tract Urothelial Carcinoma: A Systematic Review and Meta-Analysis of Propensity-Score Matched Studies
Shidong Deng, Lingzhi Liu, Yurou Wang, Chuan Zhou, Huihui Zhang
Surgical Innovation.2024; 31(5): 520. CrossRef
Differential effect of surgical technique on intravesical recurrence after radical nephroureterectomy in patients with upper tract urothelial cancer: a systematic review and Meta-analysis
Ichiro Tsuboi, Akihiro Matsukawa, Mehdi Kardoust Parizi, Jakob Klemm, Robert J Schulz, Anna Cadenar, Stefano Mancon, Sever Chiujdea, Tamás Fazekas, Marcin Miszczyk, Ekaterina Laukhtina, Tatsushi Kawada, Satoshi Katayama, Takehiro Iwata, Kensuke Bekku, Koi
World Journal of Urology.2024;[Epub] CrossRef
Comparing Oncological and Perioperative Outcomes of Open versus Laparoscopic versus Robotic Radical Nephroureterectomy for the Treatment of Upper Tract Urothelial Carcinoma: A Multicenter, Multinational, Propensity Score-Matched Analysis
Nico C. Grossmann, Francesco Soria, Tristan Juvet, Aaron M. Potretzke, Hooman Djaladat, Alireza Ghoreifi, Eiji Kikuchi, Andrea Mari, Zine-Eddine Khene, Kazutoshi Fujita, Jay D. Raman, Alberto Breda, Matteo Fontana, John P. Sfakianos, John L. Pfail, Ekater
Cancers.2023; 15(5): 1409. CrossRef
Factors Predicting Oncological Outcomes of Radical Nephroureterectomy for Upper Tract Urothelial Carcinoma in Taiwan
I-Hsuan Alan Chen, Chao-Hsiang Chang, Chi-Ping Huang, Wen-Jeng Wu, Ching-Chia Li, Chung-Hsin Chen, Chao-Yuan Huang, Chi-Wen Lo, Chih-Chin Yu, Chung-You Tsai, Wei-Che Wu, Jen-Shu Tseng, Wun-Rong Lin, Yuan-Hong Jiang, Yu-Khun Lee, Yeong-Chin Jou, Ian-Seng C
Frontiers in Oncology.2022;[Epub] CrossRef
Robotic Radical Nephroureterectomy with Bladder Cuff Excision for Upper Tract Urothelial Carcinoma: A Trend Analysis of Utilization and a Comparative Study
Hoyoung Bae, Jae Hoon Chung, Wan Song, Minyong Kang, Hwang Gyun Jeon, Byong Chang Jeong, Seong Il Seo, Seong Soo Jeon, Hyun Moo Lee, Hyun Hwan Sung
Cancers.2022; 14(10): 2497. CrossRef
Oncological outcomes of laparoscopic versus open nephroureterectomy for the treatment of upper tract urothelial carcinoma: an updated meta-analysis
Radosław Piszczek, Łukasz Nowak, Wojciech Krajewski, Joanna Chorbińska, Sławomir Poletajew, Marco Moschini, Krzysztof Kaliszewski, Romuald Zdrojowy
World Journal of Surgical Oncology.2021;[Epub] CrossRef
Laparoscopic compared with open nephroureterectomy in upper urinary tract urothelial carcinoma: A systemic review and a meta‐analysis
Guihong Liu, Zeqin Yao, Guoqiang Chen, Yalang Li, Bing Liang
International Journal of Clinical Practice.2021;[Epub] CrossRef
RETRACTED: Open Nephroureterectomy Compared to Laparoscopic in Upper Urinary Tract Urothelial Carcinoma: A Meta-Analysis
Guihong Liu, Zeqin Yao, Guoqiang Chen, Yalang Li, Bing Liang
Frontiers in Surgery.2021;[Epub] CrossRef
A retrospective multicenter comparison of conditional cancer-specific survival between laparoscopic and open radical nephroureterectomy in locally advanced upper tract urothelial carcinoma
Sung Han Kim, Mi Kyung Song, Ja Hyeon Ku, Seok Ho Kang, Byong Chang Jeong, Bumsik Hong, Ho Kyung Seo, Isaac Yi Kim
PLOS ONE.2021; 16(10): e0255965. CrossRef
Risk factor analysis of intravesical recurrence after retroperitoneoscopic nephroureterectomy for upper tract urothelial carcinoma
Masato Yanagi, Tsutomu Hamasaki, Jun Akatsuka, Yuki Endo, Hayato Takeda, Yukihiro Kondo
BMC Urology.2021;[Epub] CrossRef
Diagnosis, management, and follow-up of upper tract urothelial carcinoma: an interdisciplinary collaboration between urology and radiology
Jacob L. Roberts, Fady Ghali, Lejla Aganovic, Seth Bechis, Kelly Healy, Gerant Rivera-Sanfeliz, Riccardo Autorino, Ithaar Derweesh
Abdominal Radiology.2019; 44(12): 3893. CrossRef
Prognostic Value of Lymphovascular Invasion in Upper Urinary Tract Urothelial Carcinoma after Radical Nephroureterectomy: A Systematic Review and Meta-Analysis
Wen Liu, Lijiang Sun, Fengju Guan, Fangming Wang, Guiming Zhang
Disease Markers.2019; 2019: 1. CrossRef

7,518 View
174 Download
12 Web of Science
12 Crossref

Improved Survival of Cancer Patients Admitted to the Intensive Care Unit between 2002 and 2011 at a U.S. Teaching Hospital: Christopher Martin Sauer, Jinghui Dong, Leo Anthony Celi, Daniele Ramazzotti; Cancer Res Treat. 2019;51(3):973-981. Published online October 10, 2018; DOI: https://doi.org/10.4143/crt.2018.360

Abstract PDF Supplementary Material PubReader ePub

Purpose
Cancer patients are at increased risk of treatment- or disease-related admission to the intensive care unit. Over the past decades, both critical care and cancer care have improved substantially. Due to increased cancer-specific survival, we hypothesized that the number of cancer patients admitted to the intensive care unit (ICU) and survival have increased.
Materials and Methods
MIMIC-III was used to study trends and outcomes of cancer patients admitted to the ICU between 2002 and 2011. Multiple logistic regression analysis was performed to adjust for confounders of mortality.
Results
Among 41,468 patients analyzed, 1,083 were hemato-oncologic, 4,330 were oncologic and 66 patients had both a hematological and solid malignancy. Admission numbers more than doubled and the proportion of cancer patients in the ICU increased steadily from 2002 to 2011. In both the univariate and multivariate analyses, solid cancers and hematologic cancers were strongly associated with 28-day mortality. This association was even stronger for 1-year mortality, with odds ratios of 4.02 (95% confidence interval [CI], 3.69 to 4.38) and 2.25 (95% CI, 1.93 to 2.62), respectively. Over the 10-year study period, both 28-day and 1-year mortality decreased, with hematologic patients showing the strongest annual adjusted decrease in the odds of death. There was considerable heterogeneity among solid cancer types.
Conclusion
Between 2002 and 2011, the number of cancer patients admitted to the ICU more than doubled, while clinical severity scores remained overall unchanged, suggesting improved treatment. Although cancer patients had higher mortality rates, both 28-day and 1-year mortality of hematologic patients decreased faster than that of non-cancer patients, while mortality rates of cancer patients strongly depended on cancer type.

Citations

Citations to this article as recorded by

Characterisation and Outcomes of Patients with Solid Organ Malignancies Admitted to the Intensive Care Unit: Mortality and Impact on Functional Status and Oncological Treatment
Marta García de Herreros, Juan Carlos Laguna, Joan Padrosa, Tanny Daniela Barreto, Manoli Chicote, Carme Font, Ignacio Grafiá, Lucía Llavata, Elia Seguí, Albert Tuca, Margarita Viladot, Carles Zamora-Martínez, Sara Fernández-Méndez, Adrián Téllez, Josep M
Diagnostics.2024; 14(7): 730. CrossRef
Decreased Long-Term Survival of Patients With Newly Diagnosed Cancer Discharged Home After Unplanned ICU Admission: A Prospective Observational Study
Ana Paula Agnolon Praça, Antônio Paulo Nassar Junior, Alexandre Miras Ferreira, Pedro Caruso
Critical Care Explorations.2024; 6(8): e1136. CrossRef
Diferenças na importância relativa dos preditores de mortalidade em curto e longo prazo de pacientes críticos com câncer
Carla Marchini Dias da Silva, Bárbara Beltrame Bettim, Bruno Adler Maccagnan Pinheiro Besen, Antônio Paulo Nassar Junior
Critical Care Science.2024;[Epub] CrossRef
Differences in the relative importance of predictors of short- and long-term mortality among critically ill patients with cancer
Carla Marchini Dias da Silva, Bárbara Beltrame Bettim, Bruno Adler Maccagnan Pinheiro Besen, Antônio Paulo Nassar Junior
Critical Care Science.2024;[Epub] CrossRef
Characteristics and clinical outcomes of patients with lung cancer requiring ICU admission: a retrospective analysis based on the MIMIC-III database
Jie Qian, Ruoyan Qin, Liang Hong, Yangyang Shi, Haibin Yuan, Bo Zhang, Wei Nie, Yanwen Li, Baohui Han
Emergency Cancer Care.2023;[Epub] CrossRef
Mortality Prediction of Various Cancer Patients via Relevant Feature Analysis and Machine Learning
Caner Bozkurt, Tunç Aşuroğlu
SN Computer Science.2023;[Epub] CrossRef
Hyperlactatemia is associated with increased risks of long-term mortality and major adverse cardiovascular events in sepsis survivors
Shu-Yu Ou, Yi-Jung Lee, Yu-Mei Chou, Gwo-Ching Sun, Yuan-Yi Chia
Infectious Diseases.2023; 55(8): 576. CrossRef
Outcome prediction for critical care patients with respiratory neoplasms using a multilayer perceptron neural network
Beatriz Nistal-Nuño
einstein (São Paulo).2023;[Epub] CrossRef
Prognostic factors in oncological patients with solid tumours requiring intensive care unit admission
Raquel Bosch‑Compte, Laura Visa, Alejandro Rios, Xavier Duran, Maria Fernández‑Real, Gemma Gomariz‑Vilaldach, Joan Masclans
Oncology Letters.2023;[Epub] CrossRef
Mortality Rate, Demographics, and Clinical Attributes of Patients Dying in the Intensive Care Unit of a Comprehensive Cancer Center in Jordan: A Descriptive Study
Issa M. Almansour, Amer A. Hasanien, Zyad T. Saleh
OMEGA - Journal of Death and Dying.2022; 84(4): 1011. CrossRef
Critical Illness in Patients with Metastatic Cancer: A Population-Based Cohort Study of Epidemiology and Outcomes
Lavi Oud
Journal of Investigative Medicine.2022; 70(3): 820. CrossRef
One-year Mortality of Cancer Patients with an Unplanned ICU Admission: A Cohort Analysis Between 2008 and 2017 in the Netherlands
Esther N. van der Zee, Fabian Termorshuizen, Dominique D. Benoit, Nicolette F. de Keizer, Jan Bakker, Erwin J.O. Kompanje, Wim J.R. Rietdijk, Jelle L. Epker
Journal of Intensive Care Medicine.2022; 37(9): 1165. CrossRef
A Comprehensive Analysis of 5-Year Outcomes in Patients with Cancer Admitted to Intensive Care Units
Yoonki Hong, Woo Jin Kim, Ji Young Hong, Yun-jeong Jeong, Jinkyeong Park
Tuberculosis and Respiratory Diseases.2022; 85(2): 195. CrossRef
Functional Improvement During Prolonged Hospitalization in a Patient With Acute Myeloid Leukemia Utilizing Physical and Occupational Therapy Comanagement
Jessica A. Strikwerda, Emily A. Bodensteiner Schmitt
Journal of Acute Care Physical Therapy.2022; 13(3): 145. CrossRef
Long-term health-related quality of life, healthcare utilisation and back-to-work activities in intensive care unit survivors: Prospective confirmatory study from the Frisian aftercare cohort
Lise F. E. Beumeler, Anja van Wieren, Hanneke Buter, Tim van Zutphen, Gerjan J. Navis, E. Christiaan Boerma, Ashham Mansur
PLOS ONE.2022; 17(9): e0273348. CrossRef
A U-shaped association of tracheostomy timing with all-cause mortality in mechanically ventilated patients admitted to the intensive care unit: A retrospective cohort study
Jing-Ran Chen, Hao-Ran Gao, Yan-Lin Yang, Yan Wang, Yi-Min Zhou, Guang-Qiang Chen, Hong-Liang Li, Linlin Zhang, Jian-Xin Zhou
Frontiers in Medicine.2022;[Epub] CrossRef
Treatment Limitation Decisions in Critically Ill Patients With a Malignancy on the Intensive Care Unit
Esther N. van der Zee, Jelle L. Epker, Jan Bakker, Dominique D. Benoit, Erwin J. O. Kompanje
Journal of Intensive Care Medicine.2021; 36(1): 42. CrossRef
Intensive Care Unit Organization and Interdisciplinary Care for Critically Ill Patients with Cancer
Alexander Shimabukuro-Vornhagen
Critical Care Clinics.2021; 37(1): 19. CrossRef
Assessment of mortality and performance status in critically ill cancer patients: A retrospective cohort study
Esther N. van der Zee, Lianne M. Noordhuis, Jelle L. Epker, Nikki van Leeuwen, Bas P. L. Wijnhoven, Dominique D. Benoit, Jan Bakker, Erwin J. O. Kompanje, Ismaeel Yunusa
PLOS ONE.2021; 16(6): e0252771. CrossRef
A 12-year study evaluating the outcomes and predictors of mortality in critically ill cancer patients admitted with septic shock
Wedad B. Awad, Lama Nazer, Salam Elfarr, Maha Abdullah, Feras Hawari
BMC Cancer.2021;[Epub] CrossRef
Outcome of cancer patients considered for intensive care unit admission in two university hospitals in the Netherlands: the danger of delayed ICU admissions and off-hour triage decisions
Esther N. van der Zee, Dominique D. Benoit, Marinus Hazenbroek, Jan Bakker, Erwin J. O. Kompanje, Nuray Kusadasi, Jelle L. Epker
Annals of Intensive Care.2021;[Epub] CrossRef
Outcomes of ICU patients with and without perceptions of excessive care: a comparison between cancer and non-cancer patients
Dominique D. Benoit, Esther N. van der Zee, Michael Darmon, An K. L. Reyners, Victoria Metaxa, Djamel Mokart, Alexander Wilmer, Pieter Depuydt, Andreas Hvarfner, Katerina Rusinova, Jan G. Zijlstra, François Vincent, Dimitrios Lathyris, Anne-Pascale Meert,
Annals of Intensive Care.2021;[Epub] CrossRef
Effectiveness of Rapid Response Team on In-hospital Mortality in Patients with Hematologic Malignancy
So-Jung Park, Sang-Bum Hong, Chae-Man Lim, Youn-Suck Koh, Jin-Won Huh
Quality Improvement in Health Care.2021; 27(2): 18. CrossRef
Factors associated with intensive care admission in patients with lung cancer: a population-based observational study of 26, 731 patients
Kathryn Puxty, Christopher H. Grant, Philip McLoone, Billy Sloan, Tara Quasim, Kate Hulse, David S. Morrison
BMC Pulmonary Medicine.2020;[Epub] CrossRef
Decision-Making Processes in Surrogates of Cancer Patients in a Taiwan Intensive Care Unit
Wan-Na Sun, Hsin-Tien Hsu, Nai-Ying Ko, Yu-Tung Huang
International Journal of Environmental Research and Public Health.2020; 17(12): 4443. CrossRef
Predictive Performance of two Measures of Prognostic Mortality of Cancer Patients in Intensive Care Unit in Jordan: A Comparative Single-Centre Study
Issa M. Almansour, Mohammad K. Aldalaykeh, Zyad T. Saleh, Khalil M. Yousef, Mohammad M. Alnaeem
The Open Nursing Journal.2020; 14(1): 168. CrossRef
Critical Care, Critical Data
Christopher V Cosgriff, Leo Anthony Celi, David J Stone
Biomedical Engineering and Computational Biology.2019; 10: 117959721985656. CrossRef

7,343 View
223 Download
22 Web of Science
27 Crossref

Risk Assessment of Secondary Primary Malignancies in Nasopharyngeal Carcinoma: A Big-Data Intelligence Platform-Based Analysis of 6,377 Long-term Survivors from an Endemic Area Treated with Intensity-Modulated Radiation Therapy during 2003-2013: Lu-Lu Zhang, Guo-Hong Li, Yi-Yang Li, Zhen-Yu Qi, Ai-Hua Lin, Ying Sun; Cancer Res Treat. 2019;51(3):982-991. Published online October 11, 2018; DOI: https://doi.org/10.4143/crt.2018.298

Abstract PDF PubReader ePub

Purpose
The incidence, risk factors and survival impact of secondary primary malignancies (SPMs) among survivors of nasopharyngeal carcinoma (NPC) treated with definitive intensity-modulated radiation therapy (IMRT) with or without chemotherapy are poorly characterized.
Methods
and Materials Consecutive patients (n=6,377) from the big-data intelligence platform at Sun Yat-sen University Cancer Center, China (in a high-incidence area) with newly diagnosed non-metastatic pathologically proven non-keratinizing undifferentiated NPC treated with IMRT±chemotherapy between January 2003 and June 2013 were retrospectively analyzed. Cumulative incidence of SPMs was calculated using the Kaplan-Meier method. Cox proportional hazards model was used to identify potential risk factors for SPMs and assess whether SPMs affect overall survival.
Results
Of the 6,377 patients, 189 (3.0%) suffered SPMs (median follow-up, 62 months). One-, 2-, 3-, 4-, and 5-cumulative risks of SPMs were 0.4%, 0.9%, 1.6%, 2.2%, and 2.6%, respectively. Latency from start of IMRT to SPMs diagnosis was 37 months (range, 6 to 102 months). In patients with SPMs, 14.3% suffered SPMs within 1 year post-IMRT: 1-3 years, 38.1%; 3-5 years, 33.9%; and >5 years, 13.7%. Lung cancer was the most common SPM (50/6,377, 0.78%). Multivariate analysis demonstrated sex (male, 64% increase), age (≥50 years, 68% increase), and smoking history (41% increase) were significant risk factors for SPMs, and SPMs were associated with poorer overall survival.
Conclusion
This large cohort study confirms SPMs a dreadful complication for long-term survivors of NPC treated with IMRT. SPMs negatively impact overall survival in NPC. Close follow-up is recommended for older male survivors with a smoking history.

Citations

Citations to this article as recorded by

Age-specific characteristics of head and neck second primary malignancies in patients treated for nasopharyngeal carcinoma: a retrospective study
Q. Jiang, T. Xu, M. Zeng, Y. He, Y. Cai, Z. Huang
International Journal of Oral and Maxillofacial Surgery.2024; 53(1): 11. CrossRef
The prevalence of gastroesophageal reflux disease and laryngopharyngeal reflux in patients with dysphagia after radiotherapy for nasopharyngeal carcinoma
Peter K. M. Ku, Alexander C. Vlantis, Thomas S. C. Hui, Zenon W. C. Yeung, Ryan H. W. Cho, Marc H. K. Wong, Alex K. F. Lee, David C. M. Yeung, Simon Y. P. Chan, Becky Y. T. Chan, Wai‐tsz Chang, Florence Mok, Kam‐hung Wong, Jeffrey K. T. Wong, Victor Abdul
Head & Neck.2024; 46(7): 1637. CrossRef
Maxillary sinus anterior wall recurrence after intensity-modulated radiotherapy for nasopharyngeal carcinoma
Y Fang, L Wang, X Chen, C Cao
International Journal of Radiation Research.2024; 22(3): 803. CrossRef
Detection and staging of recurrent or metastatic nasopharyngeal carcinoma in the era of FDG PET/MR
Yongfeng Piao, Caineng Cao, Yuanfan Xu, Shuang Huang, Feng Jiang, Ting Jin, Qifeng Jin, Yonghong Hua, Qiaoying Hu, Xiaozhong Chen
European Archives of Oto-Rhino-Laryngology.2022; 279(1): 353. CrossRef
Second Primary Lung Adenocarcinoma After Intensity-Modulated Radiotherapy for Nasopharyngeal Carcinoma
Fen Xue, Xiaoshuang Niu, Chaosu Hu, Xiayun He
Frontiers in Oncology.2022;[Epub] CrossRef
Racial and ethnic disparities in nasopharyngeal cancer with an emphasis among Asian Americans
Qian Wang, Hui Xie, Yannan Li, Nicholas Theodoropoulos, Yaning Zhang, Changchuan Jiang, Chi Wen, Laura S. Rozek, Paolo Boffetta
International Journal of Cancer.2022; 151(8): 1291. CrossRef
Factors associated with the development of second primary tumours in head and neck cancer patients
Inmaculada Salcedo‐Bellido, Pilar Requena, Rocío Mateos, Carmen Ortega‐Rico, Rocío Olmedo‐Requena, Macarena Lozano‐Lorca, Juan Pedro Arrebola, Rocío Barrios‐Rodríguez
European Journal of Cancer Care.2022;[Epub] CrossRef
Nasopharyngeal carcinoma: an evolving paradigm
Kenneth C. W. Wong, Edwin P. Hui, Kwok-Wai Lo, Wai Kei Jacky Lam, David Johnson, Lili Li, Qian Tao, Kwan Chee Allen Chan, Ka-Fai To, Ann D. King, Brigette B. Y. Ma, Anthony T. C. Chan
Nature Reviews Clinical Oncology.2021; 18(11): 679. CrossRef
The Chinese Society of Clinical Oncology (CSCO) clinical guidelines for the diagnosis and treatment of nasopharyngeal carcinoma
Ling‐Long Tang, Yu‐Pei Chen, Chuan‐Ben Chen, Ming‐Yuan Chen, Nian‐Yong Chen, Xiao‐Zhong Chen, Xiao‐Jing Du, Wen‐Feng Fang, Mei Feng, Jin Gao, Fei Han, Xia He, Chao‐Su Hu, De‐sheng Hu, Guang‐Yuan Hu, Hao Jiang, Wei Jiang, Feng Jin, Jin‐Yi Lang, Jin‐Gao Li,
Cancer Communications.2021; 41(11): 1195. CrossRef
Radiation-induced second primary squamous cell carcinoma of the oral cavity after radiotherapy for nasopharyngeal carcinoma
Chao Liu, Lieqiang Liao, Guoying Wu, Honghong Yan, Xiaoqi Chen, Chao Wang, Xiajing Zheng, Ziyi Zeng, Zheng Zhao, Di Wu, Xuekui Liu
Oral Oncology.2020; 109: 104863. CrossRef
Second primary cancer after intensity-modulated radiotherapy for nasopharyngeal carcinoma: A territory-wide study by HKNPCSG
James C.H. Chow, Anthony H.P. Tam, Ka-Man Cheung, Victor H.F. Lee, Chi-Leung Chiang, Macy Tong, Edwin C.Y. Wong, Alice K.W. Cheung, Sunny P.C. Chan, Jessica W.Y. Lai, Roger K.C. Ngan, Wai-Tong Ng, Anne W.M. Lee, Kwok-Hung Au
Oral Oncology.2020; 111: 105012. CrossRef

6,894 View
150 Download
15 Web of Science
11 Crossref

Prevalence of PALB2 Germline Mutations in Early-onset and Familial Breast/Ovarian Cancer Patients from Pakistan: Muhammad Usman Rashid, Faiz Ali Khan, Noor Muhammad, Asif Loya, Ute Hamann; Cancer Res Treat. 2019;51(3):992-1000. Published online October 11, 2018; DOI: https://doi.org/10.4143/crt.2018.356

Abstract PDF PubReader ePub

Purpose
Partner and localizer of BRCA2 (PALB2) is a breast cancer susceptibility gene that plays an important role in DNA repair. This is the first study assessing the prevalence of PALB2 mutations in early-onset and familial breast/ovarian cancer patients from Pakistan.
Materials and Methods
PALB2 mutation screening was performed in 370 Pakistani patients with early-onset and familial breast/ovarian cancer, who were negative for BRCA1, BRCA2, TP53, CHEK2, and RAD51C mutations, using denaturing high-performance liquid chromatography analysis. Mutations were confirmed by DNA sequencing. Novel PALB2 alterations were analyzed for their potential effect on protein function or splicing using various in silico prediction tools. Three-hundred and seventy-two healthy controls were screened for the presence of the identified (potentially) functional mutations.
Results
A novel nonsense mutation, p.Y743*, was identified in one familial breast cancer patient (1/127, 0.8%). Besides, four in silico-predicted potentially functional mutations including three missense mutations and one 5' untranslated region mutation were identified: p.D498Y, novel p.G644R, novel p.E744K, and novel c.-134_-133delTCinsGGGT. The mutations p.Y743* and p.D498Y were identified in two familial patients diagnosed with unilateral or synchronous bilateral breast cancer at the ages of 29 and 39, respectively. The other mutations were identified in an early-onset (≤ 30 years of age) breast cancer patient each. All five mutations were absent in 372 healthy controls suggesting that they are disease associated.
Conclusion
Our findings show that PALB2 mutations account for a small proportion of early-onset and hereditary breast/ovarian cancer cases in Pakistan.

Citations

Citations to this article as recorded by

Prevalence of FANCM germline variants in BRCA1/2 negative breast and/or ovarian cancer patients from Pakistan
Muhammad Usman Rashid, Noor Muhammad, Umara Shehzad, Faiz Ali Khan, Asif Loya, Ute Hamann
Familial Cancer.2023; 22(1): 31. CrossRef
Potential prognostic role of somatic mutations in a set of cancer susceptibility genes in ovarian carcinoma: A follow-up multicentric study from Pakistan
Atika Masood, Rahat Sarfaraz, Saima Zaki, Amira Shami, Saba Khaliq, Nadia Naseem
Cancer Biomarkers.2023; 36(3): 207. CrossRef
Contribution of constitutional BRCA1 promoter methylation to early-onset and familial breast cancer patients from Pakistan
Noor Muhammad, Ayesha Azeem, Muhammad Abu Bakar, Karolina Prajzendanc, Asif Loya, Anna Jakubowska, Ute Hamann, Muhammad Usman Rashid
Breast Cancer Research and Treatment.2023; 202(2): 377. CrossRef
Low prevalence of germline TP53 and PALB2 mutations in unselected cohort of breast cancer patients from Brunei Darussalam
Siti Nur Idayu Matusin, Zen Huat Lu, Mas Rina Wati Haji Abdul Hamid
F1000Research.2023; 12: 1537. CrossRef
Germline Mutation Analysis in Sporadic Breast Cancer Cases With Clinical Correlations
Sadia Ajaz, Sani-e-Zehra Zaidi, Saleema Ali, Aisha Siddiqa, Muhammad Ali Memon
Frontiers in Genetics.2022;[Epub] CrossRef
Spectrum of germline pathogenic variants using a targeted next generation sequencing panel and genotype-phenotype correlations in patients with suspected hereditary breast cancer at an academic medical centre in Pakistan
Fizza Akbar, Zahraa Siddiqui, Muhammad Talha Waheed, Lubaina Ehsan, Syed Ibaad Ali, Hajra Wiquar, Azmina Tajuddin Valimohammed, Shaista Khan, Lubna Vohra, Sana Zeeshan, Yasmin Rashid, Munira Moosajee, Adnan Abdul Jabbar, Muhammad Nauman Zahir, Naila Zahid
Hereditary Cancer in Clinical Practice.2022;[Epub] CrossRef
Contribution of germline PALB2 variants to an unselected and prospectively registered pancreatic cancer patient cohort in Pakistan
Noor Muhammad, Rida Sadaqat, Humaira Naeemi, Iqra Masood, Usman Hassan, Bushra Ijaz, Faisal Hanif, Aamir A. Syed, Muhammed A. Yusuf, Muhammad U. Rashid
HPB.2022; 24(12): 2134. CrossRef
Prevalence of RECQL germline variants in Pakistani early-onset and familial breast cancer patients
Muhammad Usman Rashid, Noor Muhammad, Faiz Ali Khan, Umara Shehzad, Humaira Naeemi, Naila Malkani, Ute Hamann
Hereditary Cancer in Clinical Practice.2020;[Epub] CrossRef

10,721 View
333 Download
7 Web of Science
8 Crossref

Dummy Run of Quality Assurance Program before Prospective Study of Hippocampus-Sparing Whole-Brain Radiotherapy and Simultaneous Integrated Boost for Multiple Brain Metastases from Non-small Cell Lung Cancer: Korean Radiation Oncology Group (KROG) 17-06 Study: Eunah Chung, Jae Myoung Noh, Kyu Chan Lee, Jin Hee Kim, Weon Kuu Chung, Yang-Gun Suh, Jung Ae Lee, Ki Ho Seol, Hong Gyun Wu, Yeon Sil Kim, O Kyu Noh, Jae Won Park, Dong Soo Lee, Jihae Lee, Young Suk Kim, Woo-Yoon Park, Min Kyu Kang, Sunmi Jo, Yong Chan Ahn; Cancer Res Treat. 2019;51(3):1001-1010. Published online October 15, 2018; DOI: https://doi.org/10.4143/crt.2018.415

Abstract PDF PubReader ePub

Purpose
Lung Cancer Subcommittee of Korean Radiation Oncology Group (KROG) has recently launched a prospective clinical trial (KROG 17-06) of hippocampus-sparing whole brain radiotherapy (HS-WBRT) with simultaneous integrated boost (SIB) in treating multiple brain metastases from non-small cell lung cancer. In order to improve trial quality, dummy run studies among the participating institutions were designed. This work reported the results of two-step dummy run procedures of the KROG 17-06 study.
Materials and Methods
Two steps tested hippocampus contouring variability and radiation therapy planning compliance. In the first step, the variation of the hippocampus delineation was investigated for two representative cases using the Dice similarity coefficients. In the second step, the participating institutions were requested to generate a HS-WBRT with SIB treatment plan for another representative case. The compliance of the treatment plans to the planning protocol was evaluated.
Results
In the first step, the median Dice similarity coefficients of the hippocampus contours for two other dummy run cases changed from 0.669 (range, 0.073 to 0.712) to 0.690 (range, 0.522 to 0.750) and from 0.291 (range, 0.219 to 0.522) to 0.412 (range, 0.264 to 0.598) after providing the hippocampus contouring feedback. In the second step, with providing additional plan priority and extended dose constraints to the target volumes and normal structures, we observed the improved compliance of the treatment plans to the planning protocol.
Conclusion
The dummy run studies demonstrated the notable inter-institutional variability in delineating the hippocampus and treatment plan generation, which could be decreased through feedback from the trial center.

Citations

Citations to this article as recorded by

Radiotherapy trial quality assurance processes: a systematic review
Chloe Brooks, Elizabeth Miles, Peter J Hoskin
The Lancet Oncology.2024; 25(3): e104. CrossRef
Durvalumab with chemoradiotherapy for limited-stage small-cell lung cancer
Sehhoon Park, Jae Myoung Noh, Yoon-La Choi, Sang Ah Chi, Kyunga Kim, Hyun Ae Jung, Se-Hoon Lee, Jin Seok Ahn, Myung-Ju Ahn, Jong-Mu Sun
European Journal of Cancer.2022; 169: 42. CrossRef
Region-Specific Effects of Fractionated Low-Dose Versus Single-Dose Radiation on Hippocampal Neurogenesis and Neuroinflammation
Zoé Schmal, Claudia E. Rübe
Cancers.2022; 14(22): 5477. CrossRef
Non–coplanar whole brain radiotherapy is an effective modality for parotid sparing
Jaehyeon Park, Jae Won Park, Ji Woon Yea
Yeungnam University Journal of Medicine.2019; 36(1): 36. CrossRef

8,719 View
280 Download
4 Web of Science
4 Crossref

Axillary Lymph Node Dissection Does Not Improve Post-mastectomy Overall or Disease-Free Survival among Breast Cancer Patients with 1-3 Positive Nodes: Ji Hyeon Joo, Su Ssan Kim, Byung Ho Son, Seung Do Ahn, Jin Hong Jung, Eun Kyung Choi, Sei Hyun Ahn, Jong Won Lee, Hee Jeong Kim, Beom Seok Ko; Cancer Res Treat. 2019;51(3):1011-1021. Published online October 16, 2018; DOI: https://doi.org/10.4143/crt.2018.438

Abstract PDF Supplementary Material PubReader ePub

Purpose
Axillary lymph node dissection (ALND) may be avoidable for breast cancer patients with 1-2 positive lymph nodes (LN) after breast-conserving therapy. However, the effects of ALND after mastectomy remain unclear because radiation is not routinely used. Herein, we compared the benefits of post-mastectomy ALND versus sentinel node biopsy (SNB) alone for breast cancer patients with 1-3 metastatic LNs.
Materials and Methods
A total of 1,697 patients with pN1 disease who underwent mastectomy during 2000-2015 were identified from an institutional database. Outcomes were compared using the inverse probability of treatment weighted method.
Results
Patients who underwent SNB tended to have smaller tumors, a lower histology grade, a lower number of positive LNs, and better immunohistochemical findings. After correcting all confounding factors regarding patient, tumor, and adjuvant treatment, the SNB and ALND groups did not differ in terms of overall survival (OS) and disease-free survival (DFS), distant metastasis and locoregional recurrence. The 10-year DFS and OS rates were 83% and 84%, respectively, during a median follow-up period of 93 months.
Conclusion
ALND did not improve post-mastectomy survival outcomes among patients with N1 breast cancer, even after adjusting for all histopathologic and treatment-related factors.

Citations

Citations to this article as recorded by

The Impact of Sentinel Lymph Node Biopsy on Female Patients With T3-4c Breast Cancer and 1-2 Positive Lymph Nodes: A Population-Based Cohort Study
Hanzhao Yang, Yadong Sun, Peili Wang, Jianghua Qiao, Chengzheng Wang, Zhenzhen Liu
Clinical Breast Cancer.2024; 24(3): e126. CrossRef
Axillary management in patients with clinical node-negative early breast cancer and positive sentinel lymph node: a systematic review and meta-analysis
Changzai Li, Pan Zhang, Jie Lv, Wei Dong, Baoshan Hu, Jinji Zhang, Hongcheng Zhu
Frontiers in Oncology.2024;[Epub] CrossRef
Reevaluating Axillary Lymph Node Dissection in Total Mastectomy for Low Axillary Burden Breast Cancer: Insights from a Meta-Analysis including the SINODAR-ONE Trial
Munaser Alamoodi, Neill Patani, Kinan Mokbel, Umar Wazir, Kefah Mokbel
Cancers.2024; 16(4): 742. CrossRef
RecurIndex-Guided postoperative radiotherapy with or without Avoidance of Irradiation of regional Nodes in 1–3 node-positive breast cancer (RIGAIN): a study protocol for a multicentre, open-label, randomised controlled prospective, phase III trial
Jing Liu, Yuting Tan, Zhuofei Bi, Suning Huang, Na Zhang, An-du Zhang, Lina Zhao, Yu Wang, Zibin Liang, Yu Hou, Xiangying Xu, Jianying Chen, Fei Wang, Xiaowen Lan, Xiao Lin, Xiaoxue Zhang, Wenyi Zhou, Xuting Ye, Jian-gui Guo, Xiaohong Wang, Ran Ding, Jiay
BMJ Open.2024; 14(7): e078049. CrossRef
The prognostic analysis of further axillary dissection in breast cancer with 1-2 positive sentinel lymph nodes undergoing mastectomy
Xueyi Zhao, Liu Yang, Congbo Cao, Zhenchuan Song
Frontiers in Oncology.2024;[Epub] CrossRef
Sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer patients undergoing mastectomy
Damiano GENTILE, Corrado TINTERRI
Minerva Surgery.2024;[Epub] CrossRef
Can Axillary Lymph Node Dissection be Omitted in Breast Cancer Patients with Metastatic Sentinel Lymph Nodes Undergoing Mastectomy? A Systematic Review and Meta‐Analysis of Real‐World Evidence
Fulong Chen, Xiaowen Li, Xianjun Lin, Lijia Chen, Zhaoling Lin, Hao Wu, Jishang Chen
World Journal of Surgery.2023; 47(10): 2446. CrossRef
De-implementation of Axillary Dissection in Women Undergoing Mastectomy for Breast Cancer
Laura D. Leonard, Thiago B. de Araujo, Christopher Quinn, Madeline B. Thomas, Laurel Beaty, Nicole M. Mott, Kathryn Colborn, Alicia A. Heelan, Sarah E. A. Tevis, Nicole Christian, Gretchen Arhendt, Ana L. Gleisner
Annals of Surgical Oncology.2023; 30(9): 5692. CrossRef
A multi-dimensional nomogram to predict non-sentinel lymph node metastases in T1–2HR+ breast cancer
Ke Xiang, Jialin Chen, Yu Min, Hang Chen, Jiaxin Yang, Daixing Hu, Yuling Han, Guobing Yin, Yang Feng
Frontiers in Endocrinology.2023;[Epub] CrossRef
Sentinel lymph node biopsy versus axillary lymph node dissection in breast cancer patients undergoing mastectomy with one to two metastatic sentinel lymph nodes: sub-analysis of the SINODAR-ONE multicentre randomized clinical trial and reopening of enrolm
Corrado Tinterri, Giuseppe Canavese, Wolfgang Gatzemeier, Erika Barbieri, Alberto Bottini, Andrea Sagona, Giulia Caraceni, Alberto Testori, Simone Di Maria Grimaldi, Carla Dani, Luca Boni, Paolo Bruzzi, Bethania Fernandes, Marta Scorsetti, Alberto Zambell
British Journal of Surgery.2023; 110(9): 1143. CrossRef
Efficacy and safety comparison between axillary lymph node dissection with no axillary surgery in patients with sentinel node-positive breast cancer: a systematic review and meta-analysis
Yu-Jia Fan, Jin-Cheng Li, De-Miao Zhu, Hai-Long Zhu, Yi Zhao, Xin-Bing Zhu, Gang Wu, Ting-ting Bai
BMC Surgery.2023;[Epub] CrossRef
Factores predictivos de metástasis en ganglios no centinela en el cáncer de mama con ganglio centinela positivo
Mariana Peyroteo, Rita Canotilho, Ana Margarida Correia, Catarina Baía, Cátia Ribeiro, Paulo Reis, Abreu de Sousa
Cirugía Española.2022; 100(2): 81. CrossRef
Optimizing Axillary Management in Clinical T1-2N0 Mastectomy Patients with Positive Sentinel Lymph Nodes
Olga Kantor, Jessica Means, Samantha Grossmith, Tanujit Dey, Jennifer R. Bellon, Elizabeth A. Mittendorf, Tari A. King
Annals of Surgical Oncology.2022; 29(2): 972. CrossRef
Predictive factors of non-sentinel lymph node disease in breast cancer patients with positive sentinel lymph node
Mariana Peyroteo, Rita Canotilho, Ana Margarida Correia, Catarina Baía, Cátia Ribeiro, Paulo Reis, Abreu de Sousa
Cirugía Española (English Edition).2022; 100(2): 81. CrossRef
Axilla lymph node dissection can be safely omitted in patients with 1–2 positive sentinel nodes receiving mastectomy: a large multi-institutional study and a systemic meta-analysis
Weiqi Gao, Shuangshuang Lu, Yufei Zeng, Xiaosong Chen, Kunwei Shen
Breast Cancer Research and Treatment.2022; 196(1): 129. CrossRef
Comparison of survival outcomes between axillary conservation and axillary lymph node dissections in N1 early breast cancer: a propensity-matched SEER analysis
Nisha Wu, Xiaohan Su, Qiao Tan, Jing Luo, Yewei Yuan, Lingmi Hou, Junyan Li
Clinical and Translational Oncology.2022; 25(4): 1091. CrossRef
Surgeon Bias in the Management of Positive Sentinel Lymph Nodes
Brittany J. Mathias, James Sun, Weihong Sun, Jun-Min Zhou, William J. Fulp, Christine Laronga, M. Catherine Lee, John V. Kiluk
Clinical Breast Cancer.2021; 21(1): 74. CrossRef
Impact of Axillary Dissection Among Patients With Sentinel Node–Positive Breast Cancer Undergoing Mastectomy
James Sun, Brittany J. Mathias, Christine Laronga, Weihong Sun, Jun-Min Zhou, William J. Fulp, John V. Kiluk, M. Catherine Lee
Journal of the National Comprehensive Cancer Network.2021; 19(1): 40. CrossRef
Evolution of the Use of Completion Axillary Lymph Node Dissection in Patients with T1/2N0M0 Breast Cancer and Tumour-Involved Sentinel Lymph Nodes Undergoing Mastectomy: A Cohort Study
André Hennigs, Fabian Riedel, Manuel Feißt, Melitta Köpke, Mahdi Rezai, Ulrike Nitz, Mareike Moderow, Michael Golatta, Christof Sohn, Jörg Heil
Annals of Surgical Oncology.2019; 26(8): 2435. CrossRef

8,844 View
326 Download
18 Web of Science
19 Crossref

Dietary Intake of Omega-3 fatty acids and Endocrine-related Gynecological Cancer: A Meta-Analysis of Observational Studies: Tung Hoang, Seung-Kwon Myung, Thu Thi Pham; Cancer Res Treat. 2019;51(3):1022-1032. Published online October 17, 2018; DOI: https://doi.org/10.4143/crt.2018.473; Retraction in: Cancer Res Treat 2020;52(1):334

8,676 View
184 Download
4 Web of Science
3 Crossref

Genetic Risk Score, Combined Lifestyle Factors and Risk of Colorectal Cancer: Young Ae Cho, Jeonghee Lee, Jae Hwan Oh, Hee Jin Chang, Dae Kyung Sohn, Aesun Shin, Jeongseon Kim; Cancer Res Treat. 2019;51(3):1033-1040. Published online October 18, 2018; DOI: https://doi.org/10.4143/crt.2018.447

Abstract PDF Supplementary Material PubReader ePub

Purpose
Both genetic and lifestyle factors contribute to the risk of colorectal cancer, but each individual factor has a limited effect. Therefore, we investigated the association between colorectal cancer and the combined effects of genetic factors or/and lifestyle risk factors.
Materials and Methods
In a case-control study of 632 colorectal cancer patients and 1,295 healthy controls, we quantified the genetic risk score for colorectal cancer using 13 polymorphisms. Furthermore, we determined a combined lifestyle risk score including obesity, physical activity, smoking, alcohol consumption, and dietary inflammatory index. The associations between colorectal cancer and risk score using these factors were examined using a logistic regression model.
Results
Higher genetic risk scores were associated with an increased risk of colorectal cancer (odds ratio [OR], 2.57; 95% confidence interval [CI], 1.89 to 3.49 for the highest tertile vs. lowest tertile). Among the modifiable factors, previous body mass index, physical inactivity, heavy alcohol consumption, and a high inflammatory diet were associated with an increased risk of colorectal cancer. A higher lifestyle risk score was associated with an increased risk of colorectal cancer (OR, 5.82; 95% CI, 4.02 to 8.44 for the highest tertile vs. lowest tertile). This association was similar in each genetic risk category.
Conclusion
Adherence to a healthy lifestyle is associated with a substantially reduced risk of colorectal cancer regardless of individuals’ genetic risk.

Citations

Citations to this article as recorded by

CD38 gene polymorphism rs1130169 contribution to the increased gene expression and risk of colorectal cancer (pilot study)
Dmitry V. Novikov, Alexei D. Perenkov, Svetlana V. Shumilova, Nailya I. Kubysheva, Viktor V. Novikov
Molecular Biology Reports.2024;[Epub] CrossRef
Molecular subtype identification and prognosis stratification by a immunogenic cell death-related gene expression signature in colorectal cancer
Junping Lei, Jia Fu, Tianyang Wang, Yu Guo, Mingmin Gong, Tian Xia, Song Shang, Yan Xu, Ling Cheng, Binghu Lin
Expert Review of Anticancer Therapy.2024; 24(7): 635. CrossRef
Genetic risk impacts the association of menopausal hormone therapy with colorectal cancer risk
Yu Tian, Yi Lin, Conghui Qu, Volker Arndt, James W. Baurley, Sonja I. Berndt, Stephanie A. Bien, D. Timothy Bishop, Hermann Brenner, Daniel D. Buchanan, Arif Budiarto, Peter T. Campbell, Robert Carreras-Torres, Graham Casey, Andrew T. Chan, Rui Chen, Xuec
British Journal of Cancer.2024; 130(10): 1687. CrossRef
A polygenetic risk score combined with environmental factors better predict susceptibility to hepatocellular carcinoma in Chinese population
Yuanlin Zou, Jicun Zhu, Caijuan Song, Tiandong Li, Keyan Wang, Jianxiang Shi, Hua Ye, Peng Wang
Cancer Medicine.2024;[Epub] CrossRef
Functionalized liposomes as a potential drug delivery systems for colon cancer treatment: A systematic review
Eskandar Moghimipour, Somayeh Handali
International Journal of Biological Macromolecules.2024; 269: 132023. CrossRef
UHPLC-HRMS-based Multiomics to Explore the Potential Mechanisms and Biomarkers for Colorectal Cancer
Xuancheng Wang, Xuan Guan, Ying Tong, Yunxiao Liang, Zongsheng Huang, Mingsen Wen, Jichu Luo, Hongwei Chen, Shanyi Yang, Zhiyong She, Zhijuan Wei, Yun Zhou, Yali Qi, Pingchuan Zhu, Yanying Nong, Qisong Zhang
BMC Cancer.2024;[Epub] CrossRef
High glucose inhibits autophagy and promotes the proliferation and metastasis of colorectal cancer through the PI3K/AKT/mTOR pathway
Feng Li, Xing Wan, Zhigui Li, Liming Zhou
Cancer Medicine.2024;[Epub] CrossRef
Relationship Between Aspirin Use and Site-Specific Colorectal Cancer Risk Among Individuals With Metabolic Comorbidity
Seokyung An, Madhawa Gunathilake, Jeonghee Lee, Minji Kim, Jae Hwan Oh, Hee Jin Chang, Dae Kyung Sohn, Aesun Shin, Jeongseon Kim
Journal of Korean Medical Science.2024;[Epub] CrossRef
Microbiota in gastrointestinal malignancies
Ludovica Bricca, Serena Porcari, Edoardo Savarino, Massimo Rugge
Best Practice & Research Clinical Gastroenterology.2024; : 101953. CrossRef
Iron-(Fe3+)-Dependent Reactivation of Telomerase Drives Colorectal Cancers
Raghuvaran Shanmugam, Prativa Majee, Wei Shi, Mert B. Ozturk, Thamil S. Vaiyapuri, Khaireen Idzham, Anandhkumar Raju, Seung H. Shin, Kerem Fidan, Joo-Leng Low, Joelle Y.H. Chua, Yap C. Kong, Ong Y. Qi, Emile Tan, Aik Y. Chok, Isaac Seow-En, Ian Wee, Domin
Cancer Discovery.2024; 14(10): 1940. CrossRef
An atlas on risk factors for gastrointestinal cancers: A systematic review of Mendelian randomization studies
Yi-Xuan Huang, Jun-Hua Wu, Yu-Qiang Zhao, Wan-Nian Sui, Tian Tian, Wen-Xiu Han, Jing Ni
Preventive Medicine.2024; 189: 108147. CrossRef
Potential regulatory mechanism and clinical significance of synaptotagmin binding cytoplasmic RNA interacting protein in colorectal cancer
Hui Li, He-Qing Huang, Zhi-Guang Huang, Rong-Quan He, Ye-Ying Fang, Rui Song, Jia-Yuan Luo, Da-Tong Zeng, Kai Qin, Dan-Ming Wei, Gang Chen
World Journal of Clinical Oncology.2024; 15(11): 1412. CrossRef
KRAS Gene Mutation Associated with Grade of Tumor Budding and Peripheral Immunoinflammatory Indices in Patients with Colorectal Cancer
Liu Liang, Xuemin Guo, Wei Ye, Yuxiang Liu
International Journal of General Medicine.2024; Volume 17: 4769. CrossRef
Specifics of cancer detection at the outpatient stage. A case report
O.S. Skuratova, S.N. Lagutina, P.Yu. Poyminova, A.E. Guzenko, G.A. Tyukov, A.A. Pashkova, N.S. Korchagina, E.Yu. Esina, I.S. Dobrynina
Russian Journal of Preventive Medicine.2024; 27(10): 97. CrossRef
Physical activity, polygenic risk score, and colorectal cancer risk
Xuechen Chen, Feng Guo, Jenny Chang‐Claude, Michael Hoffmeister, Hermann Brenner
Cancer Medicine.2023; 12(4): 4655. CrossRef
Lifestyle, genetic risk and incidence of cancer: a prospective cohort study of 13 cancer types
Stephanie Byrne, Terry Boyle, Muktar Ahmed, Sang Hong Lee, Beben Benyamin, Elina Hyppönen
International Journal of Epidemiology.2023; 52(3): 817. CrossRef
Association of blood pressure with incident diabetic microvascular complications among diabetic patients: Longitudinal findings from the UK Biobank
Cong Li, Honghua Yu, Zhuoting Zhu, Xianwen Shang, Yu Huang, Charumathi Sabanayagam, Xiaohong Yang, Lei Liu
Journal of Global Health.2023;[Epub] CrossRef
Analysis of factors associated with postoperative acute kidney injury in patients with colorectal cancer and the development of a risk prediction model: a retrospective study
Liu Li, Xiaochen Wan, Yonglei Zhang, Minghai Zhao, Jinjun Ren, Yongchao Zhang
Updates in Surgery.2023; 75(5): 1171. CrossRef
Exosomal Circ_FMN2 Derived from the Serum of Colorectal Cancer Patients Promotes Cancer Progression by miR-338-3p/MSI1 Axis
Qiyao Yu, Yi Zhang, Yanming Tian, Ale Peng, Xiujing Cui, Boyue Ding, Lei Yang, Yabin Liu, Yingchao Ju, Chao Gao
Applied Biochemistry and Biotechnology.2023; 195(12): 7322. CrossRef
Green space exposure and colorectal cancer: A systematic review
Noor Azreen Masdor, Maryam Fatimah Abu Bakar, Rozita Hod, Azmawati Mohammed Nawi
Heliyon.2023; 9(5): e15572. CrossRef
The Anti-Adhesion Effect of Nisin as a Robust Lantibiotic on the Colorectal Cancer Cells
Hesam Soleimanifar, Hamideh Mahmoodzadeh Hosseini, Sadra Samavarchi Tehrani, Seyed Ali Mirhosseini
Advanced Biomedical Research.2023;[Epub] CrossRef
Colorectal cancer: epidemiology, carcinogenesis, molecular subtypes and cellular mechanisms of therapy resistance (analytical review)
P. E. Maksimova, E. P. Golubinskaya, B. D. Seferov, E. Yu. Zyablitskaya
Koloproktologia.2023; 22(2): 160. CrossRef
The crosstalk between ubiquitin-conjugating enzyme E2Q1 and p53 in colorectal cancer: An in vitro analysis
Maryam Rasouli, Sara Khakshournia, Omid Vakili, Sanaz Dastghaib, Atefeh Seghatoleslam, Sayed Mohammad Shafiee
Medical Oncology.2023;[Epub] CrossRef
Does postcholecystectomy increase the risk of colorectal cancer?
Zhenyu Dong, Ruixian Shi, Pengda Li, Xiaobiao Song, Fan Dong, Jianmin Zhu, Riga Wu, Zhi Liang, Mingyue Du, Jijun Wang, Zhigang Yang
Frontiers in Microbiology.2023;[Epub] CrossRef
Molecular Mechanisms of the Antitumor Effects of Mesalazine and Its Preventive Potential in Colorectal Cancer
Joanna Słoka, Marcel Madej, Barbara Strzalka-Mrozik
Molecules.2023; 28(13): 5081. CrossRef
Colorectal Cancer: From Risk Factors to Oncogenesis
Vlad Alexandru Ionescu, Gina Gheorghe, Nicolae Bacalbasa, Alexandru Laurentiu Chiotoroiu, Camelia Diaconu
Medicina.2023; 59(9): 1646. CrossRef
Modifiable Risk Factors in High-Risk Groups of Colorectal Cancer Screening: A Cross-Sectional Study with Propensity Score Method
Xuan Zhong, Nongping Feng, Binfa Ouyang, Dan Zhao, Lin Lei, Ji Peng, Xiaolin Peng
Risk Management and Healthcare Policy.2023; Volume 16: 2673. CrossRef
Bioactive Peptides: Potential Impact on the Treatment of Gastrointestinal Cancers
Ghazaleh Pourali, Danial Kazemi, Roozbeh Pourali, Nafise Rahmani, Erfan Razzaghi, Mina Maftooh, Hamid Fiuji, Elnaz Ghorbani, Majid Khazaei, Gordon A. Ferns, Seyed Mahdi Hassanian, Amir Avan
Current Pharmaceutical Design.2023; 29(31): 2450. CrossRef
A novel nutritional risk score and prognosis of oral cancer patients: A prospective study
Qing Chen, Yi Fan, Yanni Li, Jing Wang, Lin Chen, Jing Lin, Fa Chen, Jing Wang, Yu Qiu, Bin Shi, Lizhen Pan, Lisong Lin, Baochang He, Fengqiong Liu
Oral Diseases.2022; 28(1): 108. CrossRef
Antecedentes familiares de primer grado como factor de riesgo en el cáncer colorrectal
María Rubín-García, Vicente Martín, Facundo Vitelli-Storelli, Víctor Moreno, Nuria Aragonés, Eva Ardanaz, Jéssica Alonso-Molero, José J. Jiménez-Moleón, Pilar Amiano, Guillermo Fernández-Tardón, Ana Molina-Barceló, Juan Alguacil, María Dolores-Chirlaque,
Gaceta Sanitaria.2022; 36(4): 345. CrossRef
Diet and Genetic Risk Factors of Colorectal Cancer in Palestine: A Case-Control Study
Issa Ghrouz, Nuha El Sharif
Nutrition and Cancer.2022; 74(7): 2460. CrossRef
Polygenic risk prediction models for colorectal cancer: a systematic review
Michele Sassano, Marco Mariani, Gianluigi Quaranta, Roberta Pastorino, Stefania Boccia
BMC Cancer.2022;[Epub] CrossRef
Meta-Analysis of the Association between Dietary Inflammatory Index (DII) and Colorectal Cancer
Sharifah Saffinas Syed Soffian, Azmawati Mohammed Nawi, Rozita Hod, Mohd Hasni Ja’afar, Zaleha Md Isa, Huan-Keat Chan, Muhammad Radzi Abu Hassan
Nutrients.2022; 14(8): 1555. CrossRef
Lack of Association Between PDCD-1 Polymorphisms and Colorectal Cancer Risk: A Case-Control Study
Jing Lin, Hanshen Chen, Yufang Huang, Weifeng Tang, Sheng Zhang, Yu Chen
Immunological Investigations.2022; 51(6): 1867. CrossRef
Pro-Oxidant and Cytotoxic Effects of Tucum-Do-Cerrado (Bactris setosa Mart.) Extracts in Colorectal Adenocarcinoma Caco-2 Cells
Renata Cristina da Silva, Raphael Rosa Fagundes, Klaas Nico Faber, Élida Geralda Campos
Nutrition and Cancer.2022; 74(10): 3723. CrossRef
Incidence, Mortality Features and Lifetime Risk Estimation of Digestive Tract Cancers in an Urban District of Shanghai, China
Jing-Hao Bi, Hui-Yun Yuan, Yu Jiang, Yun Zhang, Wen-Wei Zheng, Lei Zhang, Zhuo-Ying Li, Hong-Lan Li, Yu-Ting Tan, Wen-Sui Zhao, Yong-Bing Xiang
Journal of Epidemiology and Global Health.2022; 12(3): 248. CrossRef
Combined Effect of Healthy Lifestyle Factors and Risks of Colorectal Adenoma, Colorectal Cancer, and Colorectal Cancer Mortality: Systematic Review and Meta-Analysis
Jiazhou Yu, Qi Feng, Jean H. Kim, Yimin Zhu
Frontiers in Oncology.2022;[Epub] CrossRef
In silico high throughput screening and in vitro validation of a novel Raf/Mek dual inhibitor against colorectal carcinoma
Hassan M. Otifi
Biologia.2022; 77(12): 3555. CrossRef
The importance of regulatory pathway mediated by Circ0001955 in colorectal cancer
Sepideh Kadkhoda, Soudeh Ghafouri-Fard, Farshid Noorbakhsh, Sima Ravaei, Farzaneh Darbeheshti, Mahsa M. Amoli, Reza Taslimi, Abbas Shakoori
Experimental and Molecular Pathology.2022; 128: 104819. CrossRef
Early detection of colorectal cancer based on circular DNA and common clinical detection indicators
Jian Li, Tao Jiang, Zeng-Ci Ren, Zhen-Lei Wang, Peng-Jun Zhang, Guo-An Xiang
World Journal of Gastrointestinal Surgery.2022; 14(8): 833. CrossRef
The Role of CEP55 Expression in Tumor Immune Response and Prognosis of Patients with Non-small Cell lung Cancer
Haiyin Fan, Jin Zhang, Bin Zou, Zhisheng He
Archives of Iranian Medicine.2022; 25(7): 432. CrossRef
Exposome approach for identifying modifiable factors for the prevention of colorectal cancer
Nanqian Chen, Hailun Liang, Tao Huang, Ninghao Huang
Scientific Reports.2022;[Epub] CrossRef
Metabolic pathways in sporadic colorectal carcinogenesis: A new proposal
Sandra Caramujo-Balseiro, Carlos Faro, Lina Carvalho
Medical Hypotheses.2021; 148: 110512. CrossRef
Lifestyle Risk Score: handling missingness of individual lifestyle components in meta-analysis of gene-by-lifestyle interactions
Hanfei Xu, Karen Schwander, Michael R. Brown, Wenyi Wang, R. J. Waken, Eric Boerwinkle, L. Adrienne Cupples, Lisa de las Fuentes, Diana van Heemst, Oyomoare Osazuwa-Peters, Paul S. de Vries, Ko Willems van Dijk, Yun Ju Sung, Xiaoyu Zhang, Alanna C. Morris
European Journal of Human Genetics.2021; 29(5): 839. CrossRef
Inhibition of indoleamine 2,3-dioxygenase 1 synergizes with oxaliplatin for efficient colorectal cancer therapy
Xiaofei Miao, Ye Zhang, Zengyao Li, Longchang Huang, Taojian Xin, Renhui Shen, Tong Wang
Molecular Therapy - Methods & Clinical Development.2021; 20: 442. CrossRef
Polygenic risk score, healthy lifestyles, and risk of incident depression
Zhi Cao, Hongxi Yang, Yixuan Ye, Yuan Zhang, Shu Li, Hongyu Zhao, Yaogang Wang
Translational Psychiatry.2021;[Epub] CrossRef
Analysis of multi-omics differences in left-side and right-side colon cancer
Yanyi Huang, Jinzhong Duanmu, Yushu Liu, Mengyun Yan, Taiyuan Li, Qunguang Jiang
PeerJ.2021; 9: e11433. CrossRef
Individual and Joint Associations of Genetic Risk and Healthy Lifestyle Score with Colorectal Neoplasms Among Participants of Screening Colonoscopy
Vanessa Erben, Prudence R. Carr, Feng Guo, Korbinian Weigl, Michael Hoffmeister, Hermann Brenner
Cancer Prevention Research.2021; 14(6): 649. CrossRef
Correlation between expression levels of lncRNA FER1L4 and RB1 in patients with colorectal cancer
Marjan Ostovarpour, Mohammad Khalaj-Kondori, Tayyebeh Ghasemi
Molecular Biology Reports.2021; 48(5): 4581. CrossRef
Solanaceous Vegetables and Colorectal Cancer Risk: A Hospital-Based Matched Case-Control Study in Northeast China
Yang Liu, Simin Li, Liqing Jiang, Yuchong Zhang, Zhi Li, Jing Shi
Frontiers in Nutrition.2021;[Epub] CrossRef
Lifestyle Score and Genetic Factors With Hypertension and Blood Pressure Among Adults in Rural China
Miaomiao Niu, Liying Zhang, Yikang Wang, Runqi Tu, Xiaotian Liu, Chongjian Wang, Ronghai Bie
Frontiers in Public Health.2021;[Epub] CrossRef
Importance of Circ0009910 in colorectal cancer pathogenesis as a possible regulator of miR-145 and PEAK1
Sepideh Kadkhoda, Reza Taslimi, Farshid Noorbakhsh, Farzaneh Darbeheshti, Javad Tavakkoly Bazzaz, Soudeh Ghafouri-Fard, Abbas Shakoori
World Journal of Surgical Oncology.2021;[Epub] CrossRef
Cancer death and potential years of life lost in Feicheng City, China
Jia Yang, Li Zhao, Nan Zhang, Zhenhua Du, Yanyan Li, Xia Li, Deli Zhao, Jialin Wang
Medicine.2021; 100(39): e27370. CrossRef
A panel of DNA methylation signature from peripheral blood may predict colorectal cancer susceptibility
Justina Ucheojor Onwuka, Dapeng Li, Yupeng Liu, Hao Huang, Jing Xu, Ying Liu, Yuanyuan Zhang, Yashuang Zhao
BMC Cancer.2020;[Epub] CrossRef
A Holistic View of Berberine Inhibiting Intestinal Carcinogenesis in Conventional Mice Based on Microbiome-Metabolomics Analysis
Haitao Chen, Fan Zhang, Jin Zhang, Xinjie Zhang, Yong Guo, Qinghua Yao
Frontiers in Immunology.2020;[Epub] CrossRef
Gastric cancer risk: between genetics and lifestyle
Massimo Rugge
The Lancet Oncology.2020; 21(10): 1258. CrossRef
Barriers of colorectal cancer screening test among adults in the Saudi Population: A Cross-Sectional study
Shatha A. Alduraywish, Leen A. Altamimi, Ashwaq A. Almajed, Bushra A. Kokandi, Rawan S. Alqahtani, Shatha G. Alghaihb, Fahad M. Aldakheel
Preventive Medicine Reports.2020; 20: 101235. CrossRef
Protective Effect of Green Tea Consumption on Colorectal Cancer Varies by Lifestyle Factors
Hyejin Kim, Jeonghee Lee, Jae Hwan Oh, Hee Jin Chang, Dae Kyung Sohn, Aesun Shin, Jeongseon Kim
Nutrients.2019; 11(11): 2612. CrossRef
The Effect of Aerobic Training with Purslane (Portulaca Oleracea) Seed on Toll Like Receptors in Colon Tumor Tissue of Adult Rats with Colon Cancer
Abdol Kheder Keshtvarz, Maghsoud Peeri, Mohammad Ali Azarbayjani, Seyed Ali Hosseini
Jorjani Biomedicine Journal.2019; 7(4): 49. CrossRef

19,185 View
471 Download
60 Web of Science
59 Crossref

Comparison of Breast Conserving Surgery Followed by Radiation Therapy with Mastectomy Alone for Pathologic N1 Breast Cancer Patients in the Era of Anthracycline Plus Taxane-Based Chemotherapy: A Multicenter Retrospective Study (KROG 1418): Gyu Sang Yoo, Won Park, Jeong Il Yu, Doo Ho Choi, Yeon-Joo Kim, Kyung Hwan Shin, Chan Woo Wee, Kyubo Kim, Kyung Ran Park, Yong Bae Kim, Sung Ja Ahn, Jong Hoon Lee, Jin Hee Kim, Mison Chun, Hyung-Sik Lee, Jung Soo Kim, Jihye Cha; Cancer Res Treat. 2019;51(3):1041-1051. Published online November 1, 2018; DOI: https://doi.org/10.4143/crt.2018.424

Abstract PDF PubReader ePub

Purpose
We compared the oncologic outcomes of breast-conserving surgery plus radiation therapy (BCS+RT) and modified radical mastectomy (MRM) under anthracycline plus taxane-based (AT) regimens and investigated the role of adjuvant radiation therapy (RT) in patients with pathologic N1 (pN1) breast cancer treated by mastectomy.
Materials and Methods
We retrospectively reviewed the medical records of 2,011 patients with pN1 breast cancer who underwent BCS+RT or MRM alone at 12 institutions between January 2006 and December 2010. Two-to-one propensity score matching was performed for balances in variables between the groups.
Results
The median follow-up duration for the total cohort was 69 months (range, 1 to 114 months). After propensity score matching, 1,074 patients (676 in the BCS+RT group and 398 in the MRM-alone group) were analyzed finally. The overall survival, disease-free survival, locoregional failure-free survival, and regional failure-free survival (RFFS) curves of the BCS+RT group vs. MRM-alone group were not significantly different. The subgroup analysis revealed that in the group with both lymphovascular invasion (LVI) and histologic grade (HG) III, the BCS+RT showed significantly superior RFFS (p=0.008). Lymphedema (p=0.007) and radiation pneumonitis (p=0.031) occurred more frequently in the BCS+RT group than in the MRM-alone group, significantly.
Conclusion
There are no differences in oncologic outcomes between BCS+RT and MRM-alone groups under the AT chemotherapy regimens for pN1 breast cancer. However, BCS+RT group showed superior RFFS to MRM-alone group in the patients with LVI and HG III. Adjuvant RT might be considerable for pN1 breast cancer patients with LVI and HG III.

Citations

Citations to this article as recorded by

21-gene recurrence score in predicting the outcome of postoperative radiotherapy in T1-2N1 luminal breast cancer after breast-conserving surgery
Shang-Jin Xie, Run-Jie Wang, San-Gang Wu, Fu-Xing Zhang
The Breast.2024; 74: 103679. CrossRef
Assessing Radiation Effects on Chemo-Treated BT20 and 4T1 Breast Cancer, and Neuroblastoma Cell Lines: A Study of Single and Multiple-Cell Ionization via Infrared Laser Trapping
Mulugeta S. Goangul, Daniel B. Erenso, Ying Gao, Li Chen, Kwame O. Eshun, Gisela Alvarez, Horace T. Crogman
Radiation.2024; 4(1): 85. CrossRef
Overall survival after mastectomy versus breast-conserving surgery with adjuvant radiotherapy for early-stage breast cancer: meta-analysis
Kiran K Rajan, Katherine Fairhurst, Beth Birkbeck, Shonnelly Novintan, Rebecca Wilson, Jelena Savović, Chris Holcombe, Shelley Potter
BJS Open.2024;[Epub] CrossRef
Radiotherapy dosimetry and radiotherapy related complications of immediate implant-based reconstruction after breast cancer surgery
Yu Zhang, Fuxiu Ye, Yun Teng, Jin Zheng, Chunlu Li, Ruilan Ma, Haichen Zhang
Frontiers in Oncology.2023;[Epub] CrossRef
Does Breast-Conserving Surgery with Radiotherapy have a Better Survival than Mastectomy? A Meta-Analysis of More than 1,500,000 Patients
Gabriel De la Cruz Ku, Manish Karamchandani, Diego Chambergo-Michilot, Alexis R. Narvaez-Rojas, Michael Jonczyk, Fortunato S. Príncipe-Meneses, David Posawatz, Salvatore Nardello, Abhishek Chatterjee
Annals of Surgical Oncology.2022; 29(10): 6163. CrossRef
Protocol for the postoperative radiotherapy in N1 breast cancer patients (PORT-N1) trial, a prospective multicenter, randomized, controlled, non-inferiority trial of patients receiving breast-conserving surgery or mastectomy
Tae Hoon Lee, Ji Hyun Chang, Bum-Sup Jang, Jae Sik Kim, Tae Hyun Kim, Won Park, Yong Bae Kim, Su Ssan Kim, Wonshik Han, Han-Byoel Lee, Kyung Hwan Shin
BMC Cancer.2022;[Epub] CrossRef
Risk factors to identify the indication for regional nodal irradiation in T1-2N1M0 breast cancer: A joint analysis of 4,243 real-world cases from two institutions
Guang-Yi Sun, Ge Wen, Yu-Jing Zhang, Yu Tang, Hao Jing, Hui Fang, Jian-Yang Wang, Jiang-Hu Zhang, Xu-Ran Zhao, Si-Ye Chen, Yong-Wen Song, Jing Jin, Yue-Ping Liu, Yuan Tang, Shu-Nan Qi, Ning Li, Bo Chen, Ning-Ning Lu, Ye-Xiong Li, Shu-Lian Wang
Frontiers in Oncology.2022;[Epub] CrossRef
Chemo-treated 4T1 breast cancer cells radiation response measured by single and multiple cell ionization using infrared laser trap
Endris Muhammed, Li Chen, Ying Gao, Daniel Erenso
Scientific Reports.2019;[Epub] CrossRef

8,820 View
314 Download
10 Web of Science
8 Crossref

Investigating Trk Protein Expression between Oropharyngeal and Non-oropharyngeal Squamous Cell Carcinoma: Clinical Implications and Possible Roles of Human Papillomavirus Infection: Yoon Ah Cho, Ji Myung Chung, Hyunmi Ryu, Eun Kyung Kim, Byoung Chul Cho, Sun Och Yoon; Cancer Res Treat. 2019;51(3):1052-1063. Published online October 24, 2018; DOI: https://doi.org/10.4143/crt.2018.411

Abstract PDF Supplementary Material PubReader ePub

Purpose
The relationship between head and neck squamous cell carcinoma (HNSCC) and subtypes of tropomyosin-related kinase (Trk) has not been studied in-depth. In this study, we evaluated the expression patterns of TrkA, TrkB, and panTrk and their clinicopathological significance as well as association with p16 expression and human papilloma virus (HPV) status.
Materials and Methods
Total of 396 radically resected oropharyngeal (n=121) and non-oropharyngeal (n=275) HNSCCs were included. Immunohistochemistry for TrkA, TrkB, and panTrk was performed. In addition, p16 immunohistochemistry was performed to assess the HPV status. Using HPV-negative HNSCC cell lines, FaDu and CAL27, HPV type 16 E6/E7 gene was transfected, and then changes of TrkA and TrkB expression were analyzed.
Results
In the clinical samples of HNSCC, high expression of TrkA and panTrk were more associated with oropharyngeal and p16 positive squamous cell carcinoma (SCC). In patients with completely resected (R0-resected) oropharyngeal SCC, high TrkA expression was related to superior overall survival and recurrence-free survival (RFS). In patients with R0-resected oral cavity SCC, high panTrk was related to poor RFS. In HPV type E6/E7 gene-transfected FaDu and CAL27 cell lines, increase of TrkA expression was observed.
Conclusion
It seems that expression pattern of panTrk and TrkA differed according to anatomical sites of HNSCC and was closely related to p16 expression and patient prognosis. Trk expression should be considered in the context of anatomical site, p16 expression or HPV status and Trk subtypes.

Citations

Citations to this article as recorded by

NTRK Gene Expression Analysis in Oral Squamous Cell Carcinoma Mexican Population
Lilibeth Stephania Escoto-Vasquez, Javier Portilla-Robertson, Josué Orlando Ramírez-Jarquín, Luis Fernando Jacinto-Alemán, Alejandro Alonso-Moctezuma, Carla Monserrat Ramírez-Martínez, Osmar Alejandro Chanes-Cuevas, Fabiola Salgado-Chavarria
Dentistry Journal.2024; 12(10): 327. CrossRef
Accuracy of magnetic resonance imaging in the assessment of depth of invasion in tongue carcinoma: A systematic review and meta-analysis
Kondajji Ramachandra Vijayalakshmi, Vanshika Jain
National Journal of Maxillofacial Surgery.2023; 14(3): 341. CrossRef
CYLD Alterations in the Tumorigenesis and Progression of Human Papillomavirus–Associated Head and Neck Cancers
Zhibin Cui, Hyunseok Kang, Jennifer R. Grandis, Daniel E. Johnson
Molecular Cancer Research.2021; 19(1): 14. CrossRef
Genome-wide analysis identifies critical DNA methylations within NTRKs genes in colorectal cancer
Zijian Chen, Zenghong Huang, Yanxin Luo, Qi Zou, Liangliang Bai, Guannan Tang, Xiaolin Wang, Guangwen Cao, Meijin Huang, Jun Xiang, Huichuan Yu
Journal of Translational Medicine.2021;[Epub] CrossRef
Ferroportin and FBXL5 as Prognostic Markers in Advanced Stage Clear Cell Renal Cell Carcinoma
Cheol Keun Park, Jayoon Heo, Won Sik Ham, Young-Deuk Choi, Sang Joon Shin, Nam Hoon Cho
Cancer Research and Treatment.2021; 53(4): 1174. CrossRef
Clinical Significance of Trk Receptor Expression as a New Therapeutic Target in Hepatocellular Carcinoma
Sangjoon Choi, Sujin Park, Yoon Ah Cho, Cheol-Keun Park, Sang Yun Ha
Pathology & Oncology Research.2020; 26(4): 2587. CrossRef
Overexpression of wild type or a Q311E mutant MB21D2 promotes a pro‐oncogenic phenotype in HNSCC
Daniel E. Gracilla, Praveen Kumar Korla, Ming‐Tsung Lai, An‐Jen Chiang, Wen‐Shiung Liou, Jim Jinn‐Chyuan Sheu
Molecular Oncology.2020; 14(12): 3065. CrossRef
NOVA1 induction by inflammation and NOVA1 suppression by epigenetic regulation in head and neck squamous cell carcinoma
Eun Kyung Kim, Yoon Ah Cho, Mi-kyoung Seo, Hyunmi Ryu, Byoung Chul Cho, Yoon Woo Koh, Sun Och Yoon
Scientific Reports.2019;[Epub] CrossRef
Characterization of head and neck squamous cell carcinoma arising in young patients: Particular focus on molecular alteration and tumor immunity
Hyang Joo Ryu, Eun Kyung Kim, Byoung Chul Cho, Sun Och Yoon
Head & Neck.2019; 41(1): 198. CrossRef

7,829 View
247 Download
10 Web of Science
9 Crossref

Oncologic, Perioperative Outcomes of Female Radical Cystectomy: Results from a Multicenter Study in Korea: Ji Sung Shim, Ho Kyung Seo, Ja Hyeon Ku, Byong Chang Jeong, Bumsik Hong, Seok Ho Kang, UCART (Urothelial Cancer-Advanced Research and Treatment Group in Korea) Group; Cancer Res Treat. 2019;51(3):1064-1072. Published online October 30, 2018; DOI: https://doi.org/10.4143/crt.2018.515

Abstract PDF PubReader ePub

Purpose
The lower incidence of bladder cancer among women has led to a lack of information on female radical cystectomy (RC). This study aimed to analyze the characteristics related with female RC in a cohort from multiple academic institutions.
Materials and Methods
This was a retrospective review of 384 female patients who underwent RC for bladder cancer. Epidemiologic, perioperative variables including urologic referral periodwith consequent pathologic stage distributions were assessed. The changes in surgical techniques over time were illustrated. Also, we evaluated recurrence-free survival (RFS) at 2 and 5 years and overall survival (OS) at 5 years with stage-specific analyses using the Kaplan-Meier method.
Results
The mean follow-up time was 35 months (interquartile rage [IQR], 9 to 55). The average time to urologic referral with initial symptoms was 5.5 (IQR, 1 to 6) months and over 20% of patients visited clinics after 6 months. In subsequent stage distributions according to referral period, T2 or higher stage distributions were abruptly increased after 1 year. Overall 2-year/5-year RFS rates were 0.72/0.57 and 5-year OS was 0.61. Notable surgical descriptions were as follows: 91% of patients underwent open RC; 80% of patients underwent an ileal conduit; and 83% of patients received anterior exenteration. However, the proportions of robotic surgery, orthotopic neobladder and organ sparing cystectomy have increased recen-tly.
Conclusion
We identified the general characteristics and changes in pattern of female RC. Our results also suggest that women are susceptible to delays in referral to an urologist and are at greater risk for worse prognosis.

Citations

Citations to this article as recorded by

Perioperative, oncological, and survival outcomes of robotic radical cystectomy with urinary diversion in females
Varun V. Agarwal, B. Yuvaraja Thyavihally, Santosh Subhash Waigankar, Preetham Dev, Abhinav P. Pednekar, Diptiman Roy, Nevitha Athikari, Meenal Hastak, Naresh Badlani, D. Harshwardhan Pokharkar, Nagaraja Sekhar Ayyalasomayajula, Archan Khandekar, Ashish A
Indian Journal of Urology.2023; 39(1): 27. CrossRef
Safety and Efficacy of Reproductive Organ-Sparing Radical Cystectomy in Women With Variant Histology and Advanced Stage
Sunil H. Patel, Shirley Wang, Meredith R. Metcalf, Natasha Gupta, Andrew Gabrielson, Esther Lee, Mary Rostom, Phil Pierorazio, Armine Smith, Noah Hahn, Mark Schoenberg, Max Kates, Jean Hoffman-Censits, Trinity J. Bivalacqua
Clinical Genitourinary Cancer.2022; 20(1): 60. CrossRef
The learning curve for robot-assisted radical cystectomy with total intracorporeal urinary diversion based on radical cystectomy pentafecta
Tae Il Noh, Ji Sung Shim, Sung Gu Kang, Jun Cheon, Jong Hyun Pyun, Seok Ho Kang
Frontiers in Oncology.2022;[Epub] CrossRef

6,799 View
144 Download
3 Web of Science
3 Crossref

A Nomogram for Predicting the Oncotype DX Recurrence Score in Women with T1-3N0-1miM0 Hormone Receptor‒Positive, Human Epidermal Growth Factor 2 (HER2)‒Negative Breast Cancer: Sae Byul Lee, Junetae Kim, Guiyun Sohn, Jisun Kim, Il Yong Chung, Hee Jeong Kim, Beom Seok Ko, Byung Ho Son, Sei-Hyun Ahn, Jong Won Lee, Kyung Hae Jung; Cancer Res Treat. 2019;51(3):1073-1085. Published online November 1, 2018; DOI: https://doi.org/10.4143/crt.2018.357

Abstract PDF Supplementary Material PubReader ePub

Purpose
This preliminary study was conducted to evaluate the association between Oncotype DX (ODX) recurrence score and traditional prognostic factors. We also developed a nomogram to predict subgroups with low ODX recurrence scores (less than 25) and to avoid additional chemotherapy treatments for those patients.
Materials and Methods
Clinicopathological and immunohistochemical variables were retrospectively retrieved and analyzed from a series of 485 T1-3N0-1miM0 hormone receptor-positive, human epidermal growth factor 2‒negative breast cancer patients with available ODX test results at Asan Medical Center from 2010 to 2016. One hundred twenty-seven patients (26%) had positive axillary lymph node micrometastases, and 408 (84%) had ODX recurrence scores of ≤25. Logistic regression was performed to build a nomogram for predicting a low-risk subgroup of the ODX assay.
Results
Multivariate analysis revealed that estrogen receptor (ER) score, progesterone receptor (PR) score, histologic grade, lymphovascular invasion (LVI), and Ki-67 had a statistically significant association with the low-risk subgroup. With these variables, we developed a nomogram to predict the low-risk subgroup with ODX recurrence scores of ≤25. The area under the receiver operating characteristic curve was 0.90 (95% confidence interval [CI], 0.85 to 0.96). When applied to the validation group the nomogram was accurate with an area under the curve = 0.88 (95% CI, 0.83 to 0.95).
Conclusion
The low ODX recurrence score subgroup can be predicted by a nomogram incorporating five traditional prognostic factors: ER, PR, histologic grade, LVI, and Ki-67. Our nomogram, which predicts a low-risk ODX recurrence score, will be a useful tool to help select patients who may or may not need additional ODX testing.

Citations

Citations to this article as recorded by

Efficacy, safety, and predictive model of Palbociclib in the treatment of HR-positive and HER2-negative metastatic breast cancer
Wei Wang, Wenqian Lei, Ziru Fang, Ruiyuan Jiang, Xiaojia Wang
BMC Cancer.2024;[Epub] CrossRef
Development and validation of a clinical breast cancer tool for accurate prediction of recurrence
Asim Dhungana, Augustin Vannier, Fangyuan Zhao, Jincong Q. Freeman, Poornima Saha, Megan Sullivan, Katharine Yao, Elbio M. Flores, Olufunmilayo I. Olopade, Alexander T. Pearson, Dezheng Huo, Frederick M. Howard
npj Breast Cancer.2024;[Epub] CrossRef
Prediction of Oncotype DX Recurrence Score Based on Systematic Evaluation of Ki-67 Scores in Hormone Receptor-Positive Early Breast Cancer
Ji Min Kim, Eun Yoon Cho
Journal of Breast Cancer.2024; 27(3): 201. CrossRef
Development of a nomogram to predict recurrence scores obtained using Oncotype DX in Japanese patients with breast cancer
Akio Shibata, Nobuko Tamura, Keiichi Kinowaki, Aya Nishikawa, Kiyo Tanaka, Yoko Kobayashi, Takuya Ogura, Yuko Tanabe, Hidetaka Kawabata
Breast Cancer.2024; 31(6): 1018. CrossRef
Shear-wave elastography-based nomograms predicting 21-gene recurrence score for adjuvant chemotherapy decisions in patients with breast cancer
Ji Hyun Youk, Eun Ju Son, Joon Jeong, Hye Mi Gweon, Na Lae Eun, Jeong-Ah Kim
European Journal of Radiology.2023; 158: 110638. CrossRef
Prediction of Oncotype DX Recurrence Score Using Clinicopathological Variables in Estrogen Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Breast Cancer
Min Chong Kim, Sun Young Kwon, Jung Eun Choi, Su Hwan Kang, Young Kyung Bae
Journal of Breast Cancer.2023; 26(2): 105. CrossRef
Clinicopathological Factors Associated with Oncotype DX Risk Group in Patients with ER+/HER2- Breast Cancer
Ran Song, Dong-Eun Lee, Eun-Gyeong Lee, Seeyoun Lee, Han-Sung Kang, Jai Hong Han, Keun Seok Lee, Sung Hoon Sim, Heejung Chae, Youngmee Kwon, Jaeyeon Woo, So-Youn Jung
Cancers.2023; 15(18): 4451. CrossRef
A simplified risk scoring system for predicting high-risk groups in gene expression tests for patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative, and node-positive breast cancer
Kwang Hyun Yoon, Suk Jun Lee, Yujin Kim, Jee Hyun Ahn, Jee Ye Kim, Hyung Seok Park, Seung Il Kim, Seho Park
Annals of Surgical Treatment and Research.2023; 105(6): 360. CrossRef
Deep Learning-Based Pathology Image Analysis Enhances Magee Feature Correlation With Oncotype DX Breast Recurrence Score
Hongxiao Li, Jigang Wang, Zaibo Li, Melad Dababneh, Fusheng Wang, Peng Zhao, Geoffrey H. Smith, George Teodoro, Meijie Li, Jun Kong, Xiaoxian Li
Frontiers in Medicine.2022;[Epub] CrossRef
A Novel Surrogate Nomogram Capable of Predicting OncotypeDX Recurrence Score©
Matthew G. Davey, Amirhossein Jalali, Éanna J. Ryan, Ray P. McLaughlin, Karl J. Sweeney, Michael K. Barry, Carmel M. Malone, Maccon M. Keane, Aoife J. Lowery, Nicola Miller, Michael J. Kerin
Journal of Personalized Medicine.2022; 12(7): 1117. CrossRef
Use of a supervised machine learning model to predict Oncotype DX risk category in node-positive patients older than 50 years of age
Austin D. Williams, Kate R. Pawloski, Hannah Y. Wen, Varadan Sevilimedu, Donna Thompson, Monica Morrow, Mahmoud El-Tamer
Breast Cancer Research and Treatment.2022; 196(3): 565. CrossRef
The Role of Oncotype DX® Recurrence Score in Predicting Axillary Response After Neoadjuvant Chemotherapy in Breast Cancer
Jaime A. Pardo, Betty Fan, Alessandra Mele, Stephanie Serres, Monica G. Valero, Isha Emhoff, Amulya Alapati, Ted A. James
Annals of Surgical Oncology.2021; 28(3): 1320. CrossRef
A nomogram to predict the high-risk RS in HR+/HER2-breast cancer patients older than 50 years of age
Jing Yu, Jiayi Wu, Ou Huang, Jianrong He, Li Zhu, Weiguo Chen, Yafen Li, Xiaosong Chen, Kunwei Shen
Journal of Translational Medicine.2021;[Epub] CrossRef
Clinicopathological correlates, oncological impact, and validation of Oncotype DX™ in a European Tertiary Referral Centre
Matthew G. Davey, Éanna J. Ryan, Sami Abd Elwahab, Jessie A. Elliott, Peter F. McAnena, Karl J. Sweeney, Carmel M. Malone, Ray McLaughlin, Michael K. Barry, Maccon M. Keane, Aoife J. Lowery, Michael J. Kerin
The Breast Journal.2021; 27(6): 521. CrossRef
Dynamic contrast enhanced-MRI and diffusion-weighted image as predictors of lymphovascular invasion in node-negative invasive breast cancer
Bo Bae Choi
World Journal of Surgical Oncology.2021;[Epub] CrossRef
Prognostic value of the 21-gene recurrence score for regional recurrence in patients with estrogen receptor-positive breast cancer
Minji Koh, Jinhong Jung, Su Ssan Kim, Seung Do Ahn, Eun Kyung Choi, Il Yong Chung, Jong Won Lee, Sung-Bae Kim, Jae Ho Jeong
Breast Cancer Research and Treatment.2021; 188(3): 583. CrossRef
A nomogram for predicting probability of low risk of MammaPrint results in women with clinically high-risk breast cancer
Young Joo Lee, Young Sol Hwang, Junetae Kim, Sei-Hyun Ahn, Byung Ho Son, Hee Jeong Kim, Beom Seok Ko, Jisun Kim, Il Yong Chung, Jong Won Lee, Sae Byul Lee
Scientific Reports.2021;[Epub] CrossRef
Development of a Nomogram to Predict the Recurrence Score of 21-Gene Prediction Assay in Hormone Receptor–Positive Early Breast Cancer
Shin Hye Yoo, Tae-Yong Kim, Miso Kim, Kyung-Hun Lee, Eunshin Lee, Han-Byoel Lee, Hyeong-Gon Moon, Wonshik Han, Dong-Young Noh, Sae-Won Han, Tae-You Kim, Seock-Ah Im
Clinical Breast Cancer.2020; 20(2): 98. CrossRef
Ki‐67 index, progesterone receptor expression, histologic grade and tumor size in predicting breast cancer recurrence risk: A consecutive cohort study
Yanna Zhang, Yidong Zhou, Feng Mao, Ru Yao, Qiang Sun
Cancer Communications.2020; 40(4): 181. CrossRef
Estrogen and Progesterone Receptor Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Guideline Update
Kimberly H. Allison, M. Elizabeth H. Hammond, Mitchell Dowsett, Shannon E. McKernin, Lisa A. Carey, Patrick L. Fitzgibbons, Daniel F. Hayes, Sunil R. Lakhani, Mariana Chavez-MacGregor, Jane Perlmutter, Charles M. Perou, Meredith M. Regan, David L. Rimm, W
Archives of Pathology & Laboratory Medicine.2020; 144(5): 545. CrossRef
Oncotype DX Predictive Nomogram for Recurrence Score Output: The Novel System ADAPTED01 Based on Quantitative Immunochemistry Analysis
Fabio Marazzi, Roberto Barone, Valeria Masiello, Valentina Magri, Antonino Mulè, Angela Santoro, Federica Cacciatori, Luca Boldrini, Gianluca Franceschini, Francesca Moschella, Giuseppe Naso, Silverio Tomao, Maria Antonietta Gambacorta, Giovanna Mantini,
Clinical Breast Cancer.2020; 20(5): e600. CrossRef

12,288 View
332 Download
26 Web of Science
21 Crossref

Effect of Platinum-Based Chemotherapy on PD-L1 Expression on Tumor Cells in Non-small Cell Lung Cancer: Junghoon Shin, Jin-Haeng Chung, Se Hyun Kim, Kyu Sang Lee, Koung Jin Suh, Ji Yun Lee, Ji-Won Kim, Jeong-Ok Lee, Jin-Won Kim, Yu-Jung Kim, Keun-Wook Lee, Jee Hyun Kim, Soo-Mee Bang, Jong-Seok Lee; Cancer Res Treat. 2019;51(3):1086-1097. Published online November 5, 2018; DOI: https://doi.org/10.4143/crt.2018.537

Abstract PDF PubReader ePub

Purpose
Programmed death-1 (PD-1)/PD-1 ligand (PD-L1) axis blockades have revolutionized the treatment of advanced non-small cell lung cancer (NSCLC). We assessed the effect of platinum-based chemotherapy on tumor PD-L1 expression and its clinical implications.
Materials and Methods
We used immunohistochemistry to retrospectively evaluate the percentage of tumor cells with membranous PD-L1 staining (tumor proportion score) in paired tumor specimens obtained before and after platinum-based neoadjuvant chemotherapy (NACT) in 86 patients with NSCLC. We analyzed the correlation between the change in PD-L1 tumor proportion score and clinicopathologic characteristics, response to NACT, and survival.
Results
The PD-L1 tumor proportion score increased in a significant proportion of patients with NSCLC after platinum-based NACT (Wilcoxon signed-rank test, p=0.002). That pattern was consistent across clinically defined subgroups except for patients with partial response to NACT. Tumors from 26 patients (30.2%) were PD-L1‒negative before NACT but PD-L1-positive after NACT, whereas the reverse pattern occurred in six patients (7%) (McNemar’s test, p < 0.001). Increase in PD-L1 tumor proportion score was significantly associated with lack of response to NACT (Fisher exact test, p=0.015). There was a tendency, albeit not statistically significant, for patients with an increase in PD-L1 tumor proportion score to have shorter survival.
Conclusion
Tumor PD-L1 expression increased after platinum-based NACT in a significant proportion of patients with NSCLC. Increase in tumor PD-L1 expression may predict poor clinical outcome.

Citations

Citations to this article as recorded by

Potential Predictive Immune and Metabolic Biomarkers of Tumor Microenvironment Regarding Pathological and Clinical Response in Esophageal Cancer After Neoadjuvant Chemoradiotherapy: A Systematic Review
H. H. Wang, E. N. Steffens, G. Kats-Ugurlu, B. van Etten, J. G. M. Burgerhof, G. A. P. Hospers, J. T. M. Plukker
Annals of Surgical Oncology.2024; 31(1): 433. CrossRef
Redetermination of PD-L1 expression after chemio-radiation in locally advanced PDL1 negative NSCLC patients: retrospective multicentric analysis
Patrizia Ciammella, Salvatore Cozzi, Paolo Borghetti, Marco Galaverni, Valerio Nardone, Maria Paola Ruggieri, Matteo Sepulcri, Vieri Scotti, Alessio Bruni, Francesca Zanelli, Roberto Piro, Elena Tagliavini, Andrea Botti, Federico Iori, Emanuele Alì, Chiar
Frontiers in Oncology.2024;[Epub] CrossRef
First exploration of the on-treatment changes in tumor and organ uptake of a radiolabeled anti PD-L1 antibody during chemoradiotherapy in patients with non-small cell lung cancer using whole body PET
Johanna E E Pouw, Sayed M S Hashemi, Marc C Huisman, Jessica E Wijngaarden, Maarten Slebe, Daniela E Oprea-Lager, Gerben J C Zwezerijnen, Danielle Vugts, Ezgi B Ulas, Tanja D de Gruijl, Teodora Radonic, Suresh Senan, C Willemien Menke-van der Houven van O
Journal for ImmunoTherapy of Cancer.2024; 12(2): e007659. CrossRef
Use of non-small cell lung cancer multicellular tumor spheroids to study the impact of chemotherapy
Pauline Hulo, Sophie Deshayes, Judith Fresquet, Anne-Laure Chéné, Stéphanie Blandin, Nicolas Boisgerault, Jean-François Fonteneau, Lucas Treps, Marc G Denis, Jaafar Bennouna, Delphine Fradin, Elvire Pons-Tostivint, Christophe Blanquart
Respiratory Research.2024;[Epub] CrossRef
Alteration of PD-L1 (SP142) status after neoadjuvant chemotherapy and its clinical significance in triple-negative breast cancer
Ji Won Woo, Eun Kyung Han, Koung Jin Suh, Se Hyun Kim, Jee Hyun Kim, So Yeon Park
Breast Cancer Research and Treatment.2024; 207(2): 301. CrossRef
Transforming Lung Cancer Management: A Promising Case Study of Immune Checkpoint Inhibitor Success Following a Multidisciplinary Approach
Tadashi Nishimura, Hajime Fujimoto, Takumi Fujiwara, Tomohito Okano, Taro Yasuma, Esteban C. Gabazza, Hidenori Ibata, Tetsu Kobayashi
Diagnostics.2024; 14(19): 2159. CrossRef
Increased Tumor Mutation Burden Levels and Sensitivity of Non–Small Cell Lung Cancer to PD-L1 Blockade—Reply
Biagio Ricciuti, Xinan Wang, Mark M. Awad
JAMA Oncology.2023; 9(4): 570. CrossRef
Add-On Effect of Hemagglutinating Virus of Japan Envelope Combined with Chemotherapy or Immune Checkpoint Inhibitor against Malignant Pleural Mesothelioma: An In Vivo Study
Kazuma Sakura, Masao Sasai, Soichiro Funaki, Yasushi Shintani, Meinoshin Okumura, Yasufumi Kaneda
Cancers.2023; 15(3): 929. CrossRef
Predictive biomarkers for PD-1/PD-L1 checkpoint inhibitor response in NSCLC: an analysis of clinical trial and real-world data
WeiQing Venus So, David Dejardin, Eva Rossmann, Jehad Charo
Journal for ImmunoTherapy of Cancer.2023; 11(2): e006464. CrossRef
Neoadjuvant treatment does not influence PD-L1 expression in stage III non-small-cell lung cancer: a retrospective analysis of tumor samples from the trials SAKK 16/96, 16/00, 16/01, and 16/14
D. König, S. Savic Prince, S. Hayoz, P. Zens, S. Berezowska, W. Jochum, E. Stauffer, V. Braunersreuther, B. Trachsel, S. Thierstein, M. Mark, S. Schmid, A. Curioni-Fontecedro, A. Addeo, I. Opitz, M. Guckenberger, M. Früh, D.C. Betticher, H.-B. Ris, R. Stu
ESMO Open.2023; 8(4): 101595. CrossRef
Poliovirus receptor (PVR) mediates carboplatin-induced PD-L1 expression in non-small-cell lung cancer cells
Chen Fu, Zongcai Liu, Taixue An, Haixia Li, Xiumei Hu, Xin Li, Xinyao Liu, Danjuan Wu, Ruyi Zhang, Kui Li, Yurong Qiu, Haifang Wang
Biochimica et Biophysica Acta (BBA) - General Subjects.2023; 1867(10): 130439. CrossRef
Remarkable Response to Immune Checkpoint Inhibitor Monotherapy in an EGFR-Mutant Pulmonary Adenocarcinoma Patient With 0% Expression of PD-L1
Tetsuo Fujita, Hiroyuki Amano, Makoto Nakamura, Satoshi Hirano, Sukeyuki Nakamura
Journal of Thoracic Oncology.2023; 18(9): e93. CrossRef
Effect of Chemotherapeutics on In Vitro Immune Checkpoint Expression in Non-Small Cell Lung Cancer
Yu Zhao, Zhe Wang, Xiuhuan Shi, Ting Liu, Wenwen Yu, Xiubao Ren, Hua Zhao
Technology in Cancer Research & Treatment.2023;[Epub] CrossRef
The Role of Regulatory T Cells in Cancer Treatment Resistance
Anna Dąbrowska, Magdalena Grubba, Amar Balihodzic, Olga Szot, Bartosz Kamil Sobocki, Adrian Perdyan
International Journal of Molecular Sciences.2023; 24(18): 14114. CrossRef
Redirecting Chemotherapeutics to the Endoplasmic Reticulum Increases Tumor Immunogenicity and Potentiates Anti‐PD‐L1 Therapy
Yucheng Xiang, Liqiang Chen, Chendong Liu, Xiaoli Yi, Lian Li, Yuan Huang
Small.2022;[Epub] CrossRef
FGFR3 Destabilizes PD-L1 via NEDD4 to Control T-cell–Mediated Bladder Cancer Immune Surveillance
Weiqiang Jing, Ganyu Wang, Zhiwei Cui, Gaozhong Xiong, Xin Jiang, Yue Li, Wushan Li, Bo Han, Shouzhen Chen, Benkang Shi
Cancer Research.2022; 82(1): 114. CrossRef
The immune modifying effects of chemotherapy and advances in chemo-immunotherapy
Daniel R. Principe, Suneel D. Kamath, Murray Korc, Hidayatullah G. Munshi
Pharmacology & Therapeutics.2022; 236: 108111. CrossRef
Adjuvant durvalumab for esophageal squamous cell carcinoma after neoadjuvant chemoradiotherapy: a placebo-controlled, randomized, double-blind, phase II study
S. Park, J.-M. Sun, Y.-L. Choi, D. Oh, H.K. Kim, T. Lee, S.A. Chi, S.-H. Lee, Y.S. Choi, S.-H. Jung, M.-J. Ahn, Y.C. Ahn, K. Park, Y.M. Shim
ESMO Open.2022; 7(1): 100385. CrossRef
Analytical validation and initial clinical testing of quantitative microscopic evaluation for PD-L1 and HLA I expression on circulating tumor cells from patients with non-small cell lung cancer
Jennifer L. Schehr, Nan Sethakorn, Zachery D. Schultz, Camila I. Hernandez, Rory M. Bade, Diego Eyzaguirre, Anupama Singh, David J. Niles, Leslie Henderson, Jay W. Warrick, Scott M. Berry, Kaitlin E. Sundling, David J. Beebe, Ticiana A. Leal, Joshua M. La
Biomarker Research.2022;[Epub] CrossRef
Translational Learnings in the Development of Chemo-Immunotherapy Combination to Bypass the Cold Tumor Microenvironment in Pancreatic Ductal Adenocarcinoma
Hélène Kaplon
Frontiers in Oncology.2022;[Epub] CrossRef
Cost-effectiveness analyses of durvalumab consolidation therapy versus no consolidation therapy after chemoradiotherapy in stage-III NSCLC
Salman Hussain, Jitka Klugarova, Miloslav Klugar
Lung Cancer.2022; 170: 11. CrossRef
Efficacy comparison of immune treating strategies for NSCLC patients with negative PD-L1 expression
Kaiyue Ding, Minhan Yi, Hui Liang, Zhongkui Li, Yuan Zhang
Expert Review of Clinical Immunology.2022; 18(7): 759. CrossRef
Dual inhibition of TGFβ signaling and CSF1/CSF1R reprograms tumor-infiltrating macrophages and improves response to chemotherapy via suppressing PD-L1
Tsung-Wei Chen, Wei-Ze Hung, Shu-Fen Chiang, William Tzu-Liang Chen, Tao-Wei Ke, Ji-An Liang, Chih-Yang Huang, Pei-Chen Yang, Kevin Chih-Yang Huang, K.S. Clifford Chao
Cancer Letters.2022; 543: 215795. CrossRef
SP142 PD-L1 Assays in Multiple Samples from the Same Patients with Early or Advanced Triple-Negative Breast Cancer
Seung Ho Baek, Jee Hung Kim, Soong June Bae, Jung Hwan Ji, Yangkyu Lee, Joon Jeong, Yoon Jin Cha, Sung Gwe Ahn
Cancers.2022; 14(13): 3042. CrossRef
Case Report: Sustained complete remission on combination therapy with olaparib and pembrolizumab in BRCA2-mutated and PD-L1-positive metastatic cholangiocarcinoma after platinum derivate
Taotao Zhou, Robert Mahn, Christian Möhring, Farsaneh Sadeghlar, Carsten Meyer, Marieta Toma, Barbara Kreppel, Markus Essler, Tim Glowka, Hanno Matthaei, Jörg C. Kalff, Christian P. Strassburg, Maria A. Gonzalez-Carmona
Frontiers in Oncology.2022;[Epub] CrossRef
Is there a place for chemotherapy in first line of treatment for metastatic NSCLC in era of immunotherapy?
D. I. Yudin, K. K. Laktionov
Medical alphabet.2022; (13): 18. CrossRef
The effect of neoadjuvant therapy on PD-L1 expression and CD8+lymphocyte density in non-small cell lung cancer
Philipp Zens, Corina Bello, Amina Scherz, Michael von Gunten, Adrian Ochsenbein, Ralph A. Schmid, Sabina Berezowska
Modern Pathology.2022; 35(12): 1848. CrossRef
MicroRNAs and Drug Resistance in Non-Small Cell Lung Cancer: Where Are We Now and Where Are We Going
Roberto Cuttano, Miriam Kuku Afanga, Fabrizio Bianchi
Cancers.2022; 14(23): 5731. CrossRef
miRNome profiling of lung cancer metastases revealed a key role for miRNA-PD-L1 axis in the modulation of chemotherapy response
Roberto Cuttano, Tommaso Colangelo, Juliana Guarize, Elisa Dama, Maria Pia Cocomazzi, Francesco Mazzarelli, Valentina Melocchi, Orazio Palumbo, Elena Marino, Elena Belloni, Francesca Montani, Manuela Vecchi, Massimo Barberis, Paolo Graziano, Andrea Pasqui
Journal of Hematology & Oncology.2022;[Epub] CrossRef
PD‐1 blockade using pembrolizumab in adolescent and young adult patients with advanced bone and soft tissue sarcoma
Tahlia Scheinberg, Anna Lomax, Martin Tattersall, David Thomas, Geoff McCowage, Michael Sullivan, Rooshdiya Karim, Peter P. Luk, Annabelle Mahar, Fiona Bonar, Vivek A. Bhadri
Cancer Reports.2021;[Epub] CrossRef
PD‐L1 versus tumor mutation burden: Which is the better immunotherapy biomarker in advanced non‐small cell lung cancer?
Aoran Dong, Yiming Zhao, Zhihua Li, Hai Hu
The Journal of Gene Medicine.2021;[Epub] CrossRef
Biomarkers predicting the response to chemotherapy and the prognosis in patients with esophageal squamous cell carcinoma
Seiya Inoue, Takahiro Yoshida, Takeshi Nishino, Masakazu Goto, Mariko Aoyama, Naoya Kawakita, Yota Yamamoto, Furukita Yoshihito, Hiromitsu Takizawa, Akira Tangoku
General Thoracic and Cardiovascular Surgery.2021; 69(3): 525. CrossRef
Patient-Reported Outcomes with Durvalumab by PD-L1 Expression and Prior Chemoradiotherapy-Related Variables in Unresectable Stage III Non-Small-Cell Lung Cancer
Marina C Garassino, Luis Paz-Ares, Rina Hui, Corinne Faivre-Finn, Alex Spira, David Planchard, Mustafa Özgüroğlu, Davey Daniel, David Vicente, Shuji Murakami, Corey Langer, Suresh Senan, David Spigel, Anna Rydén, Yiduo Zhang, Cathy O'Brien, Phillip A Denn
Future Oncology.2021; 17(10): 1165. CrossRef
Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer
S. Sugawara, J.-S. Lee, J.-H. Kang, H.R. Kim, N. Inui, T. Hida, K.H. Lee, T. Yoshida, H. Tanaka, C.-T. Yang, M. Nishio, Y. Ohe, T. Tamura, N. Yamamoto, C.-J. Yu, H. Akamatsu, Y. Namba, N. Sumiyoshi, K. Nakagawa
Annals of Oncology.2021; 32(9): 1137. CrossRef
Temporal evolution of programmed death-ligand 1 expression in patients with non-small cell lung cancer
Chang Hyun Nam, Jaemoon Koh, Chan-Young Ock, Miso Kim, Bhumsuk Keam, Tae Min Kim, Yoon Kyung Jeon, Dong-Wan Kim, Doo Hyun Chung, Dae Seog Heo
The Korean Journal of Internal Medicine.2021; 36(4): 975. CrossRef
Methylseleninic acid overcomes programmed death‐ligand 1‐mediated resistance of prostate cancer and lung cancer
Wenli Hu, Yurong Ma, Chong Zhao, Shutao Yin, Hongbo Hu
Molecular Carcinogenesis.2021; 60(11): 746. CrossRef
Immunological Status of Bladder Cancer Patients Based on Urine Leukocyte Composition at Radical Cystectomy
Elisabet Cantó, Óscar Rodríguez Faba, Carlos Zamora, Maria Mulet, Maria Soledad Garcia-Cuerva, Ana Palomino, Georgia Anguera, Alberto Breda, Pablo Maroto, Sílvia Vidal
Biomedicines.2021; 9(9): 1125. CrossRef
Ex vivo expanded allogeneic natural killer cells have potent cytolytic activity against cancer cells through different receptor-ligand interactions
Daun Jung, Young Seok Baek, In Jee Lee, Ki Yeon Kim, Heejoo Jang, Sohyun Hwang, Jieun Jung, Yong-wha Moon, Kyung-Soon Park, Yong-Soo Choi, Hee Jung An
Journal of Experimental & Clinical Cancer Research.2021;[Epub] CrossRef
Prognostic significance of T‐cell–inflamed gene expression profile and PD‐L1 expression in patients with esophageal cancer
Torben Steiniche, Sun Young Rha, Hyun Cheol Chung, Jeanette Baehr Georgsen, Morten Ladekarl, Marianne Nordsmark, Marie Louise Jespersen, Hyo Song Kim, Hyunki Kim, Carly Fein, Laura H. Tang, Ting Wu, Matthew J. Marton, Senaka Peter, David P. Kelsen, Geoffr
Cancer Medicine.2021; 10(23): 8365. CrossRef
A novel form of immunotherapy using antigen peptides conjugated on PD-L1 antibody
Eun Ji Lee, Gun-Young Jang, Sung Eun Lee, Ji won Lee, Hee Dong Han, Yeong-Min Park, Tae Heung Kang
Immunology Letters.2021;[Epub] CrossRef
Assessment of the expression of the immune checkpoint molecules PD‐1, CTLA4, TIM‐3 and LAG‐3 across different cancers in relation to treatment response, tumor‐infiltrating immune cells and survival
Lei Tu, Renguo Guan, Hanting Yang, Yu Zhou, Weifeng Hong, Liheng Ma, Guangzhe Zhao, Min Yu
International Journal of Cancer.2020; 147(2): 423. CrossRef
Smokers or non-smokers: who benefits more from immune checkpoint inhibitors in treatment of malignancies? An up-to-date meta-analysis
Jiahang Mo, Xiao Hu, Lihu Gu, Bangsheng Chen, Parikshit Asutosh Khadaroo, Zefeng Shen, Lei Dong, Yuqi Lv, Marylin Nyaradzo Chitumba, Jiequan Liu
World Journal of Surgical Oncology.2020;[Epub] CrossRef
Prognostic value of PD-L1 expression on tumor cells combined with CD8+ TIL density in patients with locally advanced non-small cell lung cancer treated with concurrent chemoradiotherapy
Kathrin Gennen, Lukas Käsmann, Julian Taugner, Chukwuka Eze, Monika Karin, Olarn Roengvoraphoj, Jens Neumann, Amanda Tufman, Michael Orth, Simone Reu, Claus Belka, Farkhad Manapov
Radiation Oncology.2020;[Epub] CrossRef
PD-L1 induction in tumor tissue after hypofractionated thoracic radiotherapy for non-small cell lung cancer
Jaanika Narits, Hannes Tamm, Jana Jaal
Clinical and Translational Radiation Oncology.2020; 22: 83. CrossRef
Variation of PD-L1 expression in locally advanced cervical cancer following neoadjuvant chemotherapy
Yun Liang, Minghua Yu, Caiyun Zhou, Xiaojun Zhu
Diagnostic Pathology.2020;[Epub] CrossRef
Application of immune checkpoint inhibitors in EGFR-mutant non-small-cell lung cancer: from bed to bench
Rui Jin, Jing Zhao, Lexin Xia, Qin Li, Wen Li, Ling Peng, Yang Xia
Therapeutic Advances in Medical Oncology.2020;[Epub] CrossRef
Independent Prognostic Value of Intratumoral Heterogeneity and Immune Response Features by Automated Digital Immunohistochemistry Analysis in Early Hormone Receptor-Positive Breast Carcinoma
Dovile Zilenaite, Allan Rasmusson, Renaldas Augulis, Justinas Besusparis, Aida Laurinaviciene, Benoit Plancoulaine, Valerijus Ostapenko, Arvydas Laurinavicius
Frontiers in Oncology.2020;[Epub] CrossRef
Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors
Lorenzo Galluzzi, Juliette Humeau, Aitziber Buqué, Laurence Zitvogel, Guido Kroemer
Nature Reviews Clinical Oncology.2020; 17(12): 725. CrossRef
Re-biopsy after first line treatment in advanced NSCLC can reveal changes in PD-L1 expression
Malene Støchkel Frank, Uffe Bødtger, Asbjørn Høegholm, Inger Merete Stamp, Julie Gehl
Lung Cancer.2020; 149: 23. CrossRef
The Mechanisms of PD-L1 Regulation in Non-Small-Cell Lung Cancer (NSCLC): Which Are the Involved Players?
Giuseppe Lamberti, Monia Sisi, Elisa Andrini, Arianna Palladini, Francesca Giunchi, Pier-Luigi Lollini, Andrea Ardizzoni, Francesco Gelsomino
Cancers.2020; 12(11): 3129. CrossRef
The Dichotomous Role of Bone Marrow Derived Cells in the Chemotherapy-Treated Tumor Microenvironment
Avital Vorontsova, Tal Kan, Ziv Raviv, Yuval Shaked
Journal of Clinical Medicine.2020; 9(12): 3912. CrossRef
Adjuvant Chemotherapy Increases Programmed Death-Ligand 1 (PD-L1) Expression in Non–small Cell Lung Cancer Recurrence
Max Lacour, Stefanie Hiltbrunner, Seok-Yun Lee, Alex Soltermann, Elisabeth Jane Rushing, Davide Soldini, Walter Weder, Alessandra Curioni-Fontecedro
Clinical Lung Cancer.2019; 20(5): 391. CrossRef
PD-L1 Testing in Non-small Cell Lung Cancer: Past, Present, and Future
Hyojin Kim, Jin-Haeng Chung
Journal of Pathology and Translational Medicine.2019; 53(4): 199. CrossRef

11,058 View
481 Download
58 Web of Science
53 Crossref

Patient and Care Delays of Breast Cancer in China: Yue-Lin Li, Ya-Chao Qin, Lu-Ying Tang, Yu-Huang Liao, Wei Zhang, Xiao-Ming Xie, Qiang Liu, Ying Lin, Ze-Fang Ren; Cancer Res Treat. 2019;51(3):1098-1106. Published online November 6, 2018; DOI: https://doi.org/10.4143/crt.2018.386

Abstract PDF Supplementary Material PubReader ePub

Purpose
This study differentiates patient and care delays of breast cancer and explores the related factors as well as the associations with the prognosis in Guangzhou, a southern city of China.
Methods
A cohort of female incident breast cancer patients (n=1,551) was recruited from October 2008 to March 2012 and followed up until January 1, 2016 (n=1,374) in the affiliated hospitals of Sun Yat-sen University. The factors associated with patient and care delays were analyzed with multivariable logistic models. Cox proportional hazards regression models were constructed to estimate the impacts of the delays on the prognosis.
Results
There were 40.4% patient delay (≥3 months) and 15.5% care delay (≥1 month). The patient delay, but not the care delay, was significantly related to the clinical stage and consequently worsened the prognosis of breast cancer (hazard ratio, 1.45; 95% confidence interval, 1.09 to 1.91 for progression-free survival). The factors related to an increased patient delay included premenopausal status, history of benign breast disease, and less physical examination.
Conclusion
Patient delay was the main type of delay in Guangzhou and resulted in higher clinical stage and poor prognosis of breast cancer. Screening for breast cancer among premenopausal women may be an effective way to reduce this delay.

Citations

Citations to this article as recorded by

Delays in diagnosis and surgery of sarcoma patients during the COVID-19 outbreak in Spain
Jaime Carrillo-García, Serena Lacerenza, Nadia Hindi, Irene Carrasco García, Gloria Marquina, Juana María Cano Cano, Javier Martínez Trufero, Alberto Rafael Sevillano Tripero, Tania Luis García, Manuel Jorge Cuesta Rioboo, David S. Moura, Marta Renshaw, J
Therapeutic Advances in Medical Oncology.2024;[Epub] CrossRef
Impact of the pandemic on surgical oncology in Piedmont, Italy: A retrospective observational study
Giuseppina Lo Moro, Paolo Ragusa, Christian Previti, Alessandro Comandone, Mario Airoldi, Massimo Aglietta, Roberta Siliquini
Journal of Surgical Oncology.2024; 129(6): 1165. CrossRef
Analysis on status quo and related factors of delays in diagnosis and treatment of breast cancer in Ningxia Hui Autonomous Region
Yuchen Wang, Zhoulan Bai, Qingyuan Liu, Hui Yu, Zhenning Tang, Xiang Liu, Qilun Liu
Medicine.2024; 103(17): e37826. CrossRef
Act or Wait? Presentation Delay in Symptomatic Breast Cancer in China
Jinghua An, Alana D. Steffen, Eileen G. Collins, Yamilé Molina, Xiaomei Li, Carol E. Ferrans
Cancer Nursing.2024;[Epub] CrossRef
Icariside II Suppresses the Malignant Behaviors of Breast Cancer Cells by Inhibiting PTGES3 Expression
Dongying Zhang, Shichao Zhuo, Bo Bi, Yong Liu
Revista Brasileira de Farmacognosia.2024; 34(6): 1353. CrossRef
Systems delay in women with breast cancer – A sequential explanatory mixed-methods study from central rural India
Juhi Raut, Abhishek Joshi, Abhay Mudey
Journal of Family Medicine and Primary Care.2024; 13(11): 5325. CrossRef
Duration of the patient interval in breast cancer and factors associated with longer delays in low‐and middle‐income countries: A systematic review with meta‐analysis
Dafina Petrova, Dunia Garrido, Zuzana Špacírová, Nicolás Francisco Fernández‐Martínez, Ganka Ivanova, Miguel Rodríguez‐Barranco, Marina Pollán, Rocío Barrios‐Rodríguez, Maria José Sánchez
Psycho-Oncology.2023; 32(1): 13. CrossRef
The Firmicutes/Bacteroidetes Ratio as a Risk Factor of Breast Cancer
Jeongshin An, Hyungju Kwon, Young Ju Kim
Journal of Clinical Medicine.2023; 12(6): 2216. CrossRef
Delayed Presentation, Diagnosis, and Treatment of Breast Cancer Among Chinese Women
Jinghua An, Patricia E. Hershberger, Carol Estwing Ferrans
Cancer Nursing.2023; 46(3): 217. CrossRef
Unravelling the predictors of late cancer presentation and diagnosis in Jordan: a cross-sectional study of patients with lung and colorectal cancers
Rana Damsees, Madi Jaghbir, Mahmoud Salam, Amal Al-Omari, Nedal Al-Rawashdeh
BMJ Open.2023; 13(5): e069529. CrossRef
Predictors of Medical Care Delay or Avoidance Among Chinese Adults During the COVID-19 Pandemic
Lili Kang, Changle Li, Huifeng Du
Patient Preference and Adherence.2023; Volume 17: 3067. CrossRef
Effects of Out-of-Hospital Continuous Nursing on Postoperative Breast Cancer Patients by Medical Big Data
Peijuan He, Bing Zhang, Songna Shen, Kalidoss Rajakani
Journal of Healthcare Engineering.2022; 2022: 1. CrossRef
Delays in the presentation and diagnosis of women with breast cancer in Yogyakarta, Indonesia: A retrospective observational study
Susanna Hilda Hutajulu, Yayi Suryo Prabandari, Bagas Suryo Bintoro, Juan Adrian Wiranata, Mentari Widiastuti, Norma Dewi Suryani, Rorenz Geraldi Saptari, Kartika Widayati Taroeno-Hariadi, Johan Kurnianda, Ibnu Purwanto, Mardiah Suci Hardianti, Matthew Joh
PLOS ONE.2022; 17(1): e0262468. CrossRef
Cryptotanshinone inhibits proliferation and induces apoptosis of breast cancer MCF-7 cells via GPER mediated PI3K/AKT signaling pathway
Danning Shi, Hongbo Li, Zeye Zhang, Yueshuang He, Meng Chen, Liping Sun, Piwen Zhao, Irina V. Lebedeva
PLOS ONE.2022; 17(1): e0262389. CrossRef
The COMT Genetic Factor Regulates Chemotherapy-Related Prospective Memory Impairment in Survivors With HER2−/+ Breast Cancer
Wen Li, Qianqian Zhang, Yinlian Cai, Tingting Chen, Huaidong Cheng
Frontiers in Oncology.2022;[Epub] CrossRef
Factors Influencing Total Delay of Breast Cancer in Northeast of China
Sihang Ren, Yuting Zhang, Pan Qin, Jia Wang
Frontiers in Oncology.2022;[Epub] CrossRef
Patient delay to diagnosis and its predictors among colorectal cancer patients: A cross-sectional study based on the Theory of Planned Behavior
Ying Jin, Mei-Chun Zheng, Xia Yang, Ting-Lan Chen, Jun-E Zhang
European Journal of Oncology Nursing.2022; 60: 102174. CrossRef
Research on body image cognition, social support and illness perception in breast cancer patients with different surgical methods
Yuhan Liu, Wanli Liu, Yinglu Ma, Xiaoyue Yang, Han Zhou, Tingting Zhang, Shuhong Shao
Frontiers in Psychology.2022;[Epub] CrossRef
Delay in Seeking Medical Attention and Diagnosis in Chinese Melanoma Patients: A Cross-Sectional Study
Xinchen Ke, Tianhao Wu, Guiyun Gao, Songchun Yang, Wenrui Lin, Yi Xiao, Minxue Shen, Mingliang Chen, Xiang Chen, Shuang Zhao, Juan Su
International Journal of Environmental Research and Public Health.2022; 19(22): 14916. CrossRef
Delay in Diagnosis and Treatment of Primary Bone Tumors during COVID-19 Pandemic in Poland
Daniel Kotrych, Dawid Ciechanowicz, Jakub Pawlik, Martyna Szyjkowska, Bartłomiej Kwapisz, Maciej Mądry
Cancers.2022; 14(24): 6037. CrossRef
Diagnostic delay in moderately/poorly differentiated breast cancer types
Constanze Elfgen, Sabrina Baumgartner, Zsuzsanna Varga, Kelly Reeve, Christoph J. Tausch, Vesna Bjelic-Radisic, Markus Fleisch, Uwe Güth
European Journal of Cancer Prevention.2022; 31(2): 152. CrossRef
Patients’ awareness about their own breast cancer characteristics
Chong Geng, Guo-Jun Lu, Jing Zhu, Yu-Yang Li
World Journal of Clinical Cases.2021; 9(24): 7043. CrossRef
Delay in the diagnosis and treatment of breast cancer in Vietnam
Sang M. Nguyen, Quang T. Nguyen, Lan M. Nguyen, Anh T. Pham, Hung N. Luu, Huong T. T. Tran, Thuan V. Tran, Xiao‐Ou Shu
Cancer Medicine.2021; 10(21): 7683. CrossRef

9,539 View
200 Download
26 Web of Science
23 Crossref

Association between Body Mass Index and Gastric Cancer Risk According to Effect Modification by Helicobacter pylori Infection: Jieun Jang, Eun-Jung Cho, Yunji Hwang, Elisabete Weiderpass, Choonghyun Ahn, Jeoungbin Choi, Soung-Hoon Chang, Hai-Rim Shin, Min Kyung Lim, Keun-Young Yoo, Sue K. Park; Cancer Res Treat. 2019;51(3):1107-1116. Published online November 21, 2018; DOI: https://doi.org/10.4143/crt.2018.182

Abstract PDF Supplementary Material PubReader ePub

Purpose
Few studies investigated roles of body mass index (BMI) on gastric cancer (GC) risk according to Helicobacter pylori infection status. This study was conducted to evaluate associations between BMI and GC risk with consideration of H. pylori infection information.
Materials and Methods
We performed a case-cohort study (n=2,458) that consists of a subcohort, (n=2,193 including 67 GC incident cases) randomly selected from the Korean Multicenter Cancer Cohort (KMCC) and 265 incident GC cases outside of the subcohort. H. pylori infection was assessed using an immunoblot assay. GC risk according to BMI was evaluated by calculating hazard ratios (HRs) and their 95% confidence intervals (95% CIs) using weighted Cox hazard regression model.
Results
Increased GC risk in lower BMI group (< 23 kg/m²) with marginal significance, (HR, 1.32; 95% CI, 0.98 to 1.77) compared to the reference group (BMI of 23-24.9 kg/m²) was observed. In the H. pylori non-infection, both lower (< 23 kg/m²) and higher BMI (≥ 25 kg/m²) showed non-significantly increased GC risk (HR, 10.82; 95% CI, 1.25 to 93.60 and HR, 11.33; 95% CI, 1.13 to 113.66, respectively). However, these U-shaped associations between BMI and GC risk were not observed in the group who had ever been infected by H. pylori.
Conclusion
This study suggests the U-shaped associations between BMI and GC risk, especially in subjects who had never been infected by H. pylori.

Citations

Citations to this article as recorded by

Ethnic-specific associations between body mass index and gastric cancer: a Mendelian randomization study in European and Korean populations
Sangjun Lee, Sue K. Park
Gastric Cancer.2024; 27(1): 19. CrossRef
Cross-phenotype association analysis of gastric cancer: in-silico functional annotation based on the disease–gene network
Sangjun Lee, Han-Kwang Yang, Hyuk-Joon Lee, Do Joong Park, Seong-Ho Kong, Sue K. Park
Gastric Cancer.2023; 26(4): 517. CrossRef
Association between metabolic syndrome and gastric cancer risk: results from the Health Examinees Study
Dan Huang, Woo-Kyoung Shin, Katherine De la Torre, Hwi-Won Lee, Sukhong Min, Aesun Shin, Jong-Koo Lee, Daehee Kang
Gastric Cancer.2023; 26(4): 481. CrossRef
Cancer Progress and Priorities: Gastric Cancer
Priya Alagesan, Jessica C. Goodwin, Katherine S. Garman, Meira Epplein
Cancer Epidemiology, Biomarkers & Prevention.2023; 32(4): 473. CrossRef
Obesity at early adulthood increases risk of gastric cancer from the Health Examinees-Gem (HEXA-G) study
Hwi-Won Lee, Dan Huang, Woo-Kyoung Shin, Katherine de la Torre, Jae Jeong Yang, Minkyo Song, Aesun Shin, Jong-koo Lee, Daehee Kang, Shengxu Li
PLOS ONE.2022; 17(2): e0260826. CrossRef
Association between Body Mass Index and Risk of Gastric Cancer by Anatomic and Histologic Subtypes in Over 500,000 East and Southeast Asian Cohort Participants
Jieun Jang, Sangjun Lee, Kwang-Pil Ko, Sarah K. Abe, Md. Shafiur Rahman, Eiko Saito, Md. Rashedul Islam, Norie Sawada, Xiao-Ou Shu, Woon-Puay Koh, Atsuko Sadakane, Ichiro Tsuji, Jeongseon Kim, Isao Oze, Chisato Nagata, Shoichiro Tsugane, Hui Cai, Jian-Min
Cancer Epidemiology, Biomarkers & Prevention.2022; 31(9): 1727. CrossRef
Impact of a Fermented High-Fiber Rye Diet on Helicobacter pylori and Cardio-Metabolic Risk Factors: A Randomized Controlled Trial Among Helicobacter pylori-Positive Chinese Adults
Kun Xue, Yuwei Liu, Kia Nøhr Iversen, Mohsen Mazidi, Zheng Qu, Chenglin Dong, Tayi Jin, Göran Hallmans, Per Åman, Anders Johansson, Gengsheng He, Rikard Landberg
Frontiers in Nutrition.2021;[Epub] CrossRef
Current therapeutic options for gastric adenocarcinoma
C.R. Akshatha, Smitha Bhat, R. Sindhu, Dharini Shashank, Sarana Rose Sommano, Wanaporn Tapingkae, Ratchadawan Cheewangkoon, Shashanka K. Prasad
Saudi Journal of Biological Sciences.2021; 28(9): 5371. CrossRef
The U‐shaped association between body mass index and gastric cancer risk in the Helicobacter pylori Biomarker Cohort Consortium: A nested case–control study from eight East Asian cohort studies
Jieun Jang, Tianyi Wang, Hui Cai, Fei Ye, Gwen Murphy, Taichi Shimazu, Philip R Taylor, You‐Lin Qiao, Keun‐Young Yoo, Sun Ha Jee, Jeongseon Kim, Sheau‐Chiann Chen, Christian C Abnet, Shoichiro Tsugane, Wei Zheng, Xiao‐Ou Shu, Michael Pawlita, Sue K. Park,
International Journal of Cancer.2020; 147(3): 777. CrossRef

13,100 View
286 Download
9 Web of Science
9 Crossref

Genetic Profiles Associated with Chemoresistance in Patient-Derived Xenograft Models of Ovarian Cancer: Lan Ying Li, Hee Jung Kim, Sun Ae Park, So Hyun Lee, Lee Kyung Kim, Jung Yun Lee, Sunghoon Kim, Young Tae Kim, Sang Wun Kim, Eun Ji Nam; Cancer Res Treat. 2019;51(3):1117-1127. Published online November 6, 2018; DOI: https://doi.org/10.4143/crt.2018.405

Abstract PDF Supplementary Material PubReader ePub

Purpose
Recurrence and chemoresistance (CR) are the leading causes of death in patients with high-grade serous carcinoma (HGSC) of the ovary. The aim of this study was to identify genetic changes associated with CR mechanisms using a patient-derived xenograft (PDX) mouse model and genetic sequencing.
Materials and Methods
To generate a CR HGSC PDX tumor, mice bearing subcutaneously implanted HGSC PDX tumors were treated with paclitaxel and carboplatin. We compared gene expression and mutations between chemosensitive (CS) and CR PDX tumors with whole exome and RNA sequencing and selected candidate genes. Correlations between candidate gene expression and clinicopathological variables were explored using the Cancer Genome Atlas (TCGA) database and the Human Protein Atlas (THPA).
Results
Three CR and four CS HGSC PDX tumor models were successfully established. RNA sequencing analysis of the PDX tumors revealed that 146 genes were significantly up-regulated and 54 genes down-regulated in the CR group compared with the CS group. Whole exome sequencing analysis showed 39 mutation sites were identified which only occurred in CR group. Differential expression of SAP25, HLA-DPA1, AKT3, and PIK3R5 genes and mutation of TMEM205 and POLR2A may have important functions in the progression of ovarian cancer chemoresistance. According to TCGA data analysis, patients with high HLA-DPA1 expression were more resistant to initial chemotherapy (p=0.030; odds ratio, 1.845).
Conclusion
We successfully established CR ovarian cancer PDX mouse models. PDX-based genetic profiling study could be used to select some candidate genes that could be targeted to overcome chemoresistance of ovarian cancer.

Citations

Citations to this article as recorded by

Creation and Validation of Patient-Derived Cancer Model Using Peritoneal and Pleural Effusion in Patients with Advanced Ovarian Cancer: An Early Experience
Ruri Nishie, Tomohito Tanaka, Kensuke Hirosuna, Shunsuke Miyamoto, Hikaru Murakami, Hiromitsu Tsuchihashi, Akihiko Toji, Shoko Ueda, Natsuko Morita, Sousuke Hashida, Atsushi Daimon, Shinichi Terada, Hiroshi Maruoka, Hiromi Konishi, Yuhei Kogata, Kohei Tan
Journal of Clinical Medicine.2024; 13(9): 2718. CrossRef
Uncovering miRNA–mRNA Regulatory Networks Related to Olaparib Resistance and Resensitization of BRCA2MUT Ovarian Cancer PEO1-OR Cells with the ATR/CHK1 Pathway Inhibitors
Łukasz Biegała, Damian Kołat, Arkadiusz Gajek, Elżbieta Płuciennik, Agnieszka Marczak, Agnieszka Śliwińska, Michał Mikula, Aneta Rogalska
Cells.2024; 13(10): 867. CrossRef
Patient-derived xenograft models in cancer therapy: technologies and applications
Yihan Liu, Wantao Wu, Changjing Cai, Hao Zhang, Hong Shen, Ying Han
Signal Transduction and Targeted Therapy.2023;[Epub] CrossRef
Deregulations of RNA Pol II Subunits in Cancer
Martina Muste Sadurni, Marco Saponaro
Applied Biosciences.2023; 2(3): 459. CrossRef
Transcriptome and Metabolome Analyses Reveal the Mechanism of Corpus Luteum Cyst Formation in Pigs
Jiage Dai, Jiabao Cai, Taipeng Zhang, Mingyue Pang, Xiaoling Xu, Jiahua Bai, Yan Liu, Yusheng Qin
Genes.2023; 14(10): 1848. CrossRef
Prediction of Chemoresistance—How Preclinical Data Could Help to Modify Therapeutic Strategy in High-Grade Serous Ovarian Cancer
Jacek Wilczyński, Edyta Paradowska, Justyna Wilczyńska, Miłosz Wilczyński
Current Oncology.2023; 31(1): 229. CrossRef
Personalization of Therapy in High-Grade Serous Tubo-Ovarian Cancer—The Possibility or the Necessity?
Jacek Wilczyński, Edyta Paradowska, Miłosz Wilczyński
Journal of Personalized Medicine.2023; 14(1): 49. CrossRef
PIK3R5 genetic predictors of hypertension induced by VEGF-pathway inhibitors
Julia C. F. Quintanilha, Alessandro Racioppi, Jin Wang, Amy S. Etheridge, Stefanie Denning, Carol E. Peña, Andrew D. Skol, Daniel J. Crona, Danyu Lin, Federico Innocenti
The Pharmacogenomics Journal.2022; 22(1): 82. CrossRef
AKT Isoforms Interplay in High-Grade Serous Ovarian Cancer Prognosis and Characterization
Eros Azzalini, Domenico Tierno, Michele Bartoletti, Renzo Barbazza, Giorgio Giorda, Fabio Puglisi, Sabrina Chiara Cecere, Nunzia Simona Losito, Daniela Russo, Giorgio Stanta, Vincenzo Canzonieri, Serena Bonin
Cancers.2022; 14(2): 304. CrossRef
Comparative analysis of cancer gene mutations using targeted sequencing in matched primary and recurrent gastric cancers after chemotherapy
Yeon-Ju Huh, Sung-Yup Cho, Min-Sun Cho, Kyoung-Eun Lee, Joo-Ho Lee
Genes & Genomics.2022; 44(11): 1425. CrossRef
Validation of a Patient-Derived Xenograft Model for Cervical Cancer Based on Genomic and Phenotypic Characterization
Shunsuke Miyamoto, Tomohito Tanaka, Kensuke Hirosuna, Ruri Nishie, Shoko Ueda, Sousuke Hashida, Shinichi Terada, Hiromi Konishi, Yuhei Kogata, Kohei Taniguchi, Kazumasa Komura, Masahide Ohmichi
Cancers.2022; 14(12): 2969. CrossRef
HCP5, as the sponge of miR-1291, facilitates AML cell proliferation and restrains apoptosis via increasing PIK3R5 expression
Yan Liu, Xue-Bing Jing, Zhen-Cheng Wang, Qing-Kun Han
Human Genomics.2021;[Epub] CrossRef
Leveraging Genomics, Transcriptomics, and Epigenomics to Understand the Biology and Chemoresistance of Ovarian Cancer
Sandra Muñoz-Galván, Amancio Carnero
Cancers.2021; 13(16): 4029. CrossRef
CD83, a Novel MAPK Signaling Pathway Interactor, Determines Ovarian Cancer Cell Fate
Aalia Batool, Hao Liu, Yi-Xun Liu, Su-Ren Chen
Cancers.2020; 12(8): 2269. CrossRef
A recombinant platform to characterize the role of transmembrane protein hTMEM205 in Pt(ii)-drug resistance and extrusion
Marc J Gallenito, Tahir S Qasim, Jasmine N Tutol, Ved Prakash, Sheel C Dodani, Gabriele Meloni
Metallomics.2020; 12(10): 1542. CrossRef
Function, Regulation and Biological Roles of PI3Kγ Variants
Bernd Nürnberg, Sandra Beer-Hammer
Biomolecules.2019; 9(9): 427. CrossRef

10,554 View
341 Download
19 Web of Science
16 Crossref

A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-Line Chemotherapy in Metastatic Colorectal Cancer Patients: Youjin Kim, Tae Won Kim, Sae Won Han, Joong Bae Ahn, Seung Tae Kim, Jeeyun Lee, Joon Oh Park, Young Suk Park, Ho Yeong Lim, Won Ki Kang; Cancer Res Treat. 2019;51(3):1128-1134. Published online November 21, 2018; DOI: https://doi.org/10.4143/crt.2018.379

Abstract PDF PubReader ePub

Purpose
Simvastatin has demonstrated anti-tumor activity in preclinical studies via tumor cell senescence, apoptosis, and anti-angiogenesis. This phase II trial evaluated the efficacy and toxicity profile of conventional XELOX and bevacizumab chemotherapy plus simvastatin in metastatic colorectal cancer patients (MCRC).
Materials and Methods
Patients with MCRC received first-line XELOX in 3-week treatment cycles of intravenous oxaliplatin 130 mg/m² plus bevacizumab 7.5 mg/kg (day 1), followed by oral capecitabine 1,000 mg/m² twice daily (day 1-14). Simvastatin 80 mg tablets were taken orally once daily every day during the period of chemotherapy. The primary endpoint was progression-free survival (PFS). Secondary endpoints were response rate, duration of response, overall survival (OS), time to progression, and toxicity.
Results
From January 2014 to April 2015, 60 patients were enrolled and 55 patients were evaluable for tumor response. The median follow-up duration was 30.1 months (range, 28.5 to 31.7 months). The median PFS was 10.4 months (95% confidence interval [CI], 9.6 to 11.1). The median OS of all patients was 19.0 months (95% CI, 11.9 to 26.0). The disease-control rate and overall response rate were 88.3% (95% CI, 74 to 96) and 58.3% (95% CI, 44 to 77), respectively, by intent-to-treat protocol analysis. There was one complete response and 34 partial responses. One patient experienced grade 3 creatine kinase elevation and liver enzyme elevation.
Conclusion
Based on the current study, the addition of 80 mg simvastatin to XELOX and bevacizumab showed comparable clinical efficacy in patients with MCRC as first-line chemotherapy and did not increase toxicity.

Citations

Citations to this article as recorded by

Therapeutic Effects of Statins: Promising Drug for Topical and Transdermal Administration
Fatemeh Zahedipour, Seyede Atefe Hosseini, Željko Reiner, Eugenia Tedeschi-Reiner, Tannaz Jamialahmadi, Amirhossein Sahebkar
Current Medicinal Chemistry.2024; 31(21): 3149. CrossRef
Are statins onco- suppressive agents for every type of tumor? A systematic review of literature
Luca Filaferro, Fabiana Zaccarelli, Giovanni Francesco Niccolini, Andrea Colizza, Federica Zoccali, Michele Grasso, Massimo Fusconi
Expert Review of Anticancer Therapy.2024; 24(6): 435. CrossRef
Cholesterol synthesis is essential for the growth of liver metastasis‐prone colorectal cancer cells
Kumiko Taniguchi, Kei Sugihara, Takashi Miura, Daisuke Hoshi, Susumu Kohno, Chiaki Takahashi, Eishu Hirata, Etsuko Kiyokawa
Cancer Science.2024; 115(11): 3817. CrossRef
Statins in Mitigating Anticancer Treatment-Related Cardiovascular Disease
Rong Jiang, Lian Lou, Wen Shi, Yuxiao Chen, Zhaoming Fu, Shuo Liu, Thida Sok, Zhihang Li, Xuan Zhang, Jian Yang
International Journal of Molecular Sciences.2024; 25(18): 10177. CrossRef
Assessment in vitro of interactions between anti-cancer drugs and noncancer drugs commonly used by cancer patients
Claes R. Andersson, Jiawei Ye, Kristin Blom, Mårten Fryknäs, Rolf Larsson, Peter Nygren
Anti-Cancer Drugs.2023; 34(1): 92. CrossRef
A phase 1 study of simvastatin in combination with topotecan and cyclophosphamide in pediatric patients with relapsed and/or refractory solid and CNS tumors
Thomas Cash, Hunter C. Jonus, Maya Tsvetkova, Jan H. Beumer, Arhanti Sadanand, Jasmine Y. Lee, Curtis J. Henry, Dolly Aguilera, R. Donald Harvey, Kelly C. Goldsmith
Pediatric Blood & Cancer.2023;[Epub] CrossRef
New insights into the therapeutic potentials of statins in cancer
Chengyu Liu, Hong Chen, Bicheng Hu, Jiajian Shi, Yuchen Chen, Kun Huang
Frontiers in Pharmacology.2023;[Epub] CrossRef
The Association of Metformin, Other Antidiabetic Medications, and Statins With the Prognosis of Colon Cancer in Patients With Type 2 Diabetes: A Retrospective Cohort Study
Sami Erkinantti, Ari Hautakoski, Reijo Sund, Martti Arffman, Elina Urpilainen, Ulla Puistola, Arja Jukkola, Karihtala Peeter, Esa Läärä
Cancer Control.2022;[Epub] CrossRef
Performance of capecitabine in novel combination therapies in colorectal cancer
Fahima Danesh Pouya, Yousef Rasmi, Irem Yalim Camci, Yusuf Tutar, Mohadeseh Nemati
Journal of Chemotherapy.2021; 33(6): 375. CrossRef
The potential use of simvastatin for cancer treatment: A review
Jaqueline Aparecida Duarte, Andre Luis Branco de Barros, Elaine Amaral Leite
Biomedicine & Pharmacotherapy.2021; 141: 111858. CrossRef
Cholesterol-Lowering Drugs on Akt Signaling for Prevention of Tumorigenesis
Navneet Kumar, Chandi C. Mandal
Frontiers in Genetics.2021;[Epub] CrossRef
Targeting Inflammatory Signaling in Prostate Cancer Castration Resistance
Shangwei Zhong, Changhao Huang, Zhikang Chen, Zihua Chen, Jun-Li Luo
Journal of Clinical Medicine.2021; 10(21): 5000. CrossRef
Osteolytic metastasis in breast cancer: effective prevention strategies
Chandi C Mandal
Expert Review of Anticancer Therapy.2020; 20(9): 797. CrossRef

9,045 View
221 Download
17 Web of Science
13 Crossref

Prognostic Implications of Extranodal Extension in Relation to Colorectal Cancer Location: Chan Wook Kim, Jihun Kim, Yangsoon Park, Dong-Hyung Cho, Jong Lyul Lee, Yong Sik Yoon, In Ja Park, Seok-Byung Lim, Chang Sik Yu, Jin Cheon Kim; Cancer Res Treat. 2019;51(3):1135-1143. Published online November 29, 2018; DOI: https://doi.org/10.4143/crt.2018.392; Correction in: Cancer Res Treat 2021;53(3):893

Abstract PDF PubReader ePub

Purpose
Extranodal extension (ENE) is closely associated with the aggressiveness of both colon and rectal cancer. This study evaluated the clinicopathologic significance and prognostic impact of ENE in separate populations of patients with colon and rectal cancers.
Materials and Methods
The medical records of 2,346 patients with colorectal cancer (CRC) who underwent curative surgery at our institution between January 2003 and December 2011 were clinically and histologically reviewed.
Results
ENE was associated with younger age, advanced tumor stage, lymphovascular invasion (LVI), and perineural invasion (PNI) in both colon and rectal cancer. ENE rates differed significantly in patients with right colon (36.9%), left colon (42.6%), and rectal (48.7%) cancers (right vs. left, p=0.037; left vs. rectum, p=0.009). The 5-year disease-free survival (DFS) rate according to ENE status and primary tumor site differed significantly in patients with ENE-negative colon cancer (80.5%), ENE-negative rectal cancer (77.4%), ENE-positive colon cancer (68.6%), and ENE-positive rectal cancer (64.2%) (p<0.001). Multivariate analysis showed that advanced tumor stage, ENE, LVI, PNI, and absence of adjuvant chemotherapy were independently prognostic of reduced DFS in colon and rectal cancer patients.
Conclusion
ENE is closely associated with the aggressiveness of colon and rectal cancers, with its frequency increasing from the right colon to the left colon to the rectum. ENE status is a significant independent predictor of DFS in CRC patients irrespective of tumor location. ENE might be more related with distally located CRC.

Citations

Citations to this article as recorded by

Assessment of prognostic indicators and KRAS mutations in rectal cancer using a fractional-order calculus MR diffusion model: whole tumor histogram analysis
Mi Zhou, Hongyun Huang, Deying Bao, Meining Chen, Fulin Lu
Abdominal Radiology.2024;[Epub] CrossRef
Tumour deposits are associated with worse survival than extranodal extension; a network meta‐analysis on tumour nodules in colorectal cancer
Nelleke P M Brouwer, Shannon van Vliet, Joanna IntHout, Johannes H W De Wilt, Femke Simmer, Niek Hugen, Iris D Nagtegaal
Histopathology.2024;[Epub] CrossRef
MRI-based multiregional radiomics for predicting lymph nodes status and prognosis in patients with resectable rectal cancer
Hang Li, Xiao-li Chen, Huan Liu, Tao Lu, Zhen-lin Li
Frontiers in Oncology.2023;[Epub] CrossRef
Prognostic significance of extranodal extension of nodal metastasis in adenocarcinoma of the ampulla of Vater
Jihyun Chun, Yeon Wook Kim, Seo-rin Jeong, Hyung Jun Cho, Kyu-Pyo Kim, Dae Wook Hwang, Seung-Mo Hong
Human Pathology.2023; 137: 36. CrossRef
Dissimilar survival and clinicopathological characteristics of mucinous adenocarcinoma located in pancreatic head and body/tail
Zheng Li, Xiao-Jie Zhang, Chong-Yuan Sun, Ze-Feng Li, He Fei, Dong-Bing Zhao
World Journal of Gastrointestinal Surgery.2023; 15(6): 1178. CrossRef
Effect of visceral fat area on the accuracy of preoperative CT-N staging of colorectal cancer
Meizhen Xie, Gangyi Liu, Yan Dong, Lan Yu, Rui Song, Wei Zhang, Ying Zhang, Shafei Huang, Jiaqian He, Yunping Xiao, Liling Long
European Journal of Radiology.2023; 168: 111131. CrossRef
Prognostic Value of the N1c in Stage III and IV Colorectal Cancer: A Propensity Score Matching Study Based on the Surveillance, Epidemiology, and End Results (SEER) Database
Chongshun Liu, Mengxiang Tian, Haiping Pei, Fengbo Tan, Yuqiang Li
Journal of Investigative Surgery.2022; 35(4): 850. CrossRef
Tumor Deposits and Perineural Invasion had Comparable Impacts on the Survival of Patients With Non-metastatic Colorectal Adenocarcinoma: A Population-Based Propensity Score Matching and Competing Risk Analysis
Bin Luo, Xianzhe Chen, Guanfu Cai, Weixian Hu, Yong Li, Junjiang Wang
Cancer Control.2022;[Epub] CrossRef
The application of apparent diffusion coefficients derived from intratumoral and peritumoral zones for assessing pathologic prognostic factors in rectal cancer
Yi Yuan, Xiao-li Chen, Zhen-lin Li, Guang-wen Chen, Hao Liu, Yi-Sha Liu, Ming-hui Pang, Si-yun Liu, Hong Pu, Hang Li
European Radiology.2022; 32(8): 5106. CrossRef
Beyond N staging in colorectal cancer: Current approaches and future perspectives
Gianluca Arrichiello, Mario Pirozzi, Bianca Arianna Facchini, Sergio Facchini, Fernando Paragliola, Valeria Nacca, Antonella Nicastro, Maria Anna Canciello, Adele Orlando, Marianna Caterino, Davide Ciardiello, Carminia Maria Della Corte, Morena Fasano, St
Frontiers in Oncology.2022;[Epub] CrossRef
Clinical Implication of Perineural and Lymphovascular Invasion in Rectal Cancer Patients Who Underwent Surgery After Preoperative Chemoradiotherapy
Young Il Kim, Chan Wook Kim, Jong Hoon Kim, Jihun Kim, Jun-Soo Ro, Jong Lyul Lee, Yong Sik Yoon, In Ja Park, Seok-Byung Lim, Chang Sik Yu, Jin Cheon Kim
Diseases of the Colon & Rectum.2022; 65(11): 1325. CrossRef
Prognostic Impact of Extranodal Extension in Rectal Cancer Patients Undergoing Radical Resection After Preoperative Chemoradiotherapy
Young Il Kim, Haeyon Cho, Chan Wook Kim, Yangsoon Park, Jihun Kim, Jun-Soo Ro, Jong Lyul Lee, Yong Sik Yoon, In Ja Park, Seok-Byung Lim, Chang Sik Yu, Jin Cheon Kim
Clinical Colorectal Cancer.2021; 20(1): e35. CrossRef
Analysis of the Clinicopathological Characteristics of Stage I–III Colorectal Cancer Patients Deficient in Mismatch Repair Proteins
Yichao Liang, Xinling Cai, Xu Zheng, Hongzhuan Yin
OncoTargets and Therapy.2021; Volume 14: 2203. CrossRef
Clinical significance of extranodal extension in sentinel lymph node positive breast cancer
Xia Yang, XiaoXi Ma, Wentao Yang, Ruohong Shui
Scientific Reports.2020;[Epub] CrossRef

8,473 View
166 Download
17 Web of Science
14 Crossref

Development of Web-Based Nomograms to Predict Treatment Response and Prognosis of Epithelial Ovarian Cancer: Se Ik Kim, Minsun Song, Suhyun Hwangbo, Sungyoung Lee, Untack Cho, Ju-Hyun Kim, Maria Lee, Hee Seung Kim, Hyun Hoon Chung, Dae-Shik Suh, Taesung Park, Yong-Sang Song; Cancer Res Treat. 2019;51(3):1144-1155. Published online November 20, 2018; DOI: https://doi.org/10.4143/crt.2018.508

Abstract PDF Supplementary Material PubReader ePub

Purpose
Discovery of models predicting the exact prognosis of epithelial ovarian cancer (EOC) is necessary as the first step of implementation of individualized treatment. This study aimed to develop nomograms predicting treatment response and prognosis in EOC.
Materials and Methods
We comprehensively reviewed medical records of 866 patients diagnosed with and treated for EOC at two tertiary institutional hospitals between 2007 and 2016. Patients’ clinico-pathologic characteristics, details of primary treatment, intra-operative surgical findings, and survival outcomes were collected. To construct predictive nomograms for platinum sensitivity, 3-year progression-free survival (PFS), and 5-year overall survival (OS), we performed stepwise variable selection by measuring the area under the receiver operating characteristic curve (AUC) with leave-one-out cross-validation. For model validation, 10-fold cross-validation was applied.
Results
The median length of observation was 42.4 months (interquartile range, 25.7 to 69.9 months), during which 441 patients (50.9%) experienced disease recurrence. The median value of PFS was 32.6 months and 3-year PFS rate was 47.8% while 5-year OS rate was 68.4%. The AUCs of the newly developed nomograms predicting platinum sensitivity, 3-year PFS, and 5-year OS were 0.758, 0.841, and 0.805, respectively. We also developed predictive nomograms confined to the patients who underwent primary debulking surgery. The AUCs for platinum sensitivity, 3-year PFS, and 5-year OS were 0.713, 0.839, and 0.803, respectively.
Conclusion
We successfully developed nomograms predicting treatment response and prognosis of patients with EOC. These nomograms are expected to be useful in clinical practice and designing clinical trials.

Citations

Citations to this article as recorded by

Comprehensive analyses of mitophagy-related genes and mitophagy-related lncRNAs for patients with ovarian cancer
Jianfeng Zheng, Shan Jiang, Xuefen Lin, Huihui Wang, Li Liu, Xintong Cai, Yang Sun
BMC Women's Health.2024;[Epub] CrossRef
Peripheral and tumor‐infiltrating immune cells are correlated with patient outcomes in ovarian cancer
Weiwei Zhang, Yawen Ling, Zhidong Li, Xingchen Peng, Yazhou Ren
Cancer Medicine.2023; 12(8): 10045. CrossRef
Nonalcoholic fatty liver disease and early prediction of gestational diabetes mellitus using machine learning methods
Seung Mi Lee, Suhyun Hwangbo, Errol R. Norwitz, Ja Nam Koo, Ig Hwan Oh, Eun Saem Choi, Young Mi Jung, Sun Min Kim, Byoung Jae Kim, Sang Youn Kim, Gyoung Min Kim, Won Kim, Sae Kyung Joo, Sue Shin, Chan-Wook Park, Taesung Park, Joong Shin Park
Clinical and Molecular Hepatology.2022; 28(1): 105. CrossRef
Toward More Comprehensive Homologous Recombination Deficiency Assays in Ovarian Cancer Part 2: Medical Perspectives
Stanislas Quesada, Michel Fabbro, Jérôme Solassol
Cancers.2022; 14(4): 1098. CrossRef
Construction and validation of a transcription factors-based prognostic signature for ovarian cancer
Qingyuan Cheng, Liman Li, Mingxia Yu
Journal of Ovarian Research.2022;[Epub] CrossRef
Predicting preterm birth through vaginal microbiota, cervical length, and WBC using a machine learning model
Sunwha Park, Jeongsup Moon, Nayeon Kang, Young-Han Kim, Young-Ah You, Eunjin Kwon, AbuZar Ansari, Young Min Hur, Taesung Park, Young Ju Kim
Frontiers in Microbiology.2022;[Epub] CrossRef
Prognostic nomogram that predicts progression-free survival and overall survival of patients with ovarian clear cell carcinoma
Jiayi Li, Dongyan Cao
Frontiers in Oncology.2022;[Epub] CrossRef
Recent Advances and Future Directions of Diagnostic and Prognostic Prediction Models in Ovarian Cancer
Judan Zeng, Wenjiao Cao, Lihua Wang
Journal of Shanghai Jiaotong University (Science).2021; 26(1): 10. CrossRef
Sphingolipids as multifaceted mediators in ovarian cancer
MelissaR Pitman, Martin K. Oehler, Stuart M. Pitson
Cellular Signalling.2021; 81: 109949. CrossRef
Development and validation for prognostic nomogram of epithelial ovarian cancer recurrence based on circulating tumor cells and epithelial–mesenchymal transition
Jiani Yang, Jun Ma, Yue Jin, Shanshan Cheng, Shan Huang, Nan Zhang, Yu Wang
Scientific Reports.2021;[Epub] CrossRef
Prediction Models for the Clinical Severity of Patients With COVID-19 in Korea: Retrospective Multicenter Cohort Study
Bumjo Oh, Suhyun Hwangbo, Taeyeong Jung, Kyungha Min, Chanhee Lee, Catherine Apio, Hyejin Lee, Seungyeoun Lee, Min Kyong Moon, Shin-Woo Kim, Taesung Park
Journal of Medical Internet Research.2021; 23(4): e25852. CrossRef
Development of Machine Learning Models to Predict Platinum Sensitivity of High-Grade Serous Ovarian Carcinoma
Suhyun Hwangbo, Se Ik Kim, Ju-Hyun Kim, Kyung Jin Eoh, Chanhee Lee, Young Tae Kim, Dae-Shik Suh, Taesung Park, Yong Sang Song
Cancers.2021; 13(8): 1875. CrossRef
M2 Macrophage-Based Prognostic Nomogram for Gastric Cancer After Surgical Resection
Jianwen Hu, Yongchen Ma, Ju Ma, Yanpeng Yang, Yingze Ning, Jing Zhu, Pengyuan Wang, Guowei Chen, Yucun Liu
Frontiers in Oncology.2021;[Epub] CrossRef
Prognosis for intrahepatic cholangiocarcinoma patients treated with postoperative adjuvant transcatheter hepatic artery chemoembolization
Ji-Bin Liu, Kai-Jian Chu, Chang-Chun Ling, Ting-Miao Wu, Hui-Min Wang, Yi Shi, Zhi-Zhen Li, Jing-Han Wang, Zhi-Jun Wu, Xiao-Qing Jiang, Gao-Ren Wang, Yu-Shui Ma, Da Fu
Current Problems in Cancer.2020; 44(6): 100612. CrossRef
Can we predict who lives long with ovarian cancer?
Michael A. Bookman
Cancer.2019; 125(S24): 4578. CrossRef

9,855 View
263 Download
16 Web of Science
15 Crossref

First
Prev
Page of 2
Next
Last

Previous issues